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Preface 
 
This report describes current knowledge and gaps in knowledge regarding FASD in the 
Netherlands.  The  steps  of  Intervention  Mapping  (IM)  are  used  as  a  framework  for 
analyzing this situation. The first chapter provides a brief introduction to the method‐
ology used  in  IM,  and  is  followed by an overview of questions  and  issues  related  to 
FASD, as formulated by the Dutch Organization of Health Research and Development 
(ZonMw). The second chapter focuses on primary prevention, and explores causes of 
and  risk  factors  related  to  FASD.  The  third  chapter addresses  secondary and  tertiary 
prevention,  including  screening,  early  detection,  and  intervention  techniques.  Issues 
regarding management and care for people with a diagnosis on the FASD spectrum are 
described  from  the  perspective  of  enhancing  quality  of  life  by  reducing  the  impact 
caused by FASD. The fourth chapter summarizes state of the art FASD knowledge and 
challenges. Conclusions and recommendations, together with a prioritization of FASD‐
related knowledge needs and questions, are presented in the fifth chapter. 
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1. INTRODUCTION 
Fetal alcohol spectrum disorders (FASD) can result in serious health problems affecting 
communities worldwide. FASD is an umbrella term used to describe a range of birth 
defects caused by prenatal exposure to ethyl alcohol. Alcohol may result in mild to 
severe damage to the development of an unborn baby [1–6]. This damage can lead to 
lifelong physical, behavioral, and cognitive disabilities. Depending on the nature and 
severity of the damage, the following diagnoses under the FASD umbrella term can be 
given: fetal alcohol syndrome (FAS), partial fetal alcohol syndrome (pFAS), alcohol-
related neurodevelopmental deficiencies (ARND), alcohol-related birth defects (ARBD), 
or neurobehavioral disorder-prenatal alcohol exposed (ND-PAE) [1,7–11]. FASD is a 
disorder that is 100% percent preventable, as alcohol consumption during pregnancy 
can be avoided. FASD is therefore one of the most important preventable forms of 
non-genetic birth defects associated with intellectual disability [12–15]. 
This FASD knowledge synthesis provides an overview of current knowledge and gaps in 
knowledge regarding FASD prevalence, prevention, diagnosis, management, and 
treatment.  It also provides a needs assessment with regard to FASD which focuses on 
health care and prevention. The synthesis ends with recommendations for an action 
plan based on a prioritization of FASD knowledge needs and questions. The framework 
and methodology outlined in this report are grounded in the Intervention Mapping 
approach.  
Intervention Mapping (IM) is a protocol that is used for planning theory- and evidence-
based health promotion programs based on the best current theory and evidence 
[16,17]. The purpose of IM is to provide those planning health promotion programs 
with a framework for effective decision making at each step in the process of interven-
tion development, implementation, and evaluation. IM is a planning approach that is 
based on using both theory and evidence as foundations for decision making. It takes 
an ecological approach to assessing and intervening in health problems and engender-
ing community participation. IM was developed in reaction to a lack of available com-
prehensive frameworks for health promotion program development. It was designed 
to guide health promoters in developing the best possible intervention. The key words 
in this protocol are planning, research, and theory. More specifically, IM ensures that 
theoretical models and empirical evidence guide planners in two areas: (1) the identifi-
cation of determinants related to behavioral and environmental causes of a target 
problem, and (2) the selection of appropriate theoretical methods and practical appli-
cations that can be used to address these identified determinants. 
IM provides a vocabulary for needs assessment, program planning, procedures related 
to planning activities, and technical assistance by identifying theory-based determi-
nants and matching them with appropriate methods for change. The IM protocol de-
Chapter 1 
12 
scribes the iterative path from problem identification to problem-solving or mitigation. 
Each of the six steps of IM comprises several tasks, each of which integrates theory 
and evidence. The completion of the tasks within a step creates a product that is the 
guide for the subsequent step. The completion of all of the steps serves as a blueprint 
for the design, implementation, and evaluation of an intervention based on a founda-
tion of theoretical, empirical, and practical information. The six steps (and related 
tasks) of the IM process are as follows. Step 1 is the development of a logic model of 
the problem, and involves conducting a needs assessment or problem analysis by iden-
tifying what, if anything, needs to be changed, and for whom. Step 2 involves setting 
program outcomes and objectives for each stage of the logic model of change. This 
entails creating matrices of change objectives by combining (sub-)behaviors with be-
havioral determinants in order to identify which beliefs should be targeted by the 
intervention. Step 3 is program design, that is, selecting theory-based intervention 
methods that match the determinants into which the identified beliefs aggregate, and 
translating these into practical applications that satisfy the parameters for effective-
ness of the selected methods. Step 4 focuses on program production, that is, integrat-
ing the practical applications into an organized program. Step 5 involves developing a 
program implementation plan for the adoption, implementation, and sustainability of 
the program in real-life contexts. This entails identifying program users and supporters 
and determining what their needs are, and how these needs can be met. Step 6 in-
volves the production of an evaluation plan so that effect and process evaluations can 
be carried out to measure program effectiveness.  
IM is a helpful tool that can be used to design health promoting programs in a system-
atic and evidence-based manner in order to increase the chance of success in reducing 
prenatal alcohol exposure and FASD [18]. It is true that it is a complex and time-
consuming process, reflecting the difficulty of changing health behaviors. IM has 
helped to bring the development of interventions to a higher level, indicating that the 
advantages associated with this approach outweigh any disadvantages.  
This knowledge synthesis will primarily focus on Step 1 of IM - the needs assessment or 
problem analysis undertaken to identify what needs to be changed and for whom. 
Where possible, attention will also be given to the next steps of IM. The following 
important knowledge issues, as formulated by the Dutch Organization of Health Re-
search and Development (ZonMw), will be addressed:  
 Description of current knowledge and gaps in knowledge about FASD (Chapters 2 
and 3) 
 Identification of shortfalls in the Dutch health care system related to FASD (recom-
mendations provided throughout chapters) 
 Inventory of existing databases in the Netherlands relevant for FASD (paragraphs 
2.3, 2.6, 3.5) 
Introduction 
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 Identification of relevant stakeholders in the Netherlands as related to FASD (in 
particular paragraph 2.10) 
 Identification of problems related to FASD in terms of stigmatization and stereotyp-
ing (paragraph 2.11) 
 Ethical and legal issues related to FASD (paragraph 2.12) 
 Identification of evidence-based prevention strategies designed to reduce the alco-
hol consumption of pregnant women and women of a childbearing age (paragraph 
2.13) 
 Description of FASD diagnostic practices (paragraph 3.2) 
 Description of costs and benefits analyses related to FASD care and treatment in-
terventions in the Netherlands (paragraph 3.6) 
 Identification of effective or promising interventions / treatment methods for FASD 
(paragraph 3.7) 
 
Figure 1 schematically represents the most important concepts that will appear in this 
report. The top half concerns primary prevention: no alcohol exposure (Chapter 2), 
while the bottom half concerns secondary and tertiary prevention: early diagnoses, 
optimal management and care (Chapter 3). In addition to the mother and child, other 
relevant individuals (actors) are depicted. The relevant sub-disciplines involved in the 
various steps are successively described in this report.  Stigma as well as legal and 
ethical issues relate are discussed in relation to each step. The report suggests differ-
ent theory- and evidence-based interventions that could be implemented in relation to 
various target groups.  
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Figure 1 Overview of Chapter and Topics Discussed in This Report 
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2. PRIMARY PREVENTION  
“Many disabilities have an unknown etiology or cause, but FASD is associated with 
prenatal alcohol exposure which may cause lifelong physical, behavioral, and cognitive 
disabilities. It is 100 per cent preventable” (Carpenter, Blackburn, and Egerton, 2013 
p.13; [19]).  
2.1. Introduction 
Different levels of functioning may be affected in persons diagnosed within the spec-
trum of FASD, including abstract reasoning, information processing, attention, execu-
tive functioning, visual perception, social cognition and interaction, memory, and self-
regulation. This can result in difficulties with daily living skills (e.g., money manage-
ment), living independently, and academic achievements (e.g., school failure), as well 
as increasing the likelihood of getting into trouble with the law [12,20–23].  
Prenatal alcohol exposure not only reduces the quality of life of affected individuals, 
but also that of their families and those around them. There are many stakeholders 
with regard to FASD, including parents (biological and adoptive parents), persons af-
fected by FASD, government (various departments), health care professionals, social 
workers, teachers, researchers, and policy makers [18]. FASD carries a social and eco-
nomic burden in every society where women drink during pregnancy. There is a clear 
need for both prevention and intervention [15,18,24].  
The goal of primary prevention is to prevent prenatal alcohol-exposed pregnancies. 
After a brief historical outline of alcohol consumption, the following paragraphs will 
discuss current knowledge and gaps in knowledge, and provide recommendations 
related to FASD etiology and pathogenesis, biomarkers for alcohol use, genetic factors 
and alcohol consumption, the role of maternity care, FASD prevalence, risk behaviors 
and target groups, psycho-social determinants of drinking behavior, environmental 
conditions, stigma, legal and ethical issues, and interventions that can be used to pre-
vent harm caused by alcohol exposure in pregnancy.  
2.2.  Alcohol Consumption 
Two scenes from the BBC series ‘Inspector Linley Mysteries’ show the main character’s 
wife opening a champagne bottle to celebrate her pregnancy - one when she an-
nounces her pregnancy to the father, the other when she tells a female colleague [25]. 
Only one of her remarks shows some sensitivity to the issue, when she says she is 
allowed to have at least one drink. The scene is clearly not intended as a statement by 
the series’ authors regarding the woman as an irresponsible person (she loses the 
fetus later on in the series due to an accident), but it indicates that in 2004, pregnant 
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women drinking alcohol was not a taboo, nor was it considered wholly inappropriate, 
as it is today.  
In the 19th century, in protestant cultures, women drinking alcohol - not only those 
who were pregnant - were condemned, mainly on moral grounds. Little concrete med-
ical knowledge was available on the teratogenic effects of alcohol use, but alcohol use 
in general was seen as undermining one’s health. Many iconographic images appear to 
depict the despicable nature and detrimental effects of women drinking alcohol. The 
consumption of spirits was chiefly a male affair, and also a public one. The temperance 
movement, and later teetotalism, directed their efforts mainly towards men. Women 
were considered to be custodians of ethical standards. They and their children were 
seen as victims of men’s drinking rather than depicted as the source of harm to the 
child and family. Additionally, social Darwinists considered alcohol use as a source of 
hereditary degeneration, with alcohol damaging reproductive cells, in both men and in 
women [26]. In fact, due to dwindling consumption rates and American Prohibition, 
the topic of alcohol and reproductive health became a non-issue in research as it was 
not considered a priority in terms of public reproductive health [26].   
Together with a declining overall consumption in the early 20th century, women’s 
drinking practices were changing, especially during U.S. prohibition. In the USA, the 
“roaring 20s” saw the birth of the flapper - and of cocktail hour, during which men and 
women could drink together in bars (or speakeasies) and restaurants, an unlikely scene 
in earlier days. After the Second World War, alcohol consumption increased in many 
Western countries, with most consumption taking place in private settings, and with 
men and women drinking together. For example, in the Netherlands, per capita con-
sumption quadrupled after the war, and was as high in 1980 as at the end of the 19th 
century. In general, female consumption was half that of men, with abstention (not-
drinking for specific time periods) also higher among women [27].  
This rise in consumption has rekindled public health concerns. In the 1970s, WHO initi-
atives formulated the so-called single distribution model, highlighting the harm caused 
by alcohol consumption. Basically, in this public health model, overall exposure to 
alcohol is the main target for prevention, and general temperance is the most im-
portant policy aim. Price and tax measures and reduced availability were thought to be 
instrumental in reducing overall exposure [28]. Implementation of these measures in 
the Netherlands has not been very successful, and alcohol policies are often targeted 
at subpopulations which are considered to be the most vulnerable, such as the under-
age youngsters and pregnant women.  
The first mention of FAS appeared in studies conducted by Lemoine et al. in 1968 [29] 
and Jones and Smith in 1973 [30], but the topic only received attention as a major 
public health problem  in the late 1980s and early 90s, when the issue acquired ele-
ments of a ‘moral panic’, with exaggerated claims of harm [31]. In this period, the 
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notion of pregnant women drinking alcohol was increasingly met with public and moral 
condemnation. Rhetorically, the phenomenon was presented as being part of an ice-
berg, with vast numbers of under-diagnosed cases of FAS children. Scientific reports on 
newly discovered effects led the media to pick up stories that contributed to the public 
image of female drinking as a major threat to children. However, scientific proof failed 
to back up this idea of a large number of unrecognized cases, and the rhetorical fervor 
subdued. What remains undisputed is the harm that excessive drinking during preg-
nancy can cause in the off-spring of mothers who drink, but the message in both scien-
tific publications and popular media has become more nuanced. However, pregnancy 
is still featured on the mandatory warning labels introduced in the US in 1988. While 
there is no mandatory labelling in effect in the EU, some EU countries do have national 
regulations, for example, mandating a pregnancy warning on alcoholic beverage con-
tainers (i.e. France).  
Social and policy responses towards the issue of heavy drinking during pregnancy seem 
to differ between countries, with some states and countries taking punitive measures, 
and others implementing more supportive laws and measures. Drabble et. al. (2011) 
[32] noted that fear of stigmatization, and the consequent creation of a threshold to 
care and intervention, is a reason to implement more supportive measures. Discussion 
on whether to caution all pregnant women to refrain from any alcohol intake remains 
an issue for debate in many countries. Although evidence is not unequivocal, most 
countries have decided ‘rationally’ to err on the side of caution  in suggesting total 
abstinence, while others have provided conditional advice [33].  
In the Netherlands, increasing attention has been given to children born to pregnant 
women who are addicted to substances or use them excessively [34], and suggestions 
have been put forward to adapt the rules concerning coercive treatment and the fetal 
age at which legal intervention is possible [35,36]. There has also been a noticeable shift 
in public health policy in the Netherlands. The conclusion of a study among women in the 
province of Drenthe in 1987 was that a specific public health campaign aimed at preg-
nant women would not be effective due to low consumption in the target group [37]. 
The recent advice provided by the Dutch Health Council - which promotes abstention - is 
indicative of a change in the conception of prenatal risks, although, as in 1987, one third 
of pregnant women still consumes alcohol, albeit in limited quantities. The Dutch Health 
Council reported that 80% of women of childbearing age indicated that they use alcohol 
(2005) [38]. In the Netherlands, the department of TNO child health (Lanting et al., 
2015), among other organizations, have published data about alcohol consumption dur-
ing pregnancy (see also paragraph 2.7: risk behaviors) [39,40]. Within the current ZonMw 
program ‘Zwangerschap en Geboorte’ (Pregnancy and Birth) [41], some of the projects 
collect new data on alcohol consumption among pregnant women (see also paragraph 
2.5: maternity care). Figure 2 presents an overview of current alcohol consumption esti-
mates (worldwide, Europe, and the Netherlands) among (pregnant) women.  
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2.3. Etiology and Pathogenesis 
Current knowledge regarding molecular pathways 
The mechanism of the teratogenic effects of prenatal alcohol exposure is not well 
understood yet. This section describes the current pathophysiological understanding of 
Fetal Alcohol Spectrum Disorders (FASD) and possible pathways for treatment.  
Alcohol (specifically ethanol, EtOH) is metabolized in two major ways [44]: by ADH 
(alcohol dehydrogenase) and by the CYP2E1 (cytochrome P450 2E1) pathway. ADH is a 
cellular enzyme which is responsible for about 90% of EtOH clearance. CYP2E1 is locat-
ed in the liver and brain and is responsible for about 10% of clearance, unless the EtOH 
concentration rises. ADH (KM = 4.5 mg/dl) is saturated much earlier than CYP2E1 (KM 
= 74 mg/dl). In the human fetus, CYP2E1 is active from week 16, while ADH is only 
active from week 26; both have much lower enzyme levels and activity than in adults 
[45]. Due to accumulation and lower clearance in the fetus (or embryo), alcohol con-
centrations are higher and longer lasting in the fetal environment.  
EtOH and its catabolite acetaldehyde are toxic themselves, but the major damage 
pathway is increasing oxidative stress. ADH and CYP2E1 (and to a much lower degree 
catalase [CAT]) catalyze the same reaction from EtOH to acetaldehyde, but CYP2E1 
produces radical oxygen species (ROS) as side products. In an uncontrolled manner, 
ROS oxidize lipids, proteins, and other metabolites, and cause DNA damage (DNA 
damage response pathway). Increased DNA damage triggers apoptosis pathways lead-
ing to neurodegeneration. Serotonergic neurons seem to be especially susceptible to 
EtOH-induced apoptosis [45]. EtOH causes dysregulation of mitochondrial bioenerget-
ics in neuronal cells leading to inhibition of mitochondrial proliferation and differentia-
tion, reduction of mitochondrial volume, and a decrease in activity of respiratory chain 
complexes and ATP synthase, leading to a general generation of ATP reduction, and 
depletion of mitochondrial GSH (reduced glutathione). Furthermore, EtOH itself as well 
as oxidative stress-induced downstream pathways causes changes in DNA methylation 
(mechanism of EtOH inhibiting TET proteins) leading to changes in epigenetic imprint-
ing which may cause changes in brain structure and function. Initial studies indicate 
that these methylation changes are also found in the germ cells (and offspring) of 
EtOH-exposed males [46].  
The cellular pathways involved in clearing ROS (which also arise in the respiratory 
chain and several other normal parts of the metabolism) involve a battery of enzymatic 
and non-enzymatic pathways including SOD, CAT, GPX, (reduced) glutathione, and 
several antioxidant metabolites (e.g. tocopherol, melatonin). Application of antioxi-
dants has been shown to rescue some EtOH toxicity-induced phenotypes in vitro but, 
to date, the in vivo application trials have not been as successful, possibly due to the 
bioavailability at the point of need (see treatment). 
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The developing brain is especially in danger of damage due to elevated ROS levels. 
First, it has the highest oxygen metabolic rate of all body tissues. Second, it is rich in 
unsaturated fatty acids and autoxidable neurotransmitters which are substrates for 
ROS [47]. Third, the reaction with ROS generates superoxide, quinones and semiqui-
nones, which are again highly reactive radicals. Fourth, the levels of antioxidant en-
zymes are lower in the brain than in other tissues (SOD, CAT, GPx). Finally, fetal cells 
are more in danger than adult ones because of a lower level of enzymes in general. 
The downstream effects of increased oxidative stress are different depending on indi-
vidual exposure and disposition (Figure 3). A decrease in cell proliferation and cell 
survival (due to increased apoptosis) has been observed, as well as effects on homeo-
stasis in general (e.g. via the FOXO pathway [48]), effects on neurogenesis and neu-
ronal migration, dysregulation of gliogenesis, alterations in gene expression and DNA 
methylation leading to changed levels of growth factors, cell adhesion molecules and 
neurotransmitter system. These are mainly pathways which coordinate growth, struc-
ture and function of the central nervous system, but other organs (for example the 
heart or immune system) can also be impaired (Figure 4).  
 
Figure 3 Factors Influencing FASD Outcomes. Individual Disposition and Environmental Factors Trigger the 
Biomolecular Mechanisms That Lead to Disease Development. Biomarkers Are Possible in Any or the Mo-
lecular Data Domains   
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Figure 4 Known Biological Processes/Molecular Pathways, Genes and Metabolites in EtOH Downstream 
Effects Leading to Adverse Developmental Outcomes Known as FASD 
Treatment 
As oxidative stress is the major pathway involved in EtOH toxicity in FASD, antioxidants 
would be the logical treatment of choice. There have been several studies demonstrat-
ing the successful rescue of EtOH-induced damaged phenotypes in vitro and in vivo 
animal models using Vitamins C and E, folic acid, glutamine, boric acid, choline, and 
selenium. Unfortunately, such treatments have shown no significant effects when used 
in humans [45]. Generally, the use of antioxidants to treat oxidative stress-related 
diseases is highly questionable, as the most reliable reviews indicate a lack of effect 
(e.g., in relation to gastro-intestinal cancer [49], age-related cataracts [50], or liver 
diseases [51]). 
As EtOH is known to interfere with several biological pathways, e.g. the cholesterol-
SHH pathway, experiments have been carried out in zebrafish, demonstrating that 
supplementation with cholesterol can rescue the phenotype [52] (Figure 4). DHM, a 
GABA receptor antagonist, has been shown to neutralize EtOH effects on GABA recep-
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tor pathways and has some protective effects in rats [45]. Neuroprotective peptides 
and neurotrophic growth factors have also been also investigated in vitro with some 
success [45].  
Chokroborty-Hoque et al. [53] have stated that brain development goes on after birth 
(and ends at adolescence), so there is time and possibility for improvement. These 
researchers have proposed that antipsychotic drugs (which include antidepressants or 
stimulants) could be used to treat intellectual disabilities including psychosis via 
changes in DNA methylation (and post-natal enrichment) associated with FASD.  
Knowledge gaps 
In short, the main gaps in knowledge in relation to FASD include that there is no clear 
pathophysiological understanding of these disorders, no cure, no safe dose for EtOH 
intake during pregnancy, and, as yet, no reliable biomarker for FASD detection and 
estimation of susceptibility (Figure 3). Currently, research on FASD includes too many 
factors that overlap and confound the results to allow any clear conclusions to be 
drawn. These factors include the following: 
● EtOH intake: amount and timing, drinking behavior (binge or events) 
● Genetic predisposition: alleles of ADH, CYP2E1 etc. 
● Epigenetic predisposition and modifications 
● Maternal body profile: age, weight 
● Nutrition and lifestyle: amount of antioxidants, fatty acids, iron, exercise 
● Drugs: medication 
● Comorbidities which involve oxidative stress: cardiovascular diseases, atherosclero-
sis, cancer, diabetes, neurodegenerative diseases including Parkinson’s disease and 
Alzheimer’s disease, toxicity of heavy metals, radiation injury, vitamin deficiency, 
inflammation (bacterial or viral infection, autoinflammatory processes) [54]. 
In terms of elucidating the pathology, biomarkers and treatment options associated 
with FASD,   the lack of clinical evidence available points to the need for further re-
search. Animal studies give valuable insight into the mechanisms but are not fully 
translatable to humans.  
Recommendations 
We recommend that continuing research should be devoted to five key areas.  Below, 
each area is briefly described. Any gaps in current knowledge and opportunities for 
more research are highlighted. 
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1. Genomic data - genetic variation creates different susceptibility for FASD. The ge-
netic background of FASD susceptibility is not yet fully understood but there are 
hints that different varieties of ADH, CYP and taste receptors play a role. For exam-
ple, GWAS studies have not yet been carried out on FASD. 
2. Epigenetic data - There is some evidence that (1) epigenetic processes are involved 
in disorder development and progression, as ethanol influences DNA methylation 
processes and (2) epigenetic changes due to ethanol influences in parents play a 
role in embryonic development and might be inherited in the following generation. 
However, the mechanisms underlying these effects are not yet fully understood. 
There are drugs available which influence DNA methylation events - do they have 
potential to restore FASD imprinting?  
3. Gene expression data - transcriptomics and proteomics change as direct down-
stream effects of ethanol. There have been initial reports mentioning that gene ex-
pression profiles are significantly changed, and one meta-study has even indicated 
systemic downregulation of gene expression. Yet there are still several unanswered 
questions: is this general downregulation of gene expression reversible? Can it be 
influenced by drugs? Which gene expression profiles could be used as biomarkers, 
in particular to detect the effects of low and medium EtOH intake? And what fur-
ther insight into the mechanisms of EtOH induced pathology can be obtained from 
gene expression profiles? 
4. Metabolomics data – Areas of interest include: (1) metabolites of ethanol metabo-
lism and (2) metabolites of ethanol-induced pathology. Due to their easy availabil-
ity in body fluids, meconium or hair, analyzing metabolites may be a highly interest-
ing way of yielding biomarkers not only for EtOH consumption behavior but also for 
early FASD detection. As single metabolites tend to fail in the detection of 
low/medium EtOH intake, especially long after after EtOH intake, multi-metabolite 
(or metabolomics) profiles could provide higher sensitivity and specificity. Another 
open question concerning EtOH metabolism is whether there are reactive nitrogen 
species involved in the generation of oxidative stress. Furthermore, it is unknown 
whether any of these biomarkers could be used for diagnosis. And if so, for whom, 
and when? 
5. Linked Data - Linked data and especially FAIR data (Findable, Accessible, Interoper-
able, Reusable) [55] is especially useful for fields of research where little primary 
data is available, as in the case of rare disorders. Collecting and combining data 
from different sources, and then re-analyzing these can all add value to data pro-
vided by smaller individual studies [56]. For FASD-related data, there is currently no 
public database, but there are several local (clinical) databases which could provide 
a starting point.  
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2.4.  Biomarkers For Alcohol Use 
Current knowledge 
Bearer and colleagues (2004) [57] among others, have discussed different biological 
samples in which biomarkers indicating prenatal alcohol exposures can be measured. 
These include maternal samples (urine, hair, blood, breath, saliva, gasses acquired 
through a skin patch, breast milk), fetal samples (blood, chorionic villus, amniotic flu-
id), and newborn samples (cord blood, placenta, umbilical cord, amniotic fluid, urine, 
hair, breath, saliva, vermix, gasses acquired through a skin patch, meconium). Ad-
vantages and disadvantages of each of the biomarkers are discussed.  
Chabenne and colleagues (2014) [58] divide FAS biomarkers into eight major types: (1) 
clinical biomarkers; (2) molecular biomarkers; (3) omic biomarkers; (4) imaging bi-
omarkers; (5) meconium biomarkers; (6) cord blood biomarkers; (7) anatomical bi-
omarkers; and (8) neurobehavioral biomarkers.    
In the Netherlands, Wassenaar and colleagues (2016) [59] point out the importance of 
using relevant biomarkers to detect alcohol consumption during pregnancy. 
The assessment of alcohol abstinence and alcohol use in pregnant women remains a 
major diagnostic challenge. On the whole, health care workers have to rely on the 
information provided by the mother and family and on psychometric tests. However, 
these methods might be unreliable due to the social stigma associated with alcohol 
use in pregnancy, leading to substantial maternal under-reporting. Therefore, sensitive 
and specific biomarkers of alcohol use could help to identify women at risk of having a 
child with fetal alcohol spectrum disorder (FASD). This would allow health care workers 
to apply risk reduction interventions to prevent - or at least minimize - the harmful 
effects of alcohol use during pregnancy in the newborn. Moreover, biomarkers may 
facilitate the diagnosis of FASD, which is not always straightforward due to the varying 
clinical presentation of FASD in newborns and children. Currently, several biomarkers 
have been studied for the detection of maternal alcohol exposure. When choosing 
which biomarker to use, several factors should be taken into account, including 
whether one wants to identify short-term vs. long-term alcohol use, the magnitude 
and timing of alcohol use to be identified and the desired sensitivity and specificity of 
the marker. In the following paragraph, we briefly describe currently available bi-
omarkers.  
Direct measurement of alcohol in blood, exhaled air or urine is considered the gold 
standard for the detection of alcohol use. However, the diagnostic yield of these tests 
is limited by the short half-life of alcohol (only a few hours). Indirect markers such as 
liver tests (including gamma-glutamyltransferase) and mean corpuscular volume can 
be chosen in cases involving chronic excessive alcohol use, but these methods lack 
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acceptable sensitivity and specificity. Carbohydrate deficient transferrin (CDT) is an 
iron transporter protein that can be detected in serum to assess moderate to excessive 
alcohol use in the 2-4 weeks prior to measurement. Improvements in analytical tech-
niques to quantify serum CDT levels may have increased its diagnostic accuracy. How-
ever, its specificity remains suboptimal, and its use in pregnancy is still controversial 
because of the concern that CDT can be affected by a number of maternal conditions 
such as advanced gestational age, iron deficiency, and hypertension. 
Direct alcohol metabolites, including ethyl glucuronide (EtG), ethyl sulfate (EtS), fatty 
acid ethyl esters (FAEEs) and phosphatidylethanol (PEth) are highly specific and, in 
general, have a wider time window of detection than alcohol itself (Figure 5).  
 
Figure 5 Temporal Window of Biomarker Detectability vs. Lowest Detectable Level of Alcohol Consumption. 
EtS: Ethyl Sulfate, EtG: Ethyl Glucuronide, % CDT: Carbohydrate-Deficient Transferrin, PEth: Phosphatidyleth-
anol, MCV: Mean Corpuscular Volume, GGT: Gamma-Glutamyltranspeptidase, FAEE: Fatty Acid Ethyl Esters. 
*the Definition of Low and Moderate Drinking in Pregnant Women Varies Greatly Among Studies. Source: 
Bakhireva & Savage (2011) [60] 
 
In recent years, EtG has gained attention as an acceptable biomarker of alcohol con-
sumption, mainly in the forensic literature. EtG is the product of the glucuronization of 
alcohol in the hepatocyte, and can be detected in blood (with only a short half-life of 
several hours), urine, hair and meconium. Urinary EtG has been described as a highly 
sensitive biomarker for the detection of alcohol use, but only provides information on 
alcohol use in the previous 48 to 72 hours, and may be positive after accidental con-
sumption of foods containing alcohol. EtG in scalp hair (hEtG) is a highly sensitive and 
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specific biomarker for the detection of chronic and excessive alcohol use. The hEtG 
concentration in the proximal 3 cm hair length correlates with the consumed amount 
of alcohol over the last 3 months in both alcohol-dependent and healthy individuals. 
With this large diagnostic window, hEtG would be an ideal biomarker to accurately 
assess alcohol intake in pregnant women, as compared to biomarkers measured in 
more traditional biological matrices such as blood and urine. However, hEtG allows no 
discrimination between abstinence on the one hand, and occasional or moderate use 
(or even intermittent binge drinking) on the other hand. This is a limitation, as even 
low amounts of alcohol use during pregnancy may lead to FASD. Meconium EtG might 
be more sensitive than hEtG. EtG possibly crosses the placenta and thus EtG in meco-
nium may reflect both fetal and maternal metabolism. EtS is another direct, non-
oxidative product of alcohol metabolism that can be measured in blood, urine, hair, 
and meconium. However, EtG is the more reliable of the two with regard to serum, has 
a longer detection period in urine, is more sensitive in meconium, and is more com-
monly used. 
Fatty acid ethyl esters (FAEE) are produced by the esterification of alcohol with fatty 
acids, triglycerides, lipoproteins and phospholipids, and can be found in meconium, 
hair, and blood. FAEE cannot pass the placenta. Thus, FAEE in the meconium are syn-
thesized by the fetus from alcohol that has crossed the placenta. The formation of 
meconium starts from a gestational age of 12-18 weeks. Therefore, FAEE in the meco-
nium represents the cumulative alcohol use in the second (when the formation of 
meconium starts) and third trimester of the pregnancy. Sensitivity decreases at mod-
erate-to-low levels of alcohol exposure. FAEEs have been detected in meconium from 
infants of women who did not consume alcohol in pregnancy, but at much lower levels 
than among women who did. A disadvantage of the analysis of meconium (this also 
applies to EtG in meconium) is that the test result is only available after pregnancy. 
FAEE can also be detected in hair but this approach is less well validated than hEtG. 
FAEE in blood can show alcohol exposure within 1 or 2 days, depending upon the mag-
nitude of exposure. 
PEth is a unique phospholipid that is only formed by the interaction of alcohol with 
phosphatidylcholine catalyzed by phospholipase D in red blood-cell membranes. It can 
be detected in blood for several weeks following low-to-moderate prenatal alcohol 
consumption.  
Biomarkers used for risk assessment and for the diagnosis of FASD 
It is important to understand the relationship between maternal alcohol exposure and 
susceptibility to developing FASD in the offspring.  Therefore, in addition to biomarkers 
of maternal alcohol use, we need markers to diagnose FASD without recourse to time-
consuming and expensive clinical diagnostic procedures. This latter research area is in 
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its infancy, but some promising results have been published. For example, with regard 
to prenatal diagnosis, a recent report demonstrated that infants who were identified 
as alcohol-affected at birth could be predicted by microRNA (miRNA) profiles in the 
maternal blood as early as the second trimester (3 to 6 months) of pregnancy [61]. 
Other work has focused on the use of second trimester ultrasound for the early detec-
tion of children with FASD [62]. As for diagnosis in early infancy, research has focused 
on phenomena such as cardiac orienting responses [63] and eye-tracking [64]. 
Given the current state of knowledge about the long-term effects of prenatal alcohol 
exposure, it should be possible to identify biomarkers that reflect the physiological 
changes occurring in persons with FASD, even later in childhood or adulthood, such as 
proteins or lipids modified by ROS.  Such biomarkers have been identified in cell lines 
[65], but have not yet been sufficiently studied for application in human studies or in 
the clinic.  
Conclusion and future perspectives 
FASD is caused by prenatal alcohol exposure and is therefore entirely preventable. 
Despite growing research efforts, a gold standard either to confirm long-term absti-
nence or to detect alcohol use is currently lacking. All the above-mentioned methods 
have their limitations, and the reported accuracies of biomarkers of alcohol use vary 
widely across studies. The ideal biomarker would: 1) be able to detect low-to-
moderate levels of drinking over extended periods of time; (2) be able to accurately 
detect drinking that has occurred during pregnancy (i.e., high sensitivity); (3) have a 
low rate of false-positive test results (i.e., high specificity) and (4) require a biological 
sample which can be obtained with minimally invasive methods [60]. Currently, none 
of the available biomarkers fulfill all of these requirements, and current evidence is 
insufficient to support the use of objective measures of prenatal alcohol exposure in 
practice. Before clinical implementation, further validation of the current biomarkers 
(or a combination thereof) is required. More specifically, the use of the proposed cut-
off levels to categorize pregnant women into different drinking groups and the correla-
tion of the test result with the consumed amount of alcohol should be assessed. In 
addition, longitudinal studies should assess the duration of abstinence required for a 
positive test outcome to become negative. This is of major importance for the inter-
pretation of a single test result in order to either detect alcohol relapse or confirm 
sustained abstinence.  
Thus far, biomarkers have not often been used for diagnosis. There is a need to devel-
op biomarkers that can be used for prenatal diagnosis, which would allow for early 
intervention to minimize the long-term effects of prenatal exposure. In addition, it 
should be possible to identify biomarkers of the long-term physiological changes that 
extend into adulthood. 
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In parallel with gaining further insight into the pathophysiology of FASD, research on 
new biomarkers in different sampling matrices is required. Future biomarkers may be 
derived from genomic, transcriptomic, proteomic and metabolomic in-depth analyses 
in pregnant women consuming alcohol. Ideally, we would like to have markers of fetal 
effects, and not just merely of alcohol exposure. It would also be interesting to explore 
the predictive value of alcohol biomarker levels in pregnant women in order to identify 
future adverse neurodevelopmental outcomes in children.  
In conclusion, given the serious consequences of prenatal exposure to alcohol, the 
following types of biomarkers are urgently needed: biomarkers of alcohol consumption 
during pregnancy, biomarkers for diagnosis during the pregnancy or at birth, and bi-
omarkers that could be used for diagnosis later in childhood or adulthood.  
2.5. Genetic Factors and Alcohol Consumption 
Current knowledge 
Identifying genetic determinants of drinking patterns may also help to identify biologi-
cal mechanisms contributing to specific drinking patterns, and to identify women at 
risk of (high) alcohol consumption. Prevention strategies for moderating and stopping 
alcohol consumption in women both before and during pregnancy could target these 
biological mechanisms and could be directed towards individuals at high risk of alcohol 
consumption and abuse due to genetic predisposition. 
Putative genetic underpinnings of drinking patterns include markers of alcohol con-
sumption and dependence identified in genome-wide association studies (GWAS), 
markers of bitter taste perception, and markers of alcohol tolerance. To date, most 
research into the genetics of alcohol consumption has focused on genetic markers of 
alcohol dependence (see the GWAS catalog at www.ebi.ac.uk/gwas/). The maximum 
number drinks consumed in 24 hours is a characteristic that is strongly correlated with 
alcohol consumption and dependence in individuals who drink alcohol, and this char-
acteristic has been shown to be heritable (approximately 50%) [66]. Very few studies 
have investigated markers of alcohol consumption at the lower end of the intake level, 
the moderate consumption level, which is common to many individuals in many socie-
ties. Moderate drinkers are difficult to distinguish from those with alcohol dependence 
in most studies. Variation in the glycosylation of transferrin has been studied exten-
sively because the concentration or proportion of less-glycosylated transferrin, re-
ferred to as carbohydrate-deficient transferrin (CDT), can serve as a biomarker of ex-
cessive alcohol consumption.  The top three SNPs from GWAS associated with CDT 
have been observed in SNPs annotated to the transferrin gene (TF) and the phos-
phoglucomutase-1 gene (PGM1) [67].  In a recent Swedish study[68], two single nucle-
otide polymorphisms (SNPs) in CNTN4 (contactin 4) were replicated in relation to self-
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reported regular alcohol consumption in two observational studies, although a distinc-
tion between regular alcohol consumption and alcohol dependence was not made. 
Since CNTN4 has been linked to olfaction and development of olfactory neurons [69], it 
can be speculated that taste preference for alcohol could act as a mechanism through 
which CNTN4 could influence drinking.  
Genetic markers of bitter taste perception are of interest in relation to bitter-tasting 
alcoholic beverages such as beer and certain types of liquor. Bitter taste perception 
has been attributed to the taste 2 receptor (TAS2R) gene cluster; in particular TAS2R38 
haplotypes have been demonstrated to clearly distinguish between non-tasters, medi-
um-tasters, and super-tasters of bitter taste [70]. Since many naturally occurring toxic 
compounds confer a bitter taste, bitter taste is thought to evoke aversion in humans, 
avoiding ingestion. Thus, non-tasters have been found to consume more alcohol than 
tasters in some studies[71–73], though not all [74,75]. Null findings may be explained 
by the fact that total alcohol intake was investigated in these studies instead of specific 
bitter-tasting alcoholic beverages, such as beer. TAS2R38 non-tasters as compared to 
tasters have been found to be at an increased risk of alcohol-associated diseases such 
as colorectal cancer, [76] but have not been investigated in relation to FASD.  
Genetic markers of alcohol tolerance in the alcohol- and acetaldehyde-dehydrogenase 
(ADH and ALDH) gene family, which is responsible for ethanol metabolism, can severe-
ly diminish an individual’s tolerance to alcohol and thereby determine drinking pat-
terns and risk of FASD. Alcohol metabolism mainly occurs in the liver, where ADH en-
zymes oxidize alcohol (i.e., ethanol) to the toxic acetaldehyde, and ALDH enzymes 
oxidize the acetaldehyde to acetate. Functional studies have been carried out on 
ADH1B and ADH1C gene variants [77]. For ALDH2, two alleles exist, one of which has a 
very low activity, resulting in acetaldehyde accumulation after alcohol consumption; 
this genetic variant is largely absent in most Caucasian individuals [77].  
Knowledge gaps 
Future research should investigate the role of genetic markers of alcohol consumption 
in relation to FASD at lower levels of alcohol intake. 
Recommendations 
There is a paucity of studies investigating the genetic determinants of moderate alco-
hol consumption. The role of genetic markers of alcohol consumption has never been 
investigated specifically in relation to FASD at lower levels of alcohol intake. A Mende-
lian-Randomization approach, using polygenic risk scores[78], could be of use to fur-
ther investigate and understand FASD at lower levels of alcohol intake. Such approach-
es would require studies with large sample sizes [78]. It is likely that this kind of future 
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genotype research will result in a better understanding of an individual’s risk of having 
a child with FASD.   
2.6. Maternity Care  
In terms of maternity care, obstetricians and midwives are important stakeholders. In the 
Netherlands, maternity care is organized within a primary, secondary and tertiary care 
model. Primary care is provided by midwives and general practitioners (GPs). GPs are 
responsible for only about 0.5% of all births, mainly in rural areas with a low population 
density. Other professionals who are active within primary care include mental 
healthcare professionals, maternity care workers, and professionals in ‘neighborhood 
teams’. Secondary care consists of obstetricians and specialized ‘clinical’ midwives in 
general hospitals, and tertiary care comprises obstetricians in academic hospitals [41,79]. 
Important steps that can be taken in order to improve maternal care include reducing 
risk factors such as stress, alcohol, smoking, nutrition, and overweight, and addressing 
their underlying mechanisms [80]. Moreover, in order to make  improvements in terms 
of prevention and care around pregnancy and birth, it is important to strengthen the 
existing knowledge infrastructure and to stimulate multidisciplinary research [41,80].  
In the following sections, maternity care will be described from the perspectives of 
obstetrics, gynecology and midwifery.  
Obstetrics and gynecology 
Current knowledge 
In the Netherlands, the National Scientific Association of Gynecologists (NVOG) moni-
tors the general health of women - in particular their gynecological, obstetric, and 
reproductive health. The association provides patients and their relatives with im-
portant information regarding these areas of health. With respect to alcohol consump-
tion during pregnancy, the NVOG’s advice for their members is based upon infor-
mation provided by the Dutch Health Council [38]. The National Steering Group GGZ 
Netherlands also incorporates this advice in their guidelines on alcohol use and preg-
nancy [81]. The Dutch Health Council recommends that women and their partners 
discontinue alcohol use as soon as they plan a pregnancy. The committee of the Health 
Council formulates it as follows: 
“The Committee’s conclusion is that it is not possible to determine a male and female 
lower limit for alcohol consumption prior to conception from which it could definitely 
be said that there was no effect upon on fertility and pregnancy.” Dutch Health Council, 
2005. [38] 
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“The Committee concludes that every reduction in alcohol consumption leads to a re-
duction in risks. It is not possible to determine a lower limit for alcohol consumption 
from which it can be stated with certainty that there would be no effect on the fetus 
and the pregnancy.” Dutch Health Council, 2005. [38] 
“The conclusion is that it is not possible to indicate a safe lower limit for alcohol con-
sumption during breastfeeding.” Dutch Health Council, 2005. [38] 
In agreement with this 2005 recommendation of the Health Council, in 2007 the com-
mittee advised professionals to discuss the topic of alcohol use [using neutrally formu-
lated questions and in a systematic way] with prospective pregnant women and their 
partners, and to recommend that any alcohol  use is discontinued  as soon as they 
want to fall pregnant [24]. As long as there is no known safe limit, the health council 
advises potential parents not to use alcohol at all.  
In practice, most women only stop using alcohol as soon as a pregnancy test is posi-
tive. This might mean that the woman is already more than 2 weeks pregnant.  
A good example of how to build consensus and develop strategies for improving pre-
conception care is the ZonMw program ‘Zwangerschap en Geboorte’ (‘Pregnancy and 
Birth’) [41]. This program comprises seven projects with a focus on preconception 
care. These projects target expectant parents and are designed to stimulate health 
care professionals to improve preconception care and make parents more aware 
about maintaining a healthy lifestyle (e.g., by not drinking alcohol during the precon-
ception period and during pregnancy). For example, one of these projects, the APRO-
POS Preconception Care project, uses a tailored preconception care approach directed 
towards couples who wish to pursue healthy (pre-) pregnancy behavior (see 
http://www.zwangerwordeninzeist.nl).  
The ZonMw program ‘Pregnancy and Birth’ was designed to improve existing 
knowledge infrastructures for maternity care by encouraging cooperation between 
various professional disciplines involved in maternity care and establishing regional 
consortia. One example of this is the Limburg Obstetric Quality System (LOQS) for 
women experiencing problems in pregnancy) [41].    
Knowledge gaps 
In the Netherlands, there are no reliable data regarding alcohol consumption by preg-
nant women (before and during pregnancy). During initial (intake) interviews with 
pregnant women the gynecologist does not usually pay much attention to the use of 
alcohol; some do not ask the question at all, others believe it is confrontational to ask 
in-depth questions about alcohol intake.  
“Mosos” is a software program designed to maximize best practice in obstetrics. The 
development of Mosos was undertaken in close cooperation with gynecologists, mid-
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wives, universities and government agencies. It is the software program most fre-
quently used by gynecologists. Perined is a Dutch foundation responsible for perinatal 
audit and registration. This foundation consists of four professional organizations 
which work together and are responsible for all aspects of maternal and child health 
care; KNOV (Koninklijke Nederlandse Organisatie van Verloskundigen), LHV (Landelijke 
Huisartsen Vereniging) including GPs who practice midwifery united in the VVAH (De 
Vereniging van Verloskundig Actieve Huisartsen), NVOG (Nederlandse Vereniging voor 
Obstetrie en Gynaecologie), NVK (Nederlandse Vereniging voor Kindergeneeskunde) 
and NVVP (Nederlandse Vereniging voor Pathologie). 
Currently, these software programs do not allow in-depth questions to be asked con-
cerning alcohol use. For instance, Mosos allows the user (under the heading of anam-
neses) to complete questions about alcohol use. However, the physician can only 
choose between four answer options: "no," "unknown," "many," "few: 1 / week". It is 
not possible to differentiate between - for instance - trimesters of pregnancy.  
Recommendations 
We recommend to use the existing infrastructure for maternity care through stimulat-
ing transcend occupations as provided among others in the ZonMw program Pregnan-
cy and Birth [41] and the program “Transitie Geboortezorg” (Program Transition Birth 
Care; https://www.transitiegeboortezorg.nl). 
A system such as “Mosos” can contribute to the monitoring of alcohol use among 
pregnant women. Questions such as “did you consume alcohol prior to conception?”, 
“did you consume alcohol during conception?”, and “how much alcohol did you con-
sume?” could be considered for inclusion. These questions should be asked for pre-
conception and for the first, second, and third trimesters of pregnancy. In addition to 
timing (when), frequency (how often) and amount (how much) should be specified.   
The data collected via “Mosos”, combined with data from in-depth interviews, and 
alongside information regarding the distribution of the sample across the Netherlands, 
gives us some idea about the scope of the problem. 
Midwifery 
Current knowledge 
Midwives in the Netherlands are registered with the Royal Dutch Organization of Mid-
wives (KNOV, Koninklijke Nederlandse Organisatie van Verloskundigen). They are the 
case managers during pregnancy, childbirth and the post-partum period. 
The KNOV, like the NVOG, follows the recommendation of the Dutch Health Council - 
that alcohol should not be  used at all during pregnancy [38].  
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Knowledge gaps 
For midwives (as well as obstetricians and gynecologists), discussing alcohol consump-
tion with their patients appears to be difficult and is not a top priority. Intervention 
programs in which alcohol use during pregnancy is discussed are scarce. Exceptions 
include an e-learning module [82] and a brief health counselling program [83]. 
Recommendations 
Midwives have a prolonged and intensive contact with (future) mothers and are there-
fore important stakeholders. There is a need for further training for midwives with 
regard to screening for alcohol use and the implementation of brief intervention 
measures related to alcohol consumption (where indicated).   
Most higher educated women are able to find and maintain contact with a midwife 
without encountering problems. Missed target groups for receiving midwife care in-
clude women of low socioeconomic status (SES) and individuals with substance abuse 
problems. It is therefore necessary to develop strategies to get in touch with these 
target groups.  
In addition, intervention programs designed to be implemented by midwives should be 
evaluated for their effectiveness.  
2.7. Prevalence of FASD 
Current knowledge 
The first systematic publications mentioning the harmful effects of prenatal alcohol 
exposure comprised a series of case studies of children born to alcoholic mothers pub-
lished in 1968 by Lemoine and colleagues in France. In 1973, Jones and Smit published 
a paper in the Lancet on the same topic. In contrast to the publication by Lemoine et 
al., this paper received international attention [29,30]. Various epidemiological studies 
have been conducted worldwide to estimate the prevalence of FASD. Since FASD is a 
birth defect, using the term ”incidence” is not appropriate [84,85].  
Roozen et al. recently researched worldwide prevalence estimates of FASD in order to 
produce a systematic literature review and meta-analysis [85]. Data revealed that 
prevalence rates were available for only seven countries (see Table 1). Prevalence 
rates were sampled from the general population and from suspected high-prevalence 
subpopulations. Prevalence estimates from suspected high-prevalence subpopulations 
were not included in the meta-analysis, as these rates are biased upwards due to the 
sample selection. Reported prevalence estimates displayed considerable heterogenei-
ty, which was largely explained by country and descent. In meta-analyses per country, 
descent, case ascertainment method, and age range also emerged as moderators. On 
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the basis of the findings of studies that sampled the general population (conducted in 
Australia, Canada, Croatia, Italy, New Zealand, South Africa, and the United States), the 
pooled prevalence rates were particularly high in South Africa for FAS (55.42 per 
1,000), ARND (20.25 per 1,000) and FASD (113.22 per 1,000). For pFAS, high rates were 
found in Croatia (43.01 per 1,000), Italy (36.89 per 1,000), and South Africa (28.29 per 
1,000). In the case of ARBD, a prevalence of 10.82 per 1,000 was found in Australia. 
Recent rates were published in the Lancet by Popova and colleagues [42]. The authors 
estimated global FAS prevalence rates to be 14.6 per 10,000 livebirths and FAS preva-
lence rates in Europe to be 37.4 per 10,000 livebirths. These figures should, however, 
be interpreted with caution, given the limitations of the study. For the Netherlands, 
there are no FASD prevalence data available. 
 
Table 1 Meta-Regressions for Global and Local FASD Prevalence Estimates 
 FAS  pFAS  ARND  ARBD  FASD  
Global 
prevalence 
2.89k=94 
[0 to 39.65] 
11.22k=17 
[0 to 76.12] 
5.19K=6 
[0 to 54.2] 
3.52k=5 
[0 to 17.81] 
22.77k=13 
[0 to 176.77] 
Local prevalence      
Australia 1.33k=11,  
[0 to 37.61] 
0.8k=3, 
[0 to 6.3] 
0.12k=2, 
[0 to 1.76] 
10.82k=1,  
[[8.05 to 13.99]] 
1.06k=6,  
[0 to 10.05] 
Canada 37.19k=3,  
[0 to 398.08] 
   30.52k=2,  
[23.81 to 38.04] 
Croatia 11.73 k=2,  
[1.23 to 31.26] 
43.01k=2,  
[25.41 to 64.85] 
   
Italy 8.2k=1,  
[[3.35 to 14.99]] 
36.89k=1,  
[[25.9 to 49.69]] 
1.03k=1,  
[[0 to 4.4]] 
1.03k=1,  
[[0 to 4.4]] 
47.13k=1,  
[[34.66 to 61.38]] 
New Zealand 0.11k=1,  
[[0.08 to 0.13]] 
    
South Africa 55.42 k=8,  
[18.42 to 110.38] 
28.29k=5,  
[0 to 108.22] 
20.25k=2,  
[0 to 148.23] 
 113.22k=3,  
[7.04 to 319.21] 
United States 0.67k=68,  
[0 to 5.44] 
2.22k=6,  
[0 to 17.09] 
9.07k=1,  
[[4.73 to 14.73]] 
2.58k=3,  
[0 to 15.79] 
33.5k=1,  
[[24.76 to 43.48]] 
Source: Roozen et al. (2016) [85]. Note. This table represents global FASD prevalence estimates including the 
associated prediction intervals followed by local FASD prevalence estimates whereby k is the number of 
samples. Double brackets signify confidence intervals (as opposed to prediction intervals). 
 
Knowledge gaps 
There is currently no reliable means of estimating the prevalence rates of FASD in most 
countries, including the Netherlands. Surveillance studies of FASD using multiple 
sources are not available for the Netherlands. Moreover, hardly any cases of children 
with FASD are reported to the Dutch Surveillance Center for Pediatricians (NSCK), alt-
hough there are studies available in the Netherlands about FASD cases. In 2012, the 
NSCK published a report consisting of an overview of problems identified over the past 
20 years by pediatricians [87]. This report included a limited number of cases involving 
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the suspicion of FAS or pFAS. The diagnoses were, for most of these cases, requested 
by adoptive or foster parents. Abdelmalik and colleagues (2013) studied a cohort of 27 
children suspected of having FASD, who were referred to the Academic Medical Center 
(AMC) in Amsterdam [88]. When FASD diagnostic guidelines (e.g., 4-Digit, IOM guide-
lines, see paragraph 3.2) were applied, 11 out of 27 patients received a FASD diagnosis. 
Swelheim, Flapper, and Van Balkom  summarized data collected from the FASD outpa-
tient center in Groningen, the Netherlands, between 2009 and 2012 [89]. During this 
period, 151 children were registered at the FASD clinic. Most of these children were 
referred by Youth Healthcare Centers. Using the 4-Digit guidelines, FASD was diag-
nosed in 112 of these children (57 mild FAS, 55 pFAS).  
In the Netherlands, FASD is flagged by professionals working in different disciplines 
(including pediatrics, genetics, and child psychiatry), and sometimes by those working 
in specialized FASD outpatient clinics. As cases are not recorded via a structured sur-
veillance system, there is no reliable evidence available on FASD prevalence in the 
Netherlands. There is, therefore, a need to better understand the current scope of the 
problem in the Netherlands.  
Recommendations 
Further epidemiological research is needed in order to establish prevalence rates. This 
research should include active case ascertainment (whereby researchers collect data in 
the field e.g., at schools); passive surveillance (whereby researchers inspect existing 
records); and clinic-based surveillance (whereby researchers examine consenting 
mother-newborn dyads following childbirth) [85]. Prevalence estimates can be calcu-
lated from the number of existing cases at a given point in time using equation 3 pro-
vided by Mason and colleagues : prevalence = 103 multiplied by the number of cases 
divided by the total number of live births [84,85].  
It is important to determine populations at risk and to use uniform diagnostic criteria 
for diagnosing FASD. The same recommendations for calculating prevalence rates as 
published in the 2016 British Medical Association (BMA) report for the UK [15] can also 
be followed in the Netherlands. The World Health Organization (WHO) is currently 
planning prevalence studies in several countries across Europe, Asia, Africa, and North 
America, which should lead to more global data about the frequency of this continuum 
of disabilities becoming available [14]. For the Netherlands, there is a need for reliable 
national FASD prevalence estimates to be established. We recommend exploring the 
possibilities of collecting data from existing databases (e.g., Perined, NSCK, NVK for 
pediatricians).   
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2.8. Risk Behaviors 
Current knowledge  
In order to develop health promoting programs aimed at reducing alcohol consump-
tion during pregnancy, it is necessary to identify which specific prenatal alcohol drink-
ing behavior(s) are most in need of intervention. 
Roozen et al. [90] conducted the first systematic literature review summarizing availa-
ble data from studies reporting maternal alcohol drinking behaviors related to FASD 
(see Table A1 in the Appendix). The majority of the studies (n = 20) were based on 
retrospective self-reports or interviews with mothers of children diagnosed within the 
spectrum of FASD. Studies used both objective measures (numerical datatypes) and 
subjective measures (dichotomous and ordinal datatypes). Variables of maternal drink-
ing behavior displayed substantial variation which precluded further aggregation and 
meta-analysis. Please refer to Table 2 for examples of variables and of how studies 
reported maternal alcohol drinking behaviors using dichotomous (e.g., alcohol con-
sumption yes or no), nominal (e.g., alcohol consumption admitted, negative, unan-
swered), ordinal (e.g., <4 drinks, >4 drinks), or continuous data type (e.g., number of 
drinks in mg, g, or oz) measures.  
Based on the available studies, substantial heterogeneity in the methods used to 
measure alcohol consumption was observed and precludes further conclusions being 
drawn about the relationship between maternal alcohol consumption and the likeli-
hood of infants developing FASD. One of the reasons for this heterogeneity is that 
none of the studies included in the analysis was conducted primarily to investigate the 
association between maternal drinking behavior and FASD. Although both variables 
were frequently measured and reported, most studies were designed to determine 
prevalence or FASD symptoms.  
Table 3 shows the percentages of women in the Netherlands consuming alcohol during 
their pregnancy. Further details on specific maternal alcohol drinking behaviors (e.g., 
drinking patterns before pregnancy, frequency of occasions when alcohol is consumed, 
and amount of alcohol per occasion), as well as data on educational attainment, are 
available for the following studies: Jentink and colleagues (2011) [91], Lanting and 
colleagues (2015) [40], and Lanting and colleagues (2015) [39].  
  
Primary Prevention 
39 
Table 2 Examples of how Variables on Maternal Alcohol Drinking Behaviors are Reported in Different Studies 
Measurement levels Variables 
Dichotomous Before pregnancy 
• Drank alcohol before pregnancy (yes/no) 
• Abstained from alcohol (yes/no) 
• Drank low amounts of alcohol (yes/no) 
• Drank moderate amounts of alcohol (yes/no) 
During pregnancy 
• Alcoholism (yes/ no) 
• Binge drinking (yes/no) 
• Binge drank 3 or more drinks per occasion (yes/no) 
• Binge drank 5 or more drinks per occasion (yes/no) 
• Drank alcohol during pregnancy (yes/no) 
1st trimester pregnancy 
• Drank alcohol during first trimester pregnancy (yes/no) 
• Abstained from alcohol (yes/no) 
• Drank low amounts of alcohol (yes/no) 
• Drank moderate amounts of alcohol (yes/no) 
2nd trimester pregnancy 
• Drank alcohol during second trimester pregnancy (yes/no) 
• Abstained from alcohol (yes/no) 
• Drank low amounts of alcohol (yes/no) 
• Drank moderate amounts of alcohol (yes/no) 
3rd trimester pregnancy 
• Drank alcohol during third trimester pregnancy (yes/no) 
• Drank alcohol during late pregnancy (yes/no) 
Nominal During pregnancy 
• Drank alcohol during pregnancy (admitted, negative, unanswered) 
Ordinal Before pregnancy 
• Drinking: abstinent (0 g/week), mild (0-20 g/week), moderate (20-80 g/week), 
heavy (>80 g/week) 
• Drank about the same compared to current use, drank less, drank more, did not 
drink, stopped during this period, drank during index pregnancy 
During pregnancy  
• Drinks during one sitting (<4 drinks, >4 drinks) 
• Number of drinking days per week (<7 days, >7 days) 
• Drinking: abstinent (0 g/week), mild (0-20 g/week), moderate (20-80 g/week), 
heavy (>80 g/week) 
• Drinks per week (0, 1-3, 4-6, 7-12, 13-20, 21-98, >98, unknown) 
1st trimester pregnancy  
• Drinking: abstinent, low (<70g and on one day no more than 2 standard drinks), 
moderate (<70g alcohol per week and 21 to 49g per occasion), moderate and binge 
drank less than weekly, heavy and binge drank 1 or 2 times a week, heavy and binge 
drank >2 times a week, heavy (<50g per occasion so no binge drinking, 70.1-140.0g a 
week), very heavy (<50g per occasion so no binge drinking, > 140.1g a week) 
• Drank about the same as compared to current use, drank less, drank more, did 
not drink, stopped during this period, drank during index pregnancy 
2nd trimester pregnancy 
• Drank about the same compared to current use, drank less, drank more, did not 
drink, stopped during this period, drank during index pregnancy 
3rd trimester pregnancy 
• Drank about the same as compared to current use, drank less, drank more, did 
not drink, stopped during this period, drank during index pregnancy 
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Measurement levels Variables 
Continuous Before pregnancy 
• Number of drinks per day  
• Number of drinks per week 
During pregnancy 
• Number of drinks per week 
• Number of drinks during a drinking day 
• Number of drinks Monday-Thursday 
• Number of drinking days per week 
• Alcohol consumption  
• Alcohol consumption during an occasion  
1st trimester pregnancy  
• Number of drinks  
• Peak estimated Blood Alcohol Content (BAC; mean, SD) 
2nd trimester pregnancy 
• Number of drinks  
• Peak estimated BAC (mean, SD) 
3rd trimester pregnancy 
• Number of drinks  
• Peak estimated BAC (mean, SD) 
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Knowledge gaps 
Current knowledge on maternal alcohol drinking behaviors in relation to FASD is lim-
ited. Behaviors have been measured using various techniques that have been opera-
tionalized in different ways. In order to develop evidence-based preventive measures, 
it is necessary to identify which prenatal alcohol drinking behavior(s) are most in need 
of intervention.  
Most of the available studies were based on retrospective sampling methods. Often, 
data was obtained years after the child was born, risking biased recall of alcohol con-
sumption patterns during pregnancy. Some studies used prospective sampling (e.g., 
Elliot et al., 2013) [103]. However, these studies were often designed to monitor the 
frequency of FASD and did not include variables on maternal alcohol drinking behav-
iors related to FASD.  
In addition to these methodological shortcomings, none of the studies included in this 
review reported paternal drinking patterns or grandparental drinking patterns. The 
role of paternal drinking and transgenerational toxicity on fetal development and FASD 
is not well understood. A recent review study by Gupta and colleagues [45] reported 
that paternal alcoholism alters the gene expression for fetal susceptibility to FAS. An-
other review by Resendiz and colleagues (2013) [104] suggests a possible role of 
transgenerational toxicity in FASD etiology. Moreover, it has been shown that the 
impact of paternal drinking via social facilitation is significantly associated with mater-
nal drinking [105]. The origin of FASD is therefore not only based on maternal drinking 
behaviors; many other factors play an important role (e.g., genetic and epigenetic 
predisposition, maternal body makeup, body mass index, and lifestyle). Gupta and 
colleagues (2016) [45] have emphasized that FAS, along with other diagnosis within 
the FASD spectrum, is based on a complex interaction of different factors, meaning 
that cautious interpretation regarding etiology is warranted  [45]. 
Recommendations 
Further research on maternal alcohol drinking behaviors in relation to FASD is needed.  
For these studies, it is importance to pay close attention to the measurement of alco-
hol consumption patterns.  
First, researchers should anticipate the need to aggregate their measures of alcohol 
consumption with measures from other studies: in other words, conversion to con-
sumption in metric units, such as grams of alcohol, in a specified time period such as 
week or month, should be possible. If such conversion cannot be performed, the study 
cannot contribute to an accumulation of evidence. This recommendation translates 
into a number of specific suggestions. Most of these are covered by following guide-
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lines for the measurement of alcohol consumption, such as those provided by Dawson 
(2003) [106] and Sobell and Sobell (1995) [107], but specifically, it is recommended 
that future studies assessing specific maternal drinking behaviors should, at the very 
least, report the following: (i) maternal characteristics (e.g., age), (ii) sample method, 
(iii) method used for maternal alcohol consumption assessment, (iv) timing of expo-
sure (e.g., in which trimester), (v) frequency of exposure (e.g., number of exposure 
sessions per week or month), (vi) amount of alcohol consumed per exposure session, 
(vii) sample size including denominator, (viii) definition of one standard drink, (ix) 
quantification of alcohol measure (e.g., oz, g). Researchers should try to avoid discon-
tinuous (categorical) measures, but if these are unavoidable, (x) the employed cut-offs 
must be clearly justified. Ideally, however, researchers would avoid self-report 
measures and instead use objective measures such as biomarkers collected by hair 
samples [58].  
The second recommendation involves the inclusion of matched control groups based 
on maternal characteristics (e.g., age). When the control group is not matched, but, for 
example, all mothers with children who do not suffer from FASD are used, any associa-
tions that may be found between alcohol consumption and FASD are more likely to be 
confounded. For example, maternal age is positively associated to birth defects, and 
mothers from different social economic background may have different behavior pat-
terns that also impact the likelihood of birth defects. 
The third recommendation involves choosing an appropriate research design. Until 
now, most studies have used retrospective sampling methods. Often, data was ob-
tained years after the child was born, risking biased recall of alcohol consumption 
patterns during pregnancy. 
Fourth, maternal drinking is based upon a complex interaction of different factors - 
including genetic and epigenetic predisposition. Studies should not only focus on the 
role of maternal drinking but also on other factors such as, for instance, the role of 
paternal drinking and transgenerational toxicity on the development of FASD.   
In short, the ideal design would comprise a large-scale prospective study in which ma-
ternal factors along with other factors influencing alcohol consumption would be as-
sessed using both self-reports and objective measures (see also paragraph 2.3). Indi-
viduals would then be assessed for FASD as soon as possible and given an accurate 
diagnosis. Moreover, FASD prevalence would be assessed in relation to the alcohol 
consumption patterns of both parents separately and in conjunction. This design 
would also enable examination of potential confounding variables such as social eco-
nomic status or age. Such an ideal design may not always be feasible. However, even 
when other designs are utilized, it is important that researchers anticipate the aggre-
gation of data across studies, and therefore attempt to measure alcohol use in metric 
units. 
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Recommendations regarding advice (guidelines for behavior) 
Some influential reports, for instance in the UK the BMA report published in 2016 and 
in the Netherlands the report published by the national Health Council in 2015 [108], 
advise women who are pregnant - or who may become pregnant - not to drink alcohol. 
So, abstinence is the recommended advice. This was formulated by the BMA 2016 as:  
“There is no proven safe amount of alcohol that you can drink during pregnancy. It is 
also often difficult to work out just how much you are drinking, especially if you have a 
drink at home. The only way to be certain that your baby is not harmed by alcohol is 
not to drink at all during pregnancy or while breastfeeding” (p. 68) [15]. 
and in the Dutch Health Council report 2015 as:  
“Voor vrouwen die zwanger willen worden, zwanger zijn of borstvoeding geven, luidt 
de aanbeveling om geen alcohol te gebruiken” (p. 59) [108].  
Although the evidence regarding the negative effects of light drinking through to heavy 
drinking is conflicting and inconclusive (also in terms of drinking patterns and timing of 
exposure), different recommendations have been published by the WHO, the British 
Medical Association, and the Dutch Health Council. According to the WHO (2016), 
there is, despite individual vulnerability, no amount of alcohol which women can safely 
drink during pregnancy [43]. According to the BMA (2016), there are three different 
recommendations made by different UK national institutes [109]. First, the National 
Institute for Health and Care Excellence (2014) recommends women not to consume 
any alcohol during the first three months of pregnancy (because there may be an in-
creased risk of miscarriage), and that if women choose to drink alcohol during preg-
nancy they should be advised to drink no more than one to two UK units once or twice 
a week [109]. Second, the Royal College of Obstetricians and Gynecologists (2015) 
advises women not to consume alcohol during pregnancy or while breastfeeding [109]. 
Third, the Department of Health, Social Services and Public Safety (2016) also recom-
mends that women do not drink at all while pregnant [109]. The  Dutch Health Council 
(2015) recommends complete abstinence for women who want to become pregnant, 
are pregnant, and women who breastfeed [108].    
In conclusion, there is no known safe amount of alcohol to drink while pregnant and 
there is no new information which states otherwise. Binge drinking is one of the most 
serious risk factors and is associated with severe forms of FASD [110]. Attention must 
be given to women who drink during pregnancy, with special focus on specific risk 
groups such as pregnant women who drink heavily (binge drink). However, such a mes-
sage should not overshadow the key message - not to consume alcohol during preg-
nancy or while breastfeeding. 
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2.9. Psychosocial Determinants of Maternal Drinking Behavior  
Current knowledge 
Theory.  Changing something requires understanding it first. In the case of behavior 
change, it is necessary to understand why people engage (or do not engage) in the 
behavior of interest. These individual reasons, as far as they exist, are commonly con-
ceptualized as ideas, cognitions, emotions, beliefs, processes, or automatic associa-
tions, etc. Behavioral determinants are generic aggregates of beliefs, which are specific 
to behavior, population, and context. It follows from this that we define personal de-
terminants as generic, modifiable psychological variables or regulatory processes that 
are assumed, on the basis of empirical or theoretical evidence, to be causal anteced-
ents of behavior [111].   
Thus, a pregnant woman might believe that consuming alcohol will contribute to the 
enjoyment of the family dinner, or that it will help her cope with stress. She may rea-
son that most of her friends drank a little whilst pregnant and that her health-care 
provider allows her a few drinks per occasion. The first two beliefs are generally 
thought to aggregate into the determinant attitude; the last two beliefs into the de-
terminant social norms. Knowledge and risk perception are aspects of attitude but are 
often measured and reported separately. Beliefs underlying self-efficacy are different 
as they concern confidence, perceived ability and control. For example, a woman may 
feel confident that she can abstain from drinking alcohol and that she can resist offers 
of drinks. Attitudes, social norms and self-efficacy are so-called ‘reasoned’ determi-
nants of behavior (they are not rational: people may have irrational reasons for their 
behavior), and together result in the intention for the behavior. A fourth type of de-
terminant reflects automatic, habitual and impulsive reactions, which are less under 
volitional control and may override reasoned intentions [17].  
This functional aggregation of similar beliefs into determinants has enabled the devel-
opment of theories that can be used to explain a wide variety of behaviors in a wide 
variety of populations and contexts. Behavior change methods attempt to change 
behavior by trying to change determinants. However, as determinants are defined 
generically, they cannot be targeted directly. Instead, behavior change methods target 
specific beliefs, and therefore, for any behavior change method, it must be clear which 
belief(s) are targeted and into which determinant(s) these beliefs aggregate. It is, un-
fortunately, very common in descriptions of behavior change interventions in the sci-
entific literature not to include (or to include only cursory) descriptions of the deter-
minants targeted by the intervention. With no determinants specified, it is impossible 
for a reader to judge whether the theory-based change methods chosen to influence 
behavior are the most appropriate ones [17]. 
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Evidence. Various studies have tried to quantitatively identify determinants of alcohol 
consumption by pregnant women, sometimes measuring dichotomous variables such 
as absolute drinking vs not-drinking, sometimes relative, i.e. amount of drinking. Their 
findings are summarized in Table 4.  
 
Table 4 Psychosocial Determinants of Maternal Drinking (*= reverse effect) 
1. Attitude 
1.1 Knowledge 
No association with: 
x Having heard of FAS [112,113] 
1.2 Risk perception  Alcohol can harm the unborn baby* [113–117] 
• Risk – likelihood* [118], severity* [118] 
• Brain damage* [118] 
• Life-long disabilities for the child* [116]  
• Mental retardation* [112]   
• Alcohol has no effect on the baby [119] 
 Only larger amounts of alcohol will harm the baby  [119,120]  
• Some alcohol is acceptable [121–123]  
• Higher alcohol quantities judged as reasonable  [124]  
• Any drinking is harmful* [119], abstinence is reasonable* [125] 
 It is never too late to stop drinking* [125] 
No association with: 
x Binge drinking is harmful [122] 
1.3 Outcome 
expectations/ 
Attitudinal beliefs 
 
 I should reduce my alcohol intake during pregnancy* [123,126] 
 Pregnant women should not drink* [116,122]  
 Advantages (pros) of not drinking, e.g. baby’s health* [118,127] 
 Disadvantages (cons) of not-drinking, e.g. more stress [118,127]  
• Drinking can help with the pregnancy [120];  
2. Perceived norms 
2.1 Subjective norms 
 Partner norm: important not to drink*[118] 
 Partner support in not drinking* [118] 
 Midwife’s advice not to drink* [118] 
• Not received advice to stop drinking from HCWs or relatives [122,124]  
 People speak about risks more with women who continued drinking [125]  
No association with: 
x Norms of significant others [127] 
2.2 Descriptive norms  Perceived partner modeling: partner does not drink in my presence* [118] 
 Alcohol intake partner [118,123,124]; no association [122]  
3. Self-efficacy/ 
perceived control 
 Self-efficacy: confidence regarding abstaining* [127]; no association [128] 
• Can hold more than four drinks, indicating binge drinking [123] 
 Being sad or discouraged in the last month [123] 
• Could use treatment at current time [123] 
• Abstinence messages made pregnant women feel negative about 
themselves [125] 
No association with: 
x Social self-efficacy, level of difficulty e.g. with friends [118]  
x Stress self-efficacy, level of difficulty e.g. when feeling sad [118] 
4. Automatic, habitual 
& impulsive behavior 
 Higher alcohol frequency before pregnancy [113,117,118,128]  
• Idem, only for smokers, not for non-smokers [127] 
• Idem, only frequency, not amount [117] 
 Greater drinking during previous pregnancy [116,120]  
 Difficulty remembering after drinking, [123];  
 Temptation – cue reactivity [128] 
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5. Intention  I will reduce alcohol intake [126] 
No association with: 
x Binge drinking intention  [126] 
6. Distant determinants  Smoking [124,127], however: smoking* [117]; no association [113,118]   
• Smoked during last pregnancy,  [116] ;  
• Intend to smoke while pregnant,  [116]; 
• Used drugs before pregnancy, [123];  
 Given birth previously [116,121]; no association with first pregnancy [117,118]                                    
• Complications last pregnancy* [118] 
• Previous abortion [123] 
• Lower rate of pregnancy planning [113] 
 Sleep duration* [117] 
 Sexual and physical abuse [123]  
 Education [116–118,128]; however: education* [113] 
• Stopped school <16 [121]  
 Age [118,121], age 30-39 highest [117]; no  association [113,116]  
 Full-time housewife* [123]  
 Married* [123], no association [118] 
 Lowest and highest income [123]; no association [113,118]  
No association with:  
x Employment  [113] 
 
Knowledge and risk perception.  Simply having knowledge about the existence of FAS 
does not influence maternal drinking behavior. Most studies report a negative associa-
tion between perceptions of the risk of maternal drinking for the unborn child and 
actual drinking behavior. However, risk perception beliefs that some alcohol is ac-
ceptable - and only higher amounts of drinking are harmful - are positively associated 
with maternal drinking. The belief that it is never too late to stop drinking is negatively 
associated with maternal drinking.  
Attitudes.  Attitudinal beliefs that pregnant women should not drink or should reduce 
their drinking, as well as recognizing the advantages of not-drinking for the baby’s 
health, are negatively associated with maternal drinking. On the other hand, recogniz-
ing the disadvantages of not-drinking, such as an increase stress, and the belief that 
drinking can help with the pregnancy, are positively related to maternal drinking.  
Social norms.  Expectations and support from the partner for not drinking alcohol are 
negatively related to maternal drinking, as well as recommendations to stop drinking 
from midwives and other health care workers (not all health care workers give this 
advice; some even suggest that “having a glass of wine is actually better for the baby”, 
i.e. Crawford-Williams et al., 2015) [129]. Expectations of others have no clear associa-
tion with maternal drinking, possibly because those expectations are most likely com-
municated when women continue to drink whilst pregnant. The partner not drinking in 
the presence of the woman is negatively associated with maternal drinking. The part-
ner consuming alcohol is repeatedly shown to be positively associated with maternal 
drinking, but not consistently.  
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Self-efficacy.  Results concerning beliefs about self-efficacy for abstaining from alcohol 
consumption are mixed. In one study, beliefs about self-efficacy regarding not drinking 
have been shown to be negatively associated with maternal drinking, but in two other 
studies there was no association. However, women’s beliefs related to being sad, dis-
couraged, in need of help, and feeling negative about themselves, are positively relat-
ed to maternal drinking.   
Automaticity.  Many studies find a positive association between drinking before preg-
nancy and drinking while pregnant; possibly more so for smokers, and only in relation 
to frequency of drinking, not the amount. Drinking during an earlier pregnancy is also 
positively associated with current maternal drinking. Women who have difficulties 
remembering after drinking also drink more often while pregnant. All these findings 
suggest that maternal drinking is partly a habitual behavior. Only one study measured 
cue-reactivity to alcohol as a measure of temptation to drink and showed a positive 
association between cue-reactivity and maternal drinking. This finding suggests that 
maternal drinking is, partly an impulse behavior. The situation is different when the 
mother is dependent on alcohol intake. In such cases, it is recommended that profes-
sional help is offered to address the dependency. 
Intention.  Pregnant women who have the intention to reduce alcohol intake do drink 
less while pregnant. There is no association between intention to binge drink and ma-
ternal drinking, possibly because most women find binge drinking while pregnant un-
acceptable.  
Distant factors.  A number of so-called distant factors have been found to be associat-
ed with maternal drinking. These factors are thought to influence maternal drinking 
through the above-mentioned determinants, but the types of mediation analyses that 
could confirm this were not executed in any of these studies. Maternal drinking was 
often - but not consistently - found to be positively associated with smoking, parity, 
lower rate of pregnancy planning, previous abortion, abuse, and education level. Ma-
ternal drinking was negatively associated with complications during the last pregnancy, 
sleep duration, being a fulltime housewife, and being married. There were no con-
sistent associations between maternal drinking and income or employment.  
Knowledge gaps 
Most of these studies were not specifically designed to systematically identify all rele-
vant determinants of maternal drinking. Moreover, not all of these studies focused on 
abstinence, but rather identified determinants of amounts and frequencies of drinking. 
Ideally, empirically identifying determinants would consist of a combination of first 
qualitative and then quantitative research. However, only two of the studies summa-
rized in Table 2 have combined qualitative and quantitative research methods 
[118,127], and only those two studies applied a theoretical model in order to identify 
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determinants (i.e. the Theory of Reasoned Action and the I-Change Model). In the 
studies summarized in Table 2, respondents could only give answers to the questions 
that were asked. From our theoretical perspective described earlier, it is therefore 
likely that many potentially relevant determinants were not investigated. Most re-
searchers appear to focus on knowledge and risk perception. Attitudes and perceived 
norms receive some attention, while self-efficacy - and especially automaticity of be-
haviors - get very little attention. Some studies discussed determinants such as want-
ing to conceal the pregnancy during the first trimester [126], or dealing with stress 
[130]. Very often, comparisons between pregnant women who drink alcohol and those 
who do not drink were not reported in these studies, even though data were available. 
Also, the specific findings of the qualitative pilot studies were not reported in these 
studies. This means that our current knowledge about determinants is very limited, 
and somewhat biased. 
Recommendations 
Target groups. The abovementioned studies are almost all about pregnant women. 
However, there are other important target groups [131], for instance women with 
unplanned pregnancies, women planning to get pregnant, and breastfeeding women. 
Women do not always plan to get pregnant; in fact alcohol use has been linked to 
sexual risk-taking and unplanned pregnancies [131]. Sedgh et al., (2014) [132] reported 
that 40% of all pregnancies worldwide were unintended, and that more than a quarter 
of all live births are a consequence of unintended pregnancies. Alcohol can disrupt 
fetal development at any stage of pregnancy, including the early stages before a wom-
an knows she is pregnant [133]. Pettigrew et al. (2016) [126] compared the attitudes 
and intentions to reduce alcohol intake of pregnant women with possibly pregnant 
women and not pregnant women. The pregnant women had attitudes and intentions 
that were significantly different from the other groups. These findings suggest a ten-
dency to continue drinking until pregnancy is confirmed. These other important target 
groups, and their environments, need to be included in future studies.  
As mentioned earlier, changing maternal drinking behavior requires understanding it 
first. However, this is a complex issue. There seem to be some differences between 
earlier studies and more recent studies, as well as across countries and between cul-
tures. Only one of the studies mentioned earlier is a Dutch study[118]. Currently, we 
do not have enough evidence to decide which determinants we need to target in order 
to promote healthy non-drinking behavior in pregnant women. We recommend that a 
theory- and evidence-based procedure is followed to identify the determinants of risk 
behaviors related to FASD. 
How, then, to identify what to change in the first place? Ideally, an overview of the 
existing literature would be supplemented with interviews with target population 
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members and possibly key environmental agents (see paragraph 2.10), and the results 
of these two steps would be quantitatively verified so that the relative importance of 
determinants and beliefs can be established. Peters (2014) [111] describes this proce-
dure as very concise and pragmatic but also carefully theory- and evidence-based, 
listing: 1) the basic steps for synthesizing the literature on determinants and beliefs, 2) 
the basic steps for qualitative exploration of determinants and beliefs, and 3) the basic 
steps for quantitative verification of determinants and beliefs.  
2.10. Environmental Conditions 
Current knowledge 
It is very difficult to imagine a health promotion intervention setting that is not em-
bedded in some kind of social or physical system (see Figure 6). The pregnant woman 
lives in an environment with - among others - a partner, relatives, family doctors and 
midwives.  A child with FASD lives in an environment that includes parents, physicians, 
psychologists, and other health and youth care workers. The mother of a child with 
FASD lives in an environment alongside a child with FASD, a partner, relatives, health 
and youth care workers, educators, insurance administrators, etc. - and has to deal 
with challenges such as the extra costs involved in care, public opinion, and stigma. 
However, health promotion interventions often focus on individual behavior change 
and do not address behavior change of environmental decision makers, or agents. As 
outlined earlier, there are good reasons why interventions designed to prevent harm 
caused by alcohol exposure in pregnancy should also target these agents (see para-
graph 2.13). 
Environmental conditions are not likely to be under the direct control of the individual 
at risk for a particular health problem. They are controlled by decision-makers, exter-
nal agents such as health and youth care workers, and other gatekeepers. Such exter-
nal agents exist at various environmental levels: interpersonal, e.g. partner, child, rela-
tives; organizational, e.g. health care, youth care, school; community, e.g. neighbor-
hood, organizations of parents with FASD children; and societal, e.g. alcohol marketing, 
alcohol policies, costs of care [16,17,134,135].  
The first step in developing an intervention for changing environmental conditions is to 
find out who may be in a position to make the expected change. The program planner 
then has to identify the desired behaviors - and their determinants - for the agent, who 
can actually change the environmental condition. The health promoter can then apply 
methods for influencing the determinants of the agent’s behavior, using methods 
which are appropriate for changing determinants at different environmental levels. 
Unfortunately, almost no evidence-based information is available regarding agents, 
agents’ behavior, and determinants thereof. The only available evidence is from stud-
Chapter 2 
52 
ies in which pregnant women reported that their health care workers communicated 
that some alcohol is acceptable, instead of promoting a non-drinking norm. Some 
women were even told that some alcohol is good for the baby [129] or might help with 
the pregnancy. It has also been reported that relatives have suggested that alcohol 
helps, and is good for mother as well as baby [136]. 
Van der Wulp et al. (2013) [137] interviewed Dutch midwives, pregnant women and 
their partners. Pregnant women and their partners considered the midwife to be an 
important and reliable source of information about alcohol in pregnancy. However, the 
level of knowledge in pregnant women found in the study was quite low. The majority 
of the Dutch midwives interviewed reported that they recommended complete absti-
nence. Nevertheless, they did not provide pro-active advice but only gave reactive 
advice (i.e. they only offered advice on this topic when clients admitted alcohol con-
sumption). Most of the interviewed midwives did not systematically screen for antena-
tal alcohol use and their knowledge about the mechanisms and consequences of alco-
hol in pregnancy was limited. The interviewed midwives largely ignored their clients’ 
partners in any advice they provided about alcohol. Moreover, the interviewed part-
ners were dissatisfied with the limited amount of information provided by midwives. In 
general, the partner’s view on alcohol consumption in pregnancy was more liberal 
than that of their pregnant spouse, and this was an issue which they discussed with 
their spouse. The interview data revealed that they would appreciate having access to 
an objective website about alcohol in pregnancy. In particular, pregnant women con-
suming alcohol had received conflicting advice about alcohol from their health profes-
sionals (midwives as well as general practitioners). Apparently, not all Dutch health 
professionals are convinced that complete abstinence yields better pregnancy out-
comes. Frequently, the recommended advice for complete abstinence is combined 
with remarks such as, “you can enjoy a glass of wine every now and then”.  
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Figure 6 Environmental Conditions and Examples of Decision Makers or Stakeholders 
Knowledge gaps  
Who are the relevant agents in the case of FASD? The two main health promotion 
issues are 1) the consumption of alcohol by the pregnant women and 2) the provision 
of care for the mother and child with FASD. The second scenario will be described in 
Chapter 3: Secondary & Tertiary Prevention – Screening, early detection, management, 
and care.  
What are the relevant environmental conditions for maternal alcohol use? To date, no 
systematic empirical evidence exists in relation to environmental influences on alcohol 
consumption by pregnant women; only incidental findings in studies on determinants: 
influence of the norms and behaviors of the partner and of relatives at the interper-
sonal level, and influence of the norms and behaviors of health care workers - especial-
ly midwives, gynecologists and obstetricians - at the organizational level. It is im-
portant to note that both sets of influences may in fact encourage rather than discour-
age alcohol consumption; relatives as well as professionals sometimes claim that alco-
hol might be good for mother and baby. In terms of environmental influences on alco-
hol consumption in general, there is evidence to support the influence of factors at 
both community and policy levels, including: drinking norms and cultures, alcohol 
policies, enforcement of policies, access and availability of alcohol, and marketing and 
pricing [e.g. ,138]. Some of these influences discourage drinking, and some promote 
drinking. On the other hand, there is also evidence for the role of genetics in alcohol 
consumption [e.g. ,139].  





Society: Policies, Marketing
Community: Schools, GP
Organization: Hospital, 
Midwives, CYHC
Interpersonal: Partner, Family
Individual: Person with FASD
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What are the relevant behaviors of the environmental agents? Currently, there is little 
available evidence. At the interpersonal level, partners and relatives of pregnant wom-
en should encourage and support the women to stop drinking and/or stop drinking 
themselves in the presence of a pregnant woman. At the organizational level, family 
doctors, midwives and other relevant health care workers should advise and help the 
pregnant women to stop drinking and to (among other things) deal with the stress of 
pregnancy in other ways than drinking alcohol. Opinion leaders in the community as 
well as decision-makers in policy and marketing should encourage and - if possible - 
enforce a non-drinking norm for pregnant women in society. Essential at all these 
levels, is the persistent misunderstanding that a little alcohol is acceptable; the current 
state of epidemiological evidence does not support this idea. The only safe guideline 
for pregnant women is not to drink at all. 
What are the determinants of these decision-makers’ behaviors? To date, no research 
has been carries out that addresses this question. For partners and relatives, the de-
terminants might be comparable to the determinants that have been reported in rela-
tion to pregnant women: risk perceptions, attitudes, perceived norms, self-efficacy 
beliefs and automaticity of alcohol drinking behaviors. For family doctors, midwives 
and other relevant health care workers, the determinants might include: awareness of 
scientific evidence on causes for FASD, risk perceptions related to FASD, attitudes, 
perceived reactions of the women, (for example, worry about drinking while not know-
ing she was pregnant, or their estimation of the advantages of drinking e.g. stress re-
duction, stigma and autonomy issues), and self-efficacy beliefs related to communi-
cating effectively with pregnant women about not-drinking. For agents at the commu-
nity and policy levels, the determinants might include: acceptance of responsibility for 
policies regarding the promotion of a non-drinking norm for pregnant women and self-
efficacy beliefs regarding the realization of such policies. Essential here is the fact that 
environmental levels are interdependent; agents’ behaviors at one level may influence 
agents’ behaviors at other levels.  Effective policy changes promoting a non-drinking 
norm will facilitate behavior change of health care professionals. 
Recommendations 
Changing maternal drinking behavior requires understanding it first - in this case un-
derstanding the environmental influences on maternal drinking at interpersonal, or-
ganizational, community and policy levels, including the agents that are responsible for 
changing these environmental conditions. We recommend that a theory- and evidence-
based procedure is used to identify the environmental conditions related to maternal 
drinking.  
How to identify environmental conditions and agents? Personal experience, existing 
documents, public consultation, and interviews - starting with obvious stakeholders - 
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can be used to identify environmental agents, or stakeholders, and their interest in the 
health promotion intervention. This process continues until no new actors can be iden-
tified. Kok et al. (2015) [140] has provided a systematic description of this process, 
acknowledging that agents can either be supportive or unsupportive of the non-
drinking message to pregnant women. When health promotors do not have enough 
influence on unsupportive agents, supportive stakeholders can be identified and mobi-
lized (because of their influence on the opposing stakeholders).  
The role of health care workers needs special attention. Communicating a non-drinking 
norm and helping pregnant women to stop drinking should be standard in health care 
provided to pregnant women. Promoting the implementation of good professional 
practices provides a rare example of an intervention targeting environmental condi-
tions [16]. There is an existing body of knowledge on the systematic implementation 
and evaluation of good practices and guidelines by health care professionals [141] that 
can be applied to this setting. 
2.11. Stigma 
Current knowledge 
FASD is highly stigmatized condition [142,143]. Stigmatization is the process by which a 
person is firstly identified as different and then devalued [144,145]. It is a process that 
occurs in social interactions but it is not limited to interpersonal interactions [144]. It 
can also take place on a broader societal level and in the intrapersonal domain. Ac-
cording to Pryor and Reeder [146], there are four types of stigma (see Figure 7). Public 
stigma represents people’s social and psychological reactions to someone they per-
ceive to have a stigmatized condition. It includes the cognitive, affective, and behav-
ioral reactions of those who stigmatize, thus it entails thoughts in the form of stereo-
types, emotional reactions in the form of prejudice, and behavior in the form of dis-
criminatory actions (see also paragraph 2.11). Self-stigma reflects the social and psy-
chological impact of having a stigma, and is something that occurs in those with a 
stigmatized condition. It includes both the anticipation of being stigmatized and the 
potential internalization of the negative beliefs and feelings associated with the stig-
matized condition. Stigma by association impacts people connected with a stigmatized 
person and includes social and psychological reactions to being associated with a stig-
matized person as well as people’s reactions to being associated with a stigmatized 
person. Finally, structural stigma is stigma that is reflected, legitimized, and perpetuat-
ed by society’s institutions and ideological systems. These four types of stigma are 
interrelated. However, public stigma is considered to be at the core of the other three 
types of stigma [144,146].  
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Figure 7 Types of Stigma (Based on Pryor and Reeder, 2011) [144,146] 
In the context of FASD, public stigma, self-stigma, stigma by association, and structural 
stigma are all relevant. With regard to public stigma - the social and psychological 
reactions of others - the literature shows that public stigma with regard to women who 
use or have used alcohol during pregnancy is pervasive. FASDs are often considered to 
represent a women’s failure as a mother [142]. Mothers are perceived as being moral-
ly culpable for a child’s prenatal exposure to alcohol and ensuing FASD [142]. There is, 
in fact, a clear discourse of agency whereby pregnant women with problematic alcohol 
use are perceived to lack ‘self-control’ and ‘voluntarily’ consume alcohol in pregnancy 
[143]. This results in the blaming and shaming of women who use or have used alcohol 
during pregnancy [142,147]. The public stigma of women who use or have used alcohol 
during pregnancy is thus perpetuated by simplified beliefs about substance use de-
pendence whereby people with problematic alcohol use are considered personally 
responsible for the onset and offset of their substance use dependence [143,148]. This 
predominantly moral view of substance use dependence is increasingly being replaced 
by biological explanations for alcohol dependence. However, research has shown that 
biological explanations are not a “magic bullet solution” that circumvents stigmatiza-
tion. They too, albeit less intentionally, have been found to contribute to the public 
stigma of mothers who use alcohol during pregnancy [143,149].  
It is not only mothers that are subject to stigmatization; individuals with FASD are also 
perceived in a negative way by society. In fact, FASD is often perceived to be indicative 
not only of mothers, but also of children, who apparently “place a drain on society” 
due to their medical and social problems (p. 68) [142]. This is in line with research 
showing that individuals with FASD report being misunderstood, underestimated, 
disrespected, bullied and blamed for the challenges they face with respect to, for ex-
ample, learning [142,150]. Although individuals with FASD are not considered to be 
personally responsible for having acquired FASD, they are nonetheless considered 
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difficult and, unjustifiably, are often held responsible for their apparent inability to 
offset the negative consequences of FASD, such as leaning difficulties and behavioral 
problems [142,151]. Children with FASD are often ‘othered’, particularly at school. 
They frequently struggle to make friends and their behavior is considered to be prob-
lematic by teachers and administrators [142]. This often leads to reduced self-esteem, 
low self-confidence, and increased social isolation [152]. Their self-esteem and poten-
tial to succeed are further impeded by beliefs that individuals with FASD will inevitably 
be societal failures who are likely engage in criminal behavior and, fueled by biological 
explanations for substance use dependence, use drugs or alcohol [142,153]. 
Unfortunately, the negative beliefs and attitudes about individuals with FASD and 
women who use or have used alcohol during pregnancy are not limited to the domain 
of others (public stigma); they are also anticipated, expected, and internalized by indi-
viduals with FASD and their mothers (self-stigma). Research has shown that women of 
children with FASD engage in self-blame and hold themselves responsible for the out-
come of prenatal exposure to alcohol, even in cases when they were unaware of the 
effects of such exposure [153,154]. In this context, mothers of children with FASD tend 
not to acknowledge the broader social and structural factors (e.g. poverty, poor access 
to treatment, other forms of marginalization) that may have contributed to their alco-
hol use during pregnancy, but rather focus on the personal responsibility they had and 
failed to take [153,155]. This self-blame has been found to impede parent-child rela-
tionships [156] and can thus decrease the problems experienced in relation to FASD. 
Self-stigma is also likely to occur in individuals with FASD who internalize negative 
beliefs about FASD, thus underestimating their own potential [157].   
The stigma of FASD extends to associates of individuals with FASD and potentially also 
to associates of women who use or have used alcohol during pregnancy. Biological 
mothers of children with FASD who are primary caregivers to their child with FASD are 
subjected to a double burden. Not only are they stigmatized directly for having con-
sumed alcohol in pregnancy, they are often also stigmatized as a result of their associ-
ation with an individual with FASD and his or her accompanying behavioral problems 
or disabilities [147,155,158]. Additionally, stigma by association is felt by non-biological 
parents who may, as a result of FASD stigma, feel compelled to disclose that their child 
was adopted in order to avoid stigmatization [159].  
Lastly, there is structural stigma surrounding FASD. The current literature points to 
three main issues that contribute to FASD-related structural stigma. The first is coer-
cive or punitive measures that aim to reduce prenatal alcohol exposure - such as com-
pulsory reporting of women who consume alcohol during pregnancy, removal of the 
parental rights of women who use alcohol during pregnancy, and criminalization of 
women (see also paragraph 2.12) who use alcohol during pregnancy [143]. These kinds 
of measures are often driven by ideological systems with strong fetus protection and 
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right to life movements but are highly detrimental to the reduction of FASD stigma and 
the prevention and identification of FASD [143]. The second major form of structural 
stigma is the use of public health initiatives that, in seeking to reduce prenatal alcohol 
exposure, promote negative judgments of alcohol use in pregnancy, and emphasize 
‘risk’ to the child and ‘responsibility’ of the mother as an individual [142,143,153]. 
These efforts seriously undermine the provision of effective support services to wom-
en who use alcohol during pregnancy and individuals with FASD [142,143,153]. They 
also obscure systemic structural social inequalities and environmental conditions that 
contribute to prenatal alcohol exposure. It is vital that we maintain an awareness of 
how FASD stigma is driven and compounded by other forms of marginalization - includ-
ing poverty and ethnic minority status [143]. 
Clearly, FASD stigma has significant consequences for individuals with FASD, women 
who use or have used alcohol during pregnancy, and the associates of people with 
FASD. We must recognize that FASD stigma is a significant impediment to the preven-
tion of prenatal exposure to alcohol for many reasons, including the fact that stigmati-
zation deters pregnant women with problematic alcohol use from seeking mainstream 
prenatal care and substance use dependence treatment [142,143,160,161]. Non-
disclosure of prenatal alcohol exposure due to fear of stigmatization and penalization 
also inhibits the identification of FASD, which, in turn, prevents children with FASD 
from receiving the support they need [142]. It is thus imperative that the stigma of 
FASD is prioritized in both research and practice. 
Knowledge gaps 
Future research should investigate aspects of public stigma, self-stigma, stigma by 
association, and structural stigma that have not yet been fully investigated in relation 
to FASD. 
Recommendations 
Specifically, with respect to delineating public stigma and the impact and repercus-
sions of such stigmatization, we recommend investigating beliefs held by the general 
population about alcohol dependence, women who use alcohol during pregnancy, and 
FASD. In this regard, stereotype endorsement, perceptions of agency, attitudes to-
wards women who use alcohol in pregnancy, and endorsement of coercive policies 
against women who use alcohol during pregnancy are all certainly worthy of investiga-
tion. As part of this research, it may also be interesting to explore the role of gender 
and how views of mothers and fathers of children with FASD differ.  
With regard to self-stigma, we recommend further exploring the extent to which socie-
ty’s negative beliefs and attitudes about FASD are anticipated and internalized by indi-
viduals with FASD and their mothers, and the ways in which stigma anticipation and 
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internalization impact on psychological and social well-being. Moreover, this kind of 
research would benefit from a delineation of the different kinds of support needed by 
individuals with FASD and for women who use (or have used) alcohol during pregnan-
cy, in order to effectively promote resilience against insidious stigmatization. 
Research efforts should also prioritize further investigation of stigma by association as 
experienced by those connected to individuals with FASD. There is a paucity of re-
search in this regard - and it would be worthwhile to look not only at how birth moth-
ers are affected by direct stigmatization but also at the effects of stigmatization as a 
result of having a child with disabilities and/or behavioral problems. Furthermore, we 
recommend investigating the unique experiences of fathers and of adoptive parents.  
Lastly, we argue for the identification of structures that contribute to stigmatization. It 
is important to explore how coercive policies contribute to stigma, and it is important 
to identify means of structural support for the reduction of FASD stigma. Additionally, 
research should explore how public health prevention goals can be met without stig-
matizing women who use or have used alcohol during pregnancy. Finally, there is a 
need for greater understanding with regard to how FASD stigma layers with other 
forms of marginalization that are linked to race, class, and ethnicity. 
The proposed research is necessary if we are to effectively reduce FASD and FASD 
stigma via theory- and evidence-based interventions across interpersonal, in-
trapersonal, and structural domains.  
2.12. Legal and Ethical Issues  
Legal and ethical issues are important and complicated in relation to FASD. The updat-
ed BMA report 2016 [109] added an appendix to address this topic; Nelson and 
Trussler (2016) [162] addressed these issues in an edited volume entitled “Fetal Alco-
hol Spectrum Disorders in adults: ethical and legal perspectives”.  
As FASD is an international concern, some of the relevant legal and ethical issues are 
considered in the following section in the abstract (i.e. not specifically limited to one 
jurisdiction). These issues are considered under the following four themes. 
1. A typology of the legal and ethical issues in FASD first requires  a consideration of 
the actors involved: the mother (biological, adoptive or foster-caregiver), the un-
born child, the child born with FASD, the genetic (or social) father, broader friends 
and family, society in general, the medical practitioners involved, and the State (po-
lice, legal process, etc.). 
2. A second axis of the legal typology comprises areas of law: human rights (privacy, 
freedom of expression, health care), child welfare and medical, tort/ delict (negli-
gence and duty of care), criminal. 
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3. A third axis represents areas of ethics: autonomy, responsibility, solidarity, and 
theoretical ethics. 
4. Key questions include: How relevant are legal and ethical issues in an area where 
there is little scientific consensus? How far should a woman’s choices be limited by 
considerations about her unborn child (cf. abortion)? Who is responsible for the 
damage caused to the child through alcohol use in pregnancy? How much, in an al-
cohol-tolerant society, can the use of alcohol be limited in order to address FASD 
(to what extent are individuals - other than the biological parents - responsible for 
the mother and the unborn child?)? 
Actors - who is at risk of harm and who might be involved in the harming?  
As seen in the medical literature, there is no consensus about the cause of FASD and  
its wide-ranging consequences, so it is worth noting at the outset that when talking 
about FASD, there is no typical person involved. However, it is still worth considering 
the range of actors involved - the people under legal and ethical consideration when 
assessing harm and protection, as well as liability, in relation to FASD. 
There are two primary actors in FASD - the mother and the child. From what we under-
stand about FASD so far, the biological mother could be a person with high or low 
dependency on alcohol (although the higher the use of alcohol, particularly in the first 
and third trimesters, the higher the chance of FASD in the child), and she could come 
from a wide range of economic and educational backgrounds. If those considerations 
cover mothers before birth, biological mothers and adoptive or foster-caregiving 
mothers are also key individuals in the care of a child who has been born with FASD. 
The child needs to be considered both before and after birth. Unborn children are at 
risk of FASD if they are exposed to alcohol (although it is not clear how much or how 
frequent this exposure has to be to constitute a risk). What is clear is that some un-
born children are exposed to a level that produces FASD. As FASD is, theoretically, 
completely preventable, this poses difficult social and regulatory dilemmas. Children 
born with FASD require particular welfare responses - they may have additional care 
needs because of their condition; meeting those needs comes at an economic cost, 
and often requires additional time and expertise. One crucial question is, who provides 
for the child with FASD? This in turn requires consideration of who is in a position to 
care for the child with FASD.  
These dilemmas continue when one considers the broader group of actors. One ap-
proach to FASD might frame it only as a maternal responsibility problem - as far as we 
can see, it is only the mother’s drinking that harms the child. However, drinking alcohol 
is a societal phenomenon. Even in cultures where drinking alcohol is outlawed and 
normatively unacceptable, evidence of FASD has been found. Historically, alcoholic 
drink was a source of reliable, safe drink; it has religious and cultural significance. Al-
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cohol is, today, undoubtedly big business, with companies producing alcohol providing 
sponsorship of major sporting and cultural events. Many communities revolve around 
‘the pub’, 'cafe' or ‘club’, and to many alcohol consumption is associated with leading a 
sophisticated lifestyle. To what extent, then, should the immediate friends and family 
of pregnant (or even sexually active) women share the responsibility for FASD-aware 
drinking? Certainly, there is an argument that, even though there is not (yet) an estab-
lished link to the genetic father for FASD, partner support (or lack thereof) and interac-
tion with the mother may exert an influence on the mother’s alcohol consumption. 
How far should this be considered within the regulatory framework to prevent FASD? 
Even if it is not a matter for regulation, medical practitioners, social workers, the police 
and judiciary (as well as the mother's immediate social circle) all have a role to play in 
supporting both the child and the mother, and in reflecting societal norms in the 
treatment of the same. 
Law - what is the range of Laws that relates to FASD? 
We have not identified any FASD-specific laws. The laws that relate to FASD tend to 
focus on the welfare of the child, and civil or criminal liability for harm. Human rights, 
particularly the right to privacy, are relevant here. Other relevant, but less obvious 
laws include advertising and licensing Laws.  
Human rights  
Laws surrounding the welfare of the child tend, following the high expectations of the 
UN Declaration of the Rights of the Child (1959), to lean towards a welfare expecta-
tion. Under UK Law, for example, following the Children Acts of 1989 and 2004 
[163,164], the established case law tradition of the paramountcy of the welfare of the 
child is established in Statute. It therefore follows that intervention decisions about 
the welfare of the child, for example in the face of the mother’s inability to care for the 
child, are measured against this high, child-centered standard; the action of a welfare-
providing authority must place the welfare of the child first because the welfare of the 
child is paramount. Thus, for a child with FASD from birth, there is a duty to consider 
intervention for his or her welfare (either within the context of the child staying with 
the mother or family, or, more drastically, by removing the child from that home envi-
ronment). As with many human rights, however, this duty does not translate into a 
right to economic stability. There are, as the result of the right to health(care) and the 
Rights of the Child, claims to health and social care, but these are restricted by domes-
tic jurisdiction economic policy limits (within the ‘margin of appreciation’ in interna-
tional law). A child with FASD does not have an absolute right to a particular level of 
support, despite the seemingly robust language of human rights. However, when a 
child with FASD is at (severe) risk in his or her environment, there is a duty on the State 
to alleviate the risk. 
Chapter 2 
62 
At the same time, the right to privacy is prominent. First, under international law - the 
Universal Declaration of Human Rights (1948) and the European Convention of Human 
Rights, (1950) for example - and in domestic constitutions, the right to private life or 
privacy is not an absolute right; privacy is tempered by, essentially, the public interest. 
Conceptually, it can perhaps best be thought of as the interaction between each indi-
vidual and all other individuals (acting individually and collectively), and therefore 
there cannot be absolute claims; privacy has to be crystallized in each situation by the 
negotiation of a legitimate claim on the individual’s freedom of choice from others 
(individually or collectively). Anita Allen, the American legal philosopher, makes a use-
ful typology of privacy in relation to genetic information that is equally useful for FASD 
situations [165]. Allen points to four dimensions of privacy: informational, decisional, 
physical and proprietary. Arguably, there is no proprietary privacy engaged in FASD, 
but the other three types play a role. Informational privacy - information, about the 
condition FASD and about the behavior leading to the condition - is covered by stand-
ard medical confidentiality, with a public interest caveat (but only a public interest 
caveat) allowing for the breach of that confidentiality. For example, under the Dutch 
WGBO, a health care professional must maintain the confidentiality of the medical 
records of both mother and child (WGBO, Article 7.457) [166]. Personal information 
related to both mother and child is also protected under data protection laws (e.g. in 
the EU under Data Protection Directive 95/46/EC) [167] with similar effect.  
Physical privacy is covered in most jurisdictions by criminal codes and civil wrong 
(Torts) codes (discussed below). Decisional privacy is, conceptually, the most interest-
ing. Decisional privacy asks - who has the right to make a decision? Allen points to the 
US discussion surrounding the abortion case of Roe v. Wade (1973) [168]. This case 
poses the question, ‘who has the right to choose, the woman or the State?’. The priva-
cy question is essentially the same for FASD: ‘Can a woman’s right to choose to drink 
endanger her unborn child?’ It is a question that can be extended: ‘Can any individual’s 
right to choose endanger the unborn child?’ As a legal question, decisional privacy 
balances are struck through a number of elements - through the disclosure of infor-
mation, through criminal sanctions, through compensation, through welfare provi-
sions, through education programs, through limiting access to alcohol, and the like. 
Criminal law  
Criminal law can operate in relation to damage to a child through FASD. Assaults 
against the person are covered under criminal law. However, FASD is an assault against 
the unborn child. These assault laws have often been part of legislation that governs 
against termination of pregnancy. Legal abortion is a relatively new development in 
the law, and is not accepted - or fully accepted - in some jurisdictions. Prior to this 
development, termination as a medical emergency (due to the health or life of the 
mother being under threat) could perhaps be accepted, but for other reasons it was 
Primary Prevention 
63 
deemed unacceptable. In relation to FASD, a difficult question arises - how, in legal 
cultures that accept abortion, can there remain space for laws related to harming the 
unborn child? First, there remains a need to deter individuals from procuring abortions 
outside the licensed channels. In most jurisdictions, abortion is limited to a point 
where the unborn child would be able to survive (assisted) outside the womb (around 
twenty-five weeks of development). This suggests, then, that jurisdictions will accept 
criminal liability towards (and therefore a limited personhood of) the unborn child that 
is later in its gestation. Equally, many jurisdictions impose criminal sanctions for the 
legally improper use of embryos in research and medical science; different jurisdictions 
have different times at which the embryo becomes protected against research. What 
emerges is that the criminal rules concerning abortion, originating in a woman’s right 
to choose, are somewhat restricted within a broader framework of limited protection 
afforded to the unborn child. This said, however, FASD does not sit well with the pro-
tection of the unborn child law, as was seen in a recent attempt to use such law in the 
UK [169].  
The origin of the UK case concerned an application to the Criminal Injuries Compensa-
tion Authority. The basis of the law in question was the Offences Against the Person 
Act 1861, s. 23. This required both a ‘guilty act’ and ‘guilty mind’ (mens rea) - the in-
tention to commit harm to the unborn child, in this case, through heavy drinking (de-
spite warnings about the potential harm). The final outcome of the case on appeal was 
that the intention to harm the unborn child had not been established - a matter of fact 
that shows the difficulty in bringing about a charge under this type of offence. One 
might argue that it is unlikely that a woman will drink heavily and against warnings 
during pregnancy without a prior dependency on alcohol; where there is dependency, 
it is strongly arguable that intention is extremely difficult to prove: “I drank to harm 
the child”, rather than “I know what it’s doing to the child, but I can’t stop drinking.” 
This would, one might suggest, equally rule out criminal negligence and recklessness. 
This is the first difficulty in defining a criminal offence in relation to FAS and FASD. 
Furthermore, while medical science remains unclear as to precisely what behavior 
produces FAS and FASD, there is insufficient clarity to be able to define an offence of 
causing FAS or FASD in a child without reference to the intention of the mother. One 
wonders if, as a matter of public policy, there is a real desire to criminalize the rela-
tionship between the mother and the unborn child. For example, is there any public 
desire for other ‘lifestyle’ choices becoming matters of criminal liability, such as food 
choices, exercise choices and the like? Is there a desire to create a policed environ-
ment against women, especially where the choices are part of established generally 
socially acceptable behavior. Tobacco smoking is the obvious precedent here. Despite 
evidence of its damaging effects, general personal choice is prized over protection 
from any specific harm caused (by manufacturers and smokers alike). In terms of crim-
inality, criminalizing FAS- and FASD-causing behaviors would open a Pandora’s Box.  
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Civil wrongs - Torts or Delict 
The same could be said for compensation for civil wrongs - Torts or Delict, depending 
on the jurisdiction. Conventional compensation is based, in many ‘fault-based’ jurisdic-
tions, on the negligent behavior of one person in relation to another. Here, the mother 
could be shown to have a duty of care towards her child (although establishing liability 
to the unborn child is problematic, as discussed above), and knowingly drinking alcohol 
where there is a specified risk of causing FASD could, where the evidence is strong, 
produce a claim of negligence. However, the question remains, a claim against whom? 
A child suing a mother diminishes family finances by paying lawyers’ fees. Even where 
there is personal liability insurance, the question remains whether this behavior would 
be excluded from the contract; practically, in cases of heavy alcohol dependence, one 
wonders if the premiums for personal liability insurance policy will have been main-
tained.  
Health and welfare law 
Whereas fault-based compensation for FASD may not be available for the extra health, 
education and general care costs of the child, jurisdictions have followed human rights 
commitments and provide either financial or in-kind provision for children with FASD, 
as they do to other children with welfare or care needs. The extent of this provision, of 
course, varies jurisdiction-by-jurisdiction (not least, because whereas the human rights 
agenda outlaws discrimination in terms of race, gender and to some extent age, it has 
yet to embrace discrimination on economic grounds). Welfare and health care are 
matters to be determined according to the politics of each country. What can be said is 
that whilst we have not yet found places where children with FASD are discriminated 
against explicitly because of the (arguably) avoidable cause of the condition, FASD 
children and their guardians still have to negotiate the general welfare and care land-
scape.  
Ethics - questions and issues related to FASD 
“Ethics” and “ethical” are interesting terms, as they have both a colloquial and a tech-
nical use. Colloquially, we use the terms - along with “moral” and “morality” - to indi-
cate a sense that something is right or wrong, acceptable or unacceptable. However, 
these claims are not grounded in common sense or authority; they are appeals to per-
sonal beliefs about probity that individuals may or may not seek to impose upon oth-
ers; they are grounded in a variety of personal or shared beliefs. There is a more tech-
nical use, however, where the claim to right and wrong is grounded in ethics theory, 
originating in philosophy, and this fits into a technical normative architecture of socie-
ty. Here, claims to authority are more systematic, and may be based in pragmatism, 
belief, or claims to abstract rationality. There is, as in the colloquial use of these terms, 
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a struggle with relativism; claimants or theorists are more or less happy to assert an 
absolute authority for their ethics or morals. Thus, we have competing, contested 
moralities and ethics. What is clear is that there is a shared understanding that the 
probity of human behavior, when it impacts on others, is a matter for evaluation and, 
perhaps, judgement. FASD, with its (arguably) avoidable causes and extreme (if rare) 
effects, attracts such debate.  
In this report, we do not rehearse the full range of technical ethical positions. Rather, 
as a general statement of the intent of ethics, we look to the four elements of Beau-
champ and Childress’ Bioethics [170]: beneficence, non-maleficence, justice, and au-
tonomy. We also note the re-emergence of ‘virtue ethics’ in recent years, and ‘dis-
course ethics’ as creating a useful ethics architecture. Not harming and seeking to do 
good can, in the FASD debate, easily heap blame on the mother. However, it can be 
argued that there is only a very small minority of women who seek to harm their child 
through their own alcohol consumption. The majority, it is more reasonable to suggest, 
either accidentally harm their child (because, for example, the pregnancy was un-
known at the early stage when the mother drank normally), or because of their de-
pendency on alcohol - despite knowing the dangers of its consumption for the unborn 
child - were unable to stop drinking.  
This is where ethics becomes challenging. Alcohol is paradoxical. Many cultures em-
brace alcohol; for many alcohol loosens social interaction; for many alcohol is 'good'. 
And at the same time, alcohol is medically and socially abominable. Our messages are 
mixed beyond belief. Our understanding of alcohol is not clear - beneficial in modera-
tion, damaging socially and medically in excess. That confusion makes culpability ex-
tremely difficult to define, and equally, and arguably, spreads responsibility. If we want 
to eradicate FASD, arguably we must share the social responsibility. We must accept 
moderation in order to support women of child-bearing age to avoid alcohol. From 
university social gatherings, cafes, pubs and restaurants, to sports sponsorship deals 
and society in general; we must all embrace the idea that alcohol is as problematic as it 
is beneficial. The parallel with tobacco smoking is clear; and the social struggle with 
tobacco is not over. 
Concepts of justice and shared responsibility are relevant to this line of argument – the 
idea that responsibility is more complicated than the obvious responsibility of the 
mother to her child, and that there is a social responsibility resulting from the confus-
ing place that alcohol has in society. Because of the difficulty in creating the clear case 
about responsibility in relation to FASD, there is a broader claim for justice through 
socially shared responsibility; FASD requires a no-fault liability collectivism. But, in the 
bioethics of Beauchamp and Childress, autonomy has first claim. It is, however, only in 
the last 35 years that, in popular and political culture, autonomy has developed into a 
suggestion of absolute freedom of choice. When one looks at the philosophy of Locke, 
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Smith, Mill, Kant, and Kropotkin, there is arguably a shared acceptance that autonomy 
rests on collectivism; that free choice depends on society, and that society has certain 
shared responsibilities that support free individual choice. This notion has, perhaps, 
been lost in the predominant neoliberal economics of the last 35 years, and political 
interpretations of autonomy have moved away from the classic ethics moorings of 
individualism. In terms of FASD, especially with its (arguably) preventable cause and 
apparent culpability of the mother in her causal behavior, autonomy in this modern 
interpretation is particularly challenging. As yet, the ‘sins of the mother’ argument has 
not been a prominent one, but in an era of personalized medicine and consumer 
choice, the benefits of solidarity are beginning to be questioned, and the notion of the 
virtuous life - not as an aspiration but as a duty – becomes a foreseeable point on the 
horizon. These are political moral choices, and that is why we raise the importance of 
discourse ethics; with its acceptance that ethics are forged through careful and consid-
ered discussion, it becomes very important in democracy. 
Key questions that must influence the policy discussion 
There are a number of questions that arise from this short normative overview. First - 
what sort of society do we want to be? What is the relationship between the individual 
and the collective (of individuals)? Solidarity means shared responsibility - but it also 
requires individual responsibility. Striking this balance is not only an issue in relation to 
FASD; FASD is a focal point for the discussion. Children with FASD are blameless; the 
unborn child can be protected; the mother (apparently) has choice; those around the 
mother create an environment in which this choice is exercised - the responses to 
these claims are moral, societal choices. FASD requires resources for education and 
welfare programs, and which of these are funded are political choices.  
A more abstract normative question related to FASD is ‘where there is little scientific 
consensus, how far can conclusions be drawn in law and ethics?’ It is clear that there 
are children who suffer from FASD, but the causes are not clear. There is a danger that 
only heavy-drinking mothers - as a most obvious target - will be blamed, when they 
may not be the only risk-takers. There are questions relating to proportionality and 
justice at one level, and effectiveness at another. FASD cannot, when the medical sci-
ence is not yet clear, be narrowly defined as a problem of alcohol abuse in mothers - 
and by extension low-income, low-educated mothers - when the causes could be much 
broader.  
The biggest challenge that emerges from a consideration of the normative issues relat-
ing to FASD is the social challenge that it represents. Throughout this report, the fact 
that the condition can be avoided has been couched in the noncommittal term “(argu-
ably) avoidable”. This is partly because of the complicated nature of the medical sci-
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ence of FASD. However, it also points to the difficulty of apportioning responsibility 
only to the mother.  
Recommendations related to ethics and law 
Given the uncertainty within medical science about this topic, it would be inappropri-
ate to criminalize women who have severe alcohol problems. Rather, the emphasis 
should first be on addressing the welfare of children born with FASD, second on clarify-
ing and understanding the relevant medical science, third on educating and investing 
in prevention, and finally, when all these are in place, addressing issues of culpability - 
and in doing so placing alcohol problems within their broad social context. 
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3. SECONDARY & TERTIARY PREVENTION  
“The diagnosis and management of the range of FASD requires a multidisciplinary ap-
proach involving a wide range of healthcare professionals – including pediatricians, 
obstetricians, psychologists, GPs, neurologists, psychiatrists, clinical geneticists, health 
visitors and midwives – as well as individuals in the fields of education and social ser-
vices.“ (BMA, 2016, p.33 [109]) 
3.1. Introduction  
The previous chapter described primary prevention related to prenatal alcohol ex-
posed pregnancies. This chapter addresses secondary and tertiary prevention. Topics 
such as stigma and ethical and legal issues, addressed in Chapter 2, are important and 
need to be kept in mind for this chapter too. Secondary and tertiary prevention aims to 
reduce and soften the impact of FASD. The following sections will discuss diagnostic 
testing of FASD, neuropsychological testing, neuroimaging, pediatrics and child and 
youth health care, socio-economic costs, and interventions designed to promote early 
detection of FASD and to optimize the management and care of FASD individuals. 
3.2. FASD Diagnosis 
Current knowledge 
Diagnostic testing. The assessment of prenatal alcohol exposure is complex. The diag-
nostic process is multi-faceted and requires a multidisciplinary clinical team. Hoyme et 
al. (2016) [182] stated “The assessment of individuals prenatally exposed to alcohol 
requires a medical assessment and team leadership by a pediatrician or clinical geneti-
cist/ dysmorphologist with expertise in the full range of human malformation syn-
dromes and the dysmorphology evaluation of children with FASD. In addition, exposed 
children should have expert psychological/ neuropsychological assessment, and a 
skilled interviewer should evaluate prenatal maternal alcohol intake. Other team 
members may include developmental behavioral pediatricians, psychiatrists, speech 
pathologists, occupational therapists, physical therapists, special educators, audiolo-
gists, and/or ophthalmologists.“ 
There is much discussion about which diagnostic criteria to use. Different tools for 
assessing FASD have been developed and several initiatives have been undertaken to 
achieve consensus on the most useful FASD criteria and diagnostic processes. Com-
monly used guidelines are:   
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- IOM criteria (Institute of Medicine United States).  
Stratton et al., (1996) [183] described five diagnostic categories recommended by an 
expert panel of the Institute of Medicine in the United States: (1) fetal alcohol syn-
drome with confirmed prenatal alcohol exposure; (2) fetal alcohol syndrome without 
confirmed prenatal alcohol exposure; (3) partial fetal alcohol syndrome with confirmed 
prenatal alcohol exposure; (4) alcohol-related birth defects; and (5) alcohol-related 
neurodevelopmental disorder. These categories, however, lack a specified set of pa-
rameters (e.g., exact facial dysmorphic features, specific cognitive characteristics). In 
2005, the IOM published revised diagnostic criteria to provide further clarification of 
the guidelines proposed in 1996 [184].  
- 4-Digit Diagnostic Code 
A 4-Digit Diagnostic Code was developed by Astley and Clarren (2000) [185] and Astley 
(2013) [186]. This tool takes into consideration the four key diagnostic features of fetal 
alcohol syndrome: (1) growth deficiency; (2) the characteristics of facial phenotype; (3) 
central nervous damage/ dysfunction; and (4) gestational alcohol consumption.   
Astley and Clarren developed this new diagnostic code to provide a more objective, 
quantitative scale to measure and report key parameters of FASD diagnosis. 
- Canadian guidelines 
In 2005, Chudley et al. [187] published the Canadian guidelines for FASD diagnosis. 
Cook et al. updated these guidelines in 2016 [188]. These Canadian guidelines are 
considered to be golden middle way between IOM and 4-Digit guidelines. 
The various guidelines provided for diagnostic testing and their subsequent refinement 
illustrates the complexity of the topic. Riley, Infante, and Warren (2011) [189], and 
recently Hoyme et al. (2016) [182] and Coles et al. (2016) [190], made a comparison of 
the existing guidelines. Agreement on a universal diagnostic system for FASD has yet to 
be reached. Hoyme et al. (2016) published an FASD diagnostic algorithm incorporating 
the updated clinical diagnostic guidelines for diagnosing FASD which provide more 
clarity and specificity for the accurate diagnosis of infants and children prenatally ex-
posed to alcohol [182]. 
FASD data of a Dutch outpatient clinic have been published by Swelheim et al. (2014) 
[89]. The applied diagnostic system was based on the 4-Digit Diagnostic Code and the 
multidisciplinary team included a pediatrician, child psychiatrist and child psycholo-
gists.     
Knowledge gaps 
Different FASD diagnostic criteria (e.g., IOM, 4-Digit, Canadian guidelines) are used 
internationally [9,14,183,185,187,188,191]. Consensus on FASD diagnostic terminology 
has not yet been reached. Significant progress has been made in clarifying and opera-
tionalizing criteria.  
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Recommendations 
Establishing a diagnosis within the spectrum of FASD is not easy, not least because of 
the lack of clear biological markers and reliable measures of prenatal alcohol exposure. 
Moreover, the consideration of differential diagnosis is important. It is essential to 
exclude related conditions before a diagnosis of FASD can be made. In order to make 
an accurate FASD diagnosis, a multidisciplinary assessment is important. Experienced 
gynecologists, clinical geneticists, pediatricians, psychiatrists, and psychologists should 
be part of the team responsible for making the diagnosis. A standardized international 
approach for the diagnosis of FASD and the application of a uniform diagnostic algo-
rithm should be a priority for the Netherlands.  
3.3. Neuropsychological Testing 
Current knowledge 
Prenatal exposure to alcohol and neurobehavioral functions. Prenatal exposure to 
alcohol has been associated with lifelong impairments in emotions, behavior regula-
tion, social interactions, and cognition. For example, numerous studies have shown 
that individuals prenatally exposed to alcohol have an increased risk for developing 
externalizing problems such as oppositional defiant disorders, conduct disorders, and 
attention-deficit/hyperactivity disorder (ADHD), as well as internalizing problems such 
as anxiety and major depressive disorder [192–194]. These so-called neurobehavioral 
functions may be ‘more sensitive’ to prenatal exposure to alcohol than e.g., physical 
features of an individual, such as facial characteristics and physical growth, since neu-
robehavioral impairments (such as cognitive impairments) are observed in both chil-
dren prenatally exposed to alcohol with and without physical dysmorphology 
[195,196]. In the following sections, the effects of prenatal exposure to alcohol on 
cognitive functioning will be discussed in more detail.  
Alcohol exposure and intelligence. Research has repeatedly shown that prenatal expo-
sure to alcohol may lead to lower scores on test batteries measuring intelligence in 
(young) children, adolescents, and adults [197,198]. Wechsler (1938) [199] defined 
‘intelligence’ as “the global capacity of an individual to understand the world around 
him and his resourcefulness to cope with its challenges”. In line with this, many re-
searchers have shown that intelligence estimates are an early and robust predictor of 
important life outcomes, such as academic performance, college readiness, and social 
interactions, in both standardization samples and clinical populations [200,201]. Alt-
hough test batteries vary in how they operationalize intelligence, intelligence esti-
mates (often referred to as ‘full scale IQ’ or FSIQ) are, in most test batteries, based on 
the summation of ‘points earned’ across multiple subtest(s) measuring one or more 
cognitive functions, with each subtest being accorded the same weight as the other(s) 
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[202]. Typically, reports on FSIQ scores in individuals prenatally exposed to alcohol 
range from low average to borderline (i.e., ≥ 1-2 standard deviations (SD) below the 
mean). However, not all of these individuals display low(er) FSIQ scores [195].  
It is tempting to conclude that FSIQ scores based on different test batteries ‘capture’ 
the same global capacity to understand one’s environment and to cope with its chal-
lenges. However, intelligence test batteries vary in terms of the subtests mentioned 
above and therefore also in the diversity of cognitive functions tapped by the test 
batteries. The correlations between scores on different cognitive subtests are far from 
perfect. Therefore, administering diverse test batteries claiming to measure intelli-
gence to one person may lead to different FSIQ scores, depending on the match be-
tween the specific cognitive functions that are tapped by the test battery and the spe-
cific strengths and weaknesses in the profile of cognitive abilities of that individual 
[203]. One could question the validity of FSIQ scores in the presence of significant 
variability in subtest scores within an individual. However, Watkins, Glutting, and Lei 
(2007) [204] have shown that FSIQ is an equally valid predictor of e.g., school success 
in a group of individuals that showed significant within-subject variability among sub-
test scores and a group that did not show such variability. Nonetheless, the identifica-
tion of an individual’s cognitive strengths and weaknesses (i.e., in terms of the specific 
cognitive subtest scores) is more likely to provide professionals with a clear direction 
regarding a plan of action (or treatment) than an FSIQ score. For instance, some chil-
dren may have attention problems explaining why they cannot cope with their envi-
ronment, while others may have intact attentional functions but problematic planning 
skills. It is likely that these problems will need to be addressed differently. It is there-
fore important to study specific cognitive functions in this context.  
Alcohol exposure and specific cognitive functions. According to Anderson (2002) [205], 
it is important to test at least four distinct, but interrelated, clusters of cognitive func-
tions when studying how well someone copes with the challenges of daily life - he 
called these ‘executive functions’: i.e., (1) attentional control, selective attention, and 
inhibition, (2) cognitive flexibility, divided attention, and working memory, (3) goal 
setting, planning, and reasoning, and (4) information processing, including fluency and 
speed of processing. These clusters are believed to ‘build on one another’ and are 
thought to be regulated by neural networks including the (dorsolateral) prefrontal 
cortex (PFC), the basal ganglia, and the thalamus [206,207].  
Ware and colleagues (2015) [208] have found that prenatal alcohol exposure is associ-
ated with both volumetric and functional changes in these neural networks. In line 
with this, for each cluster, numerous studies have revealed, on average, lower scores 
on tests measuring these clusters in individuals who are prenatally exposed to alcohol, 
compared to individuals born to mothers who did not use alcohol during pregnancy 
(e.g., [209–211]). Not only these so-called executive functions may be influenced by 
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prenatal alcohol exposure: impairments in learning, fine-motor control, auditory pro-
cessing, language delays and disorders, visuospatial weaknesses, and academic skills 
such as mathematical comprehension, reading and spelling, have repeatedly been 
reported in this context [212–214]. In sum, prenatal alcohol exposure seems to be 
associated with multiple cognitive and academic problems. Anderson (2002) [205], 
stated that professionals must always identify “the nature of a cognitive deficit (e.g., 
knowledge, performance, fluency) in this context. Students with knowledge deficits do 
not have the information or skill in their repertoire or do not know how to use a skill in 
a particular situation. Students with performance deficits have the knowledge and 
skills, but they fail to use them at acceptable levels. Fluency deficits are the result of 
insufficient exposure to models of the behaviors, insufficient opportunities to practice 
the behaviors, or inconsistent reinforcement of their performance of the behaviors”. 
It is worth noting, however, that the cognitive impairments reported in this overview 
have also been documented for groups of individuals with developmental disorders, 
such as attention-deficit/hyperactivity disorder (ADHD), autism, and learning disabili-
ties [215–217], but also in typically developing children [202,218]. As stated by Wat-
son, Westby, & Gable (2007) [219], it is essential “to recognize the characteristics of 
cognitive dysfunction, regardless of its cause, if students are to receive appropriate 
interventions”. Also, the studies discussed above report on group averages: this may 
mean that there are individuals prenatally exposed to alcohol who do not display any 
of these cognitive difficulties. Therefore, professionals should not assume that each 
individual prenatally exposed to alcohol will show cognitive difficulties (either global or 
specific).  
Triple pathway model to study neuropsychological heterogeneity. Traditionally, cogni-
tive functions are examined using so-called ‘cool’ cognitive tests, i.e., by administering 
“abstract, decontextualized problems that lack a significant affective or motivational 
component” [220]. However, Sonuga-Barke and colleagues (2010) [207]postulated in 
their triple pathway model that - in order to predict how well an individual under-
stands the world around him (or her) and can cope in it - one should not only study 
these ‘cool’ cognitive functions, but also the influence of motivation (or as they also 
call it reward processing, signaling of delayed rewards, and delay aversion) and tem-
poral processing (also called timing). To illustrate this, think about a child who has 
recently failed his geometry exam. Many factors could have contributed to this end 
result: the child may not have known how to prepare for the test, or may have difficul-
ties with visuospatial reasoning. These are cognitive explanations. However, there are 
alternative explanations; he child might have sufficient cognitive abilities but have 
underestimated the time needed to prepare for the test sufficiently (i.e., a time per-
ception problem) and/or he might have lacked the motivation - or not received enough 
immediate reward - to prepare for it, and therefore did not spend enough time study-
ing.  
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Neuroimaging studies have validated the claim that different (though partly overlap-
ping and interdependent) neural networks underlie these three components. To pro-
vide an example, motivation and reward processing seem to be regulated by neural 
networks including the (ventrolateral, orbito) PFC, the basal ganglia, and the thalamus, 
whereas the cerebellum, basal ganglia, and the PFC seem to regulate temporal pro-
cessing [207]. In line with this, research has shown, for instance, that damage to the 
orbito PFC can lead to normal performances on tests measuring ‘cool’ cognitive func-
tions, but to abnormal performances on tests measuring motivation, such as the Iowa 
Gambling Task, or to reports of problems in daily living [221,222]. In everyday life, 
(cognitive) decision making is rarely conducted in the absence of e.g., motivational 
influences and temporal processing. This might explain the inconsistencies often ob-
served between performances on traditional measures, testing primarily ‘cool’ cogni-
tive functions, and real life behavior [205].  
The number of studies investigating motivation and/or temporal processing, and the 
neural networks underlying these components, in individuals prenatally exposed to 
alcohol is highly limited - especially in comparison to the large amount of studies inves-
tigating effects of prenatal alcohol exposure on ‘cool’ cognitive functions. Neverthe-
less, these studies provide support for the notion that prenatal exposure to alcohol can 
indeed influence both motivation and reward processing [209,223], and temporal 
processing or timing [224], and that these alcohol-related findings are not fully ex-
plained by impairments in ‘cool’ cognitive functions [209].  
Although these three components - cognition, motivation, and temporal processing - 
are interrelated, they represent unique and independent neuropsychological functions 
and, as a consequence, can be uniquely impaired in individuals. It is highly likely that 
studying these distinct domains will reveal a neuropsychological heterogeneity among 
individuals prenatally exposed to alcohol, although this claim has not yet been investi-
gated to the best of our knowledge. However, Sonuga-Barke showed that a substantial 
subgroup of individuals with ADHD, a developmental disorder often diagnosed in chil-
dren prenatally exposed to alcohol [225], are affected in only one domain (i.e., 6.4% of 
the individuals were affected only in terms of ‘cool’ cognitions, 19.5% only in terms of 
motivation, and 24.7% only in terms of temporal processing). It is important, therefore, 
that when studying the neuropsychological profile of children prenatally exposed to 
alcohol, all three components are tested separately. As mentioned before, the identifi-
cation of an individual’s strengths and weaknesses in the neuropsychological profile 
(i.e., on these three components) can provide professionals with a clear direction re-
garding a plan of action (or treatment). Remember the child who did not pass his ge-
ometry exam.  
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Knowledge gaps  
Future research should investigate tests measuring cognition, motivation, and/or tem-
poral processing. Moreover, research should focus on the validity of these tests (in 
relation to FASD) in a developmental context, and norm data should be collected for 
representative standardization samples. 
Recommendations 
In order to plan and develop specific individual- interventions that are aligned with 
diverse needs (for instance in a school environment), it is essential that professionals 
are able to accurately assess these individual strengths and weaknesses (e.g., as relat-
ed to cognition, motivation, and temporal processing). Care should be taken to select 
tests that are appropriate for testing a specific person and that are psychometrically 
sound (i.e., reliable and valid) [195,226]. Unfortunately, the list of possible neuropsy-
chological tests measuring cognition, motivation, and/or temporal processing is 
somewhat limited. Tests measuring the latter two components are still scarce, and 
often only available in a research context. Moreover, many of the tests available were 
originally designed to study adult performance. Adult-derived tests may tap into other 
skills in children [205], therefore the validity of using these tests in a developmental 
context needs to be established. Furthermore, norm data collected for representative 
standardization samples are often lacking. There are several factors that should be 
taken into consideration when collecting norm data, for example: the number of indi-
viduals included in standardization samples should be large enough, the samples 
should be representative (e.g., of age, sex, school type, degree of urbanization or per-
centage of immigrants, level of parental education), and the individuals should be 
randomly recruited, since these factors are likely to influence neuropsychological test 
performances [226]. Importantly, these tests need to be validated and norm data need 
to be collected for specific developmental stages, in order to provide optimal care to 
individuals prenatally exposed to alcohol.  
An additional problem in this field is that the reliability coefficients of these neuropsy-
chological tests (independent of what they are measuring) are often low to moderate. 
This leads to (fairly) large margins of measurement error, even for tests with reliability 
coefficients of above 0.90, which are qualified by most test reviewing committees as 
'good' [226]. The findings of Van Boxtel & Hemker (2009) [227] illustrate this point. 
They studied the effects of measurement errors related to a specific Dutch Intelligence 
Test for school-aged children, that has a high reliability of about 0.95 (depending on 
the IQ index score used). FSIQ scores on this test have an average of 100 points and a 
SD of 15 points. The authors found that this reliability coefficient leads to a 90% confi-
dence interval of plus or minus 6.61 FSIQ points. So, one knows with 90% certainty 
that the observed FSIQ score for an individual on this test will fall within a range of 13 
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IQ points on any given day. This means, for example, that when an individual’s FSIQ 
score is recorded as 86 on day 1, another administration of the test will likely lead to a 
FSIQ score falling between 79.4 (which is interpreted as a borderline to moderate im-
pairment) and 92.6 (interpreted as an average score) on day 2. This is not unique to 
this specific test, but typical for any test with similarly high reliability. The problem 
becomes greater when a test with lower reliability is used. Unfortunately, the reliabil-
ity coefficients of many neuropsychological tests are in fact lower.  
Furthermore, the main outcome measure of the majority of traditional neuropsycho-
logical tests is an overall performance score (e.g., the number of correct responses 
over time). However, these neuropsychological tests mostly tap into a variety of both 
executive functions and non-executive functions. Therefore, this overall outcome 
measure does not provide information about the specific mechanisms underlying poor 
test performance. To overcome this limitation, Anderson (2002) [205], for one, sug-
gested that test performance should be analyzed using “a micro-analytic approach that 
incorporates quantitative (e.g., latency, number of errors etc.), qualitative (e.g., moti-
vation, distractions) and cognitive process (e.g., strategies, actions) methodologies”. 
Scoring systems that are devised to register as much (specific) information about test 
performance and normative data as possible, in order to compare these (sub)scores to 
those of other individuals, are likely to enhance the diagnostic utility of neuropsycho-
logical tests. It should also be noted that traditional tests provide little understanding 
of the child's potential to learn after obtaining instruction [228]. Multiple factors - such 
as the amount of education, practice with testing, and parental support - influence test 
performance. Dynamic testing paradigms seem to be a promising method that can be 
used to quantify “the learning potential of the child during the acquisition of new cog-
nitive operations” [229]. Here, children continuously receive feedback on how they 
perform, while the tasks administered become increasingly difficult or challenging for 
the child. The idea is that “with graduated prompting and trial-by-trial-assessment this 
method could reveal the development of children's strategy use while tested” [230]. 
Modern technology provides the opportunity to construct dynamic test protocols that 
can be used to quantify learning potential and progress in individuals prenatally ex-
posed to alcohol.  
Researchers such as D’Onofrio and colleagues (2007) [231] have indicated that it is 
necessary to investigate factors which may confound the results in studies associating 
neurobehavioral impairments with prenatal exposure to alcohol, for example: expo-
sure to multiple drugs, the timing of drinking alcohol during pregnancy, family-related 
factors (e.g., family conflict), parental characteristics (e.g., parenting styles, parental 
cognitive abilities, and income), and the level of alcohol exposure. To illustrate this 
point, a dose-response relationship between the amount of maternal alcohol con-
sumed and the severity of the children’s neurobehavioral impairment (e.g., in terms of 
cognitive functions) has been identified repeatedly, although maternal alcohol con-
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sumption even at low levels has already been shown to be adversely related to neuro-
behavior [232,233]. These potentially confounding factors may also have influenced 
the results discussed above on the association of prenatal exposure to alcohol and 
cognition. 
Finally, it should be stressed that the proper diagnosis of a child’s strengths and weak-
nesses is not limited to the collection of test data and observations alone. It is essential 
to interpret these test data in the context of e.g., age, developmental stage, and the 
psycho-social environment of the individual. Diagnosing an individual’s strengths and 
weaknesses is just the starting point. Finding an explanation for the problems should 
lead to one or more appropriate recommendations or interventions. The first step in 
addressing problems is to inform and educate the individual and the individual’s envi-
ronment (e.g., partner, parents, a child, a teacher or a boss), i.e., psychoeducation. 
Here, professionals need to realize that an individual has often received earlier diagno-
ses to explain their behavior - and that a new diagnosis should be integrated into exist-
ing beliefs about what is going on with the individual. The professional care giver 
needs to discuss the expectations of the individual and/or the environment and, if 
necessary, help to adjust these expectations in relation to the findings of the psychodi-
agnostic assessment. In addition to psychoeducation, the professional can, based on 
the analysis of the individual’s strengths and weaknesses, opt for a range of additional 
(cognitive) behavioral techniques and/or pharmacological therapies [234]. Ideally, 
these interventions should be carried out systematically, intensively, and aligned with 
the specific needs of the individual, in order to produce positive results [235]. Again, 
remember the child who did not pass his geometry exam: if the child does not under-
stand the content of the materials that he had to study, he will need a different kind of 
guidance to, for example, a motivated child who doesn’t have a realistic view on how 
much preparation time it takes to pass the exam and does not know when to start 
studying in time. Within the group of individuals prenatally exposed to alcohol, these 
needs can be heterogeneous and can vary per person, as explained earlier. Unfortu-
nately, studies evaluating the effects of neuropsychological interventions are still in-
conclusive, and only very few studies have investigated their effectiveness and efficacy 
in individuals prenatally exposed to alcohol [209,236]. The majority of research on 
neuropsychological interventions has been conducted in healthy individuals (children, 
adults) and/or children with learning disabilities, such as ADHD, without taking the 
heterogeneity of these populations into consideration (i.e., a ‘one-size-fits-all’ ap-
proach). Moreover, research on neuropsychological interventions has often focused 
only on improving specific ‘cool’ cognitive functions, such as working memory. In gen-
eral, these studies have shown that, by repeating a task (e.g., a working memory task), 
individuals become better in performing that task (i.e., near transfer effects), and they 
often also perform better on tasks that resemble the task practiced (for instance on 
other working memory tasks; i.e., intermediate transfer). However, in most cases, this 
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practice does not seem to transfer to improvements on tasks measuring other cogni-
tive functions (e.g., nonverbal reasoning tasks; i.e., far transfer). Interestingly, although 
the majority of these studies did not find far transfer effects, some studies did. Re-
searchers need to further investigate what causes these far transfer effects, such as 
changes in motivation or a strategically different use of cognitive resources [237], so 
that they can optimally assist individuals in need.  
3.4. Neuroimaging  
Current knowledge 
Since many of the symptoms of FASD relate to behavioral and cognitive differences, 
great interest has been shown in how these symptoms may correlate to changes in the 
brain itself. This may involve changes in function, changes in structure, or both. Various 
techniques exist for examining the brain, which can be grouped together under the 
term ‘neuroimaging’. The application of neuroimaging to FASD has been summarized 
in several good reviews of the literature [238–240].  
In terms of examining brain activation, several techniques are available and have been 
applied to this area of research, particularly MEG, PET, SPECT, and MRI, each with their 
own benefits and restrictions. MEG – magnetoencephalography – uses sensitive sen-
sors to detect the tiny changes in magnetic field caused by neuronal currents when a 
piece of cortex is active. MEG has a very good time resolution but suffers from poorer 
spatial resolution. PET – positron emission tomography – and SPECT – single photon 
emission computed tomography – instead use radioactive tracers (such as flouridioxy-
glucose) whose concentration in tissue is related to some physical parameter (e.g. the 
metabolism of glucose). PET and SPECT tend to have poorer time and spatial resolu-
tion, but the results can be accurately related to physiological parameters. A disad-
vantage of these techniques is that the necessity of administering radioactive tracers 
means that these methods are considered to be rather invasive. 
Many studies have instead used MRI – magnetic resonance imaging. MRI uses the 
magnetic resonance phenomenon to detect molecules containing hydrogen - predom-
inantly in water - and create images of the subject. Various methods are available 
within MRI to collect different kinds of information from the tissue being examined. 
Most simply, an image of the structure of the brain can be made with good resolution 
(submillimeter in some cases) to look at the overall structure and morphology of the 
tissue. It is also possible to sensitize the acquisition to the direction of the diffusion of 
water within the tissue. By making multiple acquisitions while changing the sensitizing 
direction and then performing a tensor analysis, it is possible to determine the pre-
dominant direction of the water diffusion, a technique referred to as diffusion tensor 
imaging (DTI). FASD studies that have used DTI have mostly examined two derived 
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parameters, the fractional anisotropy FA (i.e. a measure of how non-isotropic the dif-
fusion of water is, which is thought to correspond to how organized and structured the 
tissue is) and the mean diffusivity (i.e. how far the water can diffuse, which is believed 
to correspond to how restricted the water is and therefore how organized the tissue 
is). DTI studies of FASD subjects have shown significant differences between FASD 
subjects and controls, suggesting that cortical networks may be altered (for a review of 
DTI in  see [241]).  
Additionally, MRI can be used to look at brain function – functional MRI or fMRI – 
through an effect known as BOLD – blood oxygen level dependent contrast. This occurs 
due to the fact that oxy- and deoxyhemoglobin have different magnetic properties, 
and so a change in oxygenation level can cause a small change in the MRI image inten-
sity. By acquiring a time series of images while e.g., presenting visual stimuli and then 
analyzing this time course for these small changes, it is possible to detect where blood 
flow has changed, and this is then related to brain activation. While this method is 
indirect and with a coarser time resolution than MEG, the spatial resolution is excel-
lent, and there is no requirement for tracer injections as with PET and SPECT. 
In terms of brain morphology, many neuroimaging studies of FASD have shown a cor-
relation between prenatal alcohol exposure and reduced total brain size. These reduc-
tions are not necessarily uniform, and some studies which corrected for overall brain 
size reported that size variations were still observable in specific brain areas, even in 
subjects with no facial dysmorphia. Changes in brain shape (e.g., cortical folding) have 
also been observed, with particular effects in the corpus callosum.  
Functional brain studies, particularly fMRI studies, have examined both the level and 
the pattern of brain activity during cognitive tasks as well as measuring functional 
connectivity between cortical areas. Of note here is that differences have been ob-
served in which areas are activated in the brain when the same task is performed by 
subjects and controls, implying that different cognitive strategies are being used. 
Knowledge gaps  
Despite the fast-growing field of MRI, researchers have not yet been able to measure 
the direct impact of prenatal alcohol exposure on the brain. Further research is needed 
to understand brain morphology and functional connectivity between cortical areas.   
Recommendations  
The observed changes - in both structure and function within the brains of individuals 
with FASD - are of great potential value for both understanding the cognitive deficits 
exhibited, as well as for improving future treatments. The knowledge that individuals 
with FASD likely employ different cognitive strategies may imply the need for different 
Chapter 3 
82 
therapy approaches to build on the cognitive strategies that individuals with FASD are 
already using. 
It is worth bearing in mind that MRI is in itself a fast-growing field, with new and im-
proved techniques being rapidly developed. These have the potential to enhance our 
knowledge and deepen our understanding of FASD. For instance, while studies have so 
far concentrated on FA and MD, diffusion MRI may be able to deliver much more de-
tailed information about tissue structure. Examples include the developments in high-
er spatial and directional resolution for DTI in initiatives such as the Connectome study 
(which help reduce confounding effects such as crossing fiber tracts), as well as the 
development of methods used to extract information such as axonal diameters. These 
may contribute to a much better understanding of the effect of PEA on the exact struc-
ture and connectivity of the brain. Another example is the improved spatial and tem-
poral resolution of fMRI with Simultaneous MultiSlice (SMS) techniques, which can 
lead to improved detail of the differences in cortical connections and activation areas. 
A better understanding of these different networks, their differences in construction, 
and differences in cognitive processes, may contribute towards improved therapy for 
individuals with FASD. 
3.5. Child and Youth Health Care 
Lifespan is one of the important dimensions around which the Dutch health care sys-
tem is organized. In the following sections, the management and care provided for 
infants, children, adolescents, and adults from the perspective of the stakeholders - 
pediatricians and child and youth health care professionals - will be described. For 
maternity care see paragraph 2.6. 
Current knowledge in pediatrics 
In the Netherlands, an existing national perinatal database collects data on most preg-
nancies and neonates, including all academic patients (see paragraph 2.6). Registration 
of FAS in this database is almost non-existent, pointing to a severe problem of under-
registration (or under-diagnosis). The Dutch Pediatric Center collects data on specified 
disorders over several years (Nederlands Signaleringscentrum Kindergeneeskunde), 
and collected data on FAS in 2007 and 2008 [242]. In total, data on only 56 children 
were gathered, mainly from adopted children or children under custody, pointing to an 
enormous selection bias. Using questionnaires, only 39 of the 56 were confirmed to 
have FASD [243]. 
Pediatricians and pediatric health care workers are regularly confronted by alcohol 
problems in adolescents. Pediatric multidisciplinary alcohol clinics may have a preven-
tative effect on later pregnancy-related alcohol consumption and possibly contribute 
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to the prevention of FASD in this high-risk group. However, pediatricians and pediatric 
health care workers are less familiar with FASD itself. As syndromes in the spectrum of 
FASD are not easy to diagnose and FASD has a wide differential diagnosis, it is im-
portant to be alert to the possibility of FASD and to have a thorough and up-to-date 
knowledge of the diagnostic criteria (see paragraph 3.2). Reasons for missing the diag-
nosis include insufficient knowledge and time constraints - but also fear of stigmatiza-
tion (see paragraph 2.11).  
Knowledge gaps in pediatrics 
There is a need for better registration of FASD problems in the field of pediatrics. 
There are currently no guidelines for interventions once the diagnosis of syndromes in 
the FASD spectrum has been established. 
There is a lack of knowledge about (bio)markers which can assist in the diagnosis of 
FAS (see paragraph 2.4). New MRI techniques, biochemical biomarkers of damage or 
development in the brain or other organs (e.g., liver), biomarkers of alcohol products 
(e.g., in meconium), and many other developments have not been explored to their 
full potential in relation to FAS. In summary, more research is needed. 
Recommendations for pediatric care 
More emphasis placed on FASD and a better structural education (e.g., recognition, 
diagnostic approaches, management and care) for all caregivers in pediatric care is 
clearly needed. This should start in basic professional education (for doctors at MD 
bachelor and Masters level), and it is especially important that this should continue 
during specialist training (for pediatricians, geneticists, and child neurologists, to speci-
fy all potential members of a FASD multidisciplinary team), and in post-graduate train-
ing courses. Paying particular attention to FAS within the pediatric training syllabus 
(covering themes that must be learned) would be a good start. Also, translation of 
existing guidelines into national and local protocols is necessary (in hospitals but also 
in the public health field). 
Accurately diagnosing individuals within the spectrum of FASD is of great clinical im-
portance, given the high rates of missed diagnosis and misdiagnosis. Good examples of 
decision trees for identifying children affected by prenatal alcohol exposure within 
pediatric care are available and should be used [244].  
In conclusion, recognition of FASD needs to be improved, and more attention should 
be paid to education, intervention implementation and research. More research is also 
required to further our basic knowledge on (bio)markers that can help diagnosis of 
FASD. 
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Current knowledge in child and youth health care (CYHC) 
Prevention, early recognition and timely identification of FASD cases are  necessary - 
first to reduce the adverse effects of FASD and second because affected children need 
long-term support [245,246].  
In 2005, the Dutch Health Council published an advisory report on the risks of alcohol 
consumption as related to conception, pregnancy and breastfeeding [247] (see para-
graph 2.6). However, this report did not at any point address the potential contribution 
of the child and youth health care system in reducing morbidity related to FASD. This is 
noteworthy because the Netherlands has established a high quality system of preven-
tive child and youth health care based on a unique standardized child and youth health 
program underpinned by legislation (Public Health Act) [38].   
Preventive child and youth health care (CYHC) in the Netherlands (in Dutch: jeugdge-
zondheidszorg, JGZ 0-18) provides preventive care for all children aged 0 to 18 years. 
Until the age of 4, children visit child health centers (in Dutch: consultatiebureaus, JGZ 
0-4) for health check-ups. The child health centers also provide medical and parenting 
advice. The most important aspects of preventive child health care are monitoring of 
growth and development, early detection of health problems (or risks) or social prob-
lems, screening and vaccination, and providing advice and information concerning 
health and development. This care is provided by specialized physicians and nurses. 
The child health care centers have a high coverage: almost all children have more than 
one appointment in their first year of life. Before their fourth birthday, children have 
visited a child health center on average about 15 times. After the child’s fourth birth-
day, preventive child health care is taken over by the Youth Health Care Division of 
community health services (in Dutch: GGD) for children and adolescents aged 4-18 
years. Specialized physicians and school nurses offer routine health checks to all chil-
dren at the ages of 5, 10, 13 and 16 years, free of charge, in addition to health and 
developmental assessments and anticipatory guidance for children at risk. They work 
together with other healthcare professionals, schools and welfare services. At each 
appointment, specialized physicians and school nurses look at the specific circum-
stances of the juvenile and their family. If needed, additional appointments can be 
arranged; for example, home visits and other evidence-based interventions are availa-
ble. Challenges for professionals working in child and youth health care include both 
the prevention and early detection of FASD.  
Challenges for CYHC in the field of prevention: 
Prior to pregnancy, preventive interventions may focus on contraception, pregnancy 
planning, and awareness of FASD [248]. 
The complex issues surrounding FASD challenges CYHC professionals to contribute to 
preventive interventions: 
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 by stimulating health education at secondary schools to increase awareness about 
the importance of primary prevention of alcohol-exposed pregnancies; 
 by focusing on non-pregnant adolescent women with risk factors (substance abuse, 
mental ill-health, low SES, women having already given birth to a child diagnosed 
with FASD, women born to biological parents with a history of alcohol abuse, wom-
en fostered/adopted during their childhood) [182];  
 by offering at-risk adolescents anticipatory guidance, helping adolescents develop 
the skills to make responsible decisions and healthy choices (in terms of preventing 
unintended pregnancies), and advising adolescents, prior to conception, about the 
risks of alcohol use during pregnancy and about FASD; 
 by focusing on any subsequent pregnancies of a mother with a child with FASD: 
whenever a child receives an FASD diagnosis, an opportunity arises for discussing 
FASD prevention for any future pregnancies. 
Knowledge gaps in child and youth health care 
Many children with FASD remain undiagnosed because there is a lack of accurate, 
routine screening in preventive child and youth health care. Thus, present prevalence 
rates of FASD underestimate the extent of these disorders: documentation on intrau-
terine alcohol exposure is inconsistent and registration of early symptoms characteris-
tic of prenatal alcohol exposure is incoherent. Assuming that pregnant women do not 
drink alcohol is unjustified. Reassuring pregnant women with information “that a glass 
of wine occasionally is no problem” is incorrect and should be regarded as bad prac-
tice. Greater awareness and consistent screening are needed to be effective in identi-
fying early symptoms and signs included under the FASD umbrella. Early and timely 
identification of FASD-suggestive dysmorphic features and associated problems is 
exactly what should occur during well-child visits to the health centers. Greater aware-
ness and consistent screening are needed in order to be effective in identifying and 
diagnosing FASD [182]. 
Recommendations for child and youth health care 
Professionals involved in child and youth health care should bear FASD in mind when 
evaluating children with developmental problems, behavioral concerns, or school fail-
ure. This is particularly relevant for children in foster care, especially if drug or alcohol 
use by a parent was a contributing factor to the child being placed in care. Like other 
children with complex medical or behavioral disabilities, children with FASD need spe-
cial attention in terms of the provision and coordination of care, and to ensure that the 
necessary medical, behavioral, social, and educational services are provided. Early 
diagnosis of FASD has a protective effect; children who are not diagnosed experience 
higher rates of secondary problems, including disrupted education, delinquency, insti-
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tutional confinement, inappropriate sexual behaviors, and alcohol/drug problems 
[245]. Finally, certain sociodemographic factors should trigger an assessment for an 
FASD, such as foster care, international adoption, or belonging to known risk groups 
[249].  
Professionals working in child and youth care have a basic task in public health for 
children and adolescents [250], so they should not evade their responsibilities in terms 
of the spectrum of FASD prevention approaches available. It is important for profes-
sionals working in child and youth health care to encourage cooperation between 
disciplines in order to tackle both alcohol consumption during pregnancy and FASD-
related problems.  
3.6. Socio-economic Costs 
Current knowledge 
The high prevalence of FASD produces an immense burden on society in financial 
terms, unrealized productivity, and human suffering. In the United States, annual cost 
estimates have ranged from $74.6 million in 1984 to $4.0 billion in 1998. In 2007, the 
estimated annual cost of FASD in Canada was CAD $5.3 billion [14].  
Little is known about the societal costs of FASD. One systematic review of studies con-
cerning the economic impact showed that the literature on this subject is scarce, and 
that the evidence is limited to North America, i.e. Canada, and USA [21]. An update 
carried out for this knowledge synthesis revealed additional studies on this topic - one 
from Canada relating to different aspects of FASD [251–259], and another study from 
Sweden [260]. This limited number of studies looking at the societal costs of FASD do, 
however, show comparable results - that is, that the costs of FASD are relatively high - 
for the individual, the family, and for society. Moreover, these studies show that the 
costs of FASD are not only related to the healthcare sector but that the majority of the 
costs are borne by other sectors, for examples, costs due to (special) education, 
productivity losses, and law enforcement. 
To our current knowledge, there are only three economic evaluation studies [261–263] 
which look at the cost-effectiveness of interventions for FASD based on a model. A 
study by Hopkins et. al., (2008) [261] compared universal screening versus targeted 
screening for fetal alcohol exposure. This study examined the cost-effectiveness of 
testing meconium to detect fetal alcohol spectrum disorder in newborns. From a socie-
tal perspective, screening and treatment was economically attractive if it was imple-
mented universally, and was a dominant strategy if it was targeted to those at high 
risk. Another study by Thanh and colleagues (2015) [263] looked at the cost-
effectiveness of a parent-child assistance program for preventing FASD. The results of 
this study indicate that implementing a parent-child assistance program can also be 
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cost-effective. Finally, Popova et al. (2013) [254] proposed that the use of specialized 
addiction treatment for clients with FASD could reduce the overall costs to society. 
Knowledge gaps 
There are no available economic evaluation studies for FASD in the Netherlands. Re-
cently, the RIVM report, ‘Maatschappelijke kosten-batenanalyse van beleidsmaat-
regelen om alcoholgebruik te verminderen’ (Social cost-benefit analysis of regulatory 
policies to reduce alcohol use in the Netherlands) was published [264]. It is not easy to 
express all of the costs and benefits of alcohol use in monetary terms, and this is defi-
nitely the case for any FASD costs-benefit analyses.  Lastly, it is worth noting that these 
considerations not only influence national government policies, but also policies at a 
European level.   
Recommendations 
Based on the limited available evidence, we can surmise that FASD is a serious health 
problem with high inter-sectoral costs. Interventions focusing on prevention, parent-
child assistance programs, and specialized addiction treatment appear to be cost-
effective ways of reducing this burden.  
3.7. Interventions to Promote Early Detection and to Optimize 
Management and Care 
Current knowledge 
Accurate diagnosis of FASD provides the basis for future research aiming to identify 
developmental trajectories and refine intervention strategies. Until now, too many 
children in the Netherlands affected by prenatal alcohol exposure are not accurately 
identified. Examples of how diagnostic processes and associated interventions should 
be implemented can be found in relation to other diseases in pediatrics such as diabe-
tes type I, obesity, and in relation to many well organized rare disease clinics 
[265,266]. 
As elaborated upon in paragraph 2.13, planned health promotion interventions de-
signed to change behavior need to address three issues: correct identification of the 
desired behaviors and their determinants, the selection and correct application of 
behavior change methods in an intervention, and adequate implementation of that 
intervention.  
Early Detection. Child and Youth Health Care professionals should consider FASD when 
evaluating children with developmental problems, behavioral concerns, or school fail-
ure. These diagnoses should particularly be considered for children in foster care, es-
pecially if drug or alcohol use by a parent contributed to the child being placed in care. 
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Like other children with complex medical or behavioral disabilities, children with FASD 
need special attention in terms of the provision and coordination of care, and to en-
sure that the necessary medical, behavioral, social, and educational services are pro-
vided. Early diagnosis of FASD has a protective effect; children who are not diagnosed 
experience higher rates of secondary problems, including disrupted education, delin-
quency, institutional confinement, inappropriate sexual behaviors, and alcohol/drug 
problems [230]. Finally, certain sociodemographic factors should trigger an assessment 
for an FASD, such as foster care, international adoption, or belonging to known risk 
groups [236].  
Who are the actors for early detection? First, the mother or caretaker. Many children 
with FASD remain undiagnosed because there is a lack of accurate, routine screening in 
preventive child and youth health care. As mentioned earlier, early and timely identifi-
cation of FASD should occur during well-child visits to child health centers. Greater 
awareness and consistent screening are needed to be effective in identifying and diag-
nosing FASD [235].  As FASD is not easy to diagnose, and has a wide range of differen-
tial diagnoses, it is important to pay continuous attention to the possibility of FASD and 
especially a good knowledge of the diagnostic criteria. Reasons to miss the diagnosis 
are insufficient knowledge, time constraints but also fear of stigmatization. More at-
tention needs to be given to the topic of FASD, along with a better education for all 
caregivers in child health. This needs to start in basic professional and should continue 
during further specialized training (e.g., for pediatrician, geneticist, child neurologist) 
and in post-graduate training courses. The translation of existing guidelines into na-
tional and local protocols is also necessary (in hospitals but also in the public health 
field). 
What is the evidence for the effectiveness of interventions designed to promote early 
diagnoses? As far as we know, there is no systematic evidence available to answer this 
question. The case study from Sweden outlined in the WHO report (2016) [43] sug-
gests the need for the development of materials to both support and train teachers 
and child health care workers, but the report does not provide information on specific 
behaviors and determinants. As a consequence, there are no systematic descriptions 
or evaluations of interventions designed to promote early diagnosis for FASD.  
Management and Care. Actors for management and care include parents or other 
caretakers, teachers, pediatricians and pediatric health care workers, neuropsycholo-
gists, psychiatrists, and other child and youth health care professionals involved in the 
care of an individual with FASD. 
What is the evidence for the effectiveness of interventions designed to promote early 
detection and to optimize management and care? Again, as far as we know, there is no 
systematic evidence available to answer this question.  Studies evaluating the effects of 
neuropsychological interventions are still limited, and only a very few studies have 
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investigated their effectiveness and efficacy in individuals prenatally exposed to alcohol 
[e.g. ,267,268].  
In the Netherlands, there are currently no guidelines for the use of interventions once 
the diagnosis of FASD has been established. Clearly, the Netherlands has good support 
systems in place for social, psychological, medical and learning disorders but there is 
no coordination in terms of the management and care of FASD.  More research is 
needed on how to coordinate these efforts in a multidisciplinary fashion.  
Lack of knowledge and recommendations 
It is obvious that evidence-based knowledge about the early diagnoses of FASD - and in 
particular the management of and care provided for children with FASD and their care-
takers - is insufficient, also in the Netherlands. 
Given the complex nature of FASD, it is not only the health system that should be in-
volved, but also other systems such as educational, social, vocational, and justice sys-
tems. The need for intervention from infancy onward, and the importance of recogniz-
ing and addressing comorbidities, is warranted. Environment modification in order to 
assist the individual diagnosed within the spectrum of FASD is of utmost importance.    
As mentioned earlier, inspiration for establishing good clinical practices - for all profes-
sional groups that are involved with prevention and/or management of children and 
adults with FASD - can be gleaned from looking at recent developments in the Nether-
lands and in Europe regarding specialized rare disease clinics [265,266]. For infants, 
children, and adolescents, it is the responsibility of child and youth health care systems 
(disciplines participating in a multidisciplinary team for the diagnosis of FASD, see par-
agraph 3.2), not only to provide timely diagnoses and optimal care but also to take the 
lead when it comes to implementing best practices.   
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4. STATE OF THE ART 
“Only if you understand the core of FASD problems can you think about solutions”  
This chapter summarizes state of the art of FASD challenges as discussed in Chapters 2 
and 3. The following topics will be addressed: alcohol consumption, etiology and path-
ogenesis, biomarkers for alcohol use, genetic factors and alcohol consumption, mater-
nity care, prevalence of FASD, risk behaviors, psychosocial determinants of maternal 
drinking behavior, environmental conditions, stigma, legal and ethical issues, interven-
tions designed to prevent harm caused by alcohol exposure in pregnancy, FASD diag-
nosis, neuropsychological testing, neuroimaging, child and youth health care, socio-
economic costs, and interventions designed to promote early detection and to opti-
mize management and care.  
Alcohol consumption (paragraph 2.2) 
The percentage of women who drink alcohol has increased over time; in the Nether-
lands, 81.9% of all women drink alcohol [39]. Concern about alcohol use in pregnancy 
has also increased, but more slowly and much later. The latest data indicate that, in 
the Netherlands, 8.9% of pregnant women drink alcohol, 6.9% in the first three months 
of pregnancy and 3.2% after three months [39]. The current health promoting message 
in most countries recommends abstinence during pregnancy. Binge drinking is espe-
cially risky; in the Netherlands, 80.5% of all pregnant women drinking alcohol con-
sumed 1-3 glasses per occasion and 0.8% drank 4 or more glasses per occasion [39,40].  
Etiology and pathogenesis (paragraph 2.3) 
Ethanol intake of the mother damages the fetus in multiple ways. Beside ethanol and 
acetaldehyde toxicity, the main effect is increased oxidative stress which triggers sev-
eral downstream pathways including changes in epigenetic imprinting, gene expres-
sion, and metabolite levels. Clinical studies on low to moderate levels of alcohol expo-
sure yield conflicting results, while animal studies with controlled levels of exposure 
may yield results that are not directly transferable to humans. The main gaps in our 
knowledge about FASD are a lack of pathophysiological understanding, a lack of 
agreement on whether there is a safe dose for EtOH intake during pregnancy, and the 
fact that there are no reliable biomarkers for either FASD detection or estimation of 
susceptibility, and no cure. 
Biomarkers for alcohol use (paragraph 2.4) 
Several groups of biomarkers have been discovered in relation to FASD: (1) clinical; (2) 
molecular; (3) omic; (4) imaging; (5) meconium; (6) cord blood; (7) anatomical; and (8) 
neurobehavioral biomarkers. Heavy drinkers can be identified using biomarkers of 
alcohol metabolism or alcohol induced pathophysiology (e.g. EtG, FAEE, PEth) but in 
the range of low and middle (as well as irregular) consumption, none of the markers 
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are currently sensitive enough. When it comes to assessment of alcohol abstinence or 
alcohol consumption in pregnant women, none of the biomarkers is yet reliable 
enough to estimate the risk of FASD or make a diagnosis of FASD. 
Genetic factors and alcohol consumption (paragraph 2.5) 
Genetic research contributes to a better understanding of the pathogenesis of FASD. 
Identifying genetic determinants of drinking patterns may be useful when it comes to 
identifying biological mechanisms that contribute to specific drinking patterns and to 
identifying women at risk of alcohol consumption, especially at high levels. Thus, it is 
important to investigate the role of genomic variation in FASD as related to different 
levels of alcohol intake. The application of new genetic technologies offers opportuni-
ties for using this information in clinical diagnosis and management. In addition, this 
knowledge is important for prevention. Prevention strategies for moderating and 
stopping alcohol consumption in women before and during pregnancy may target 
these pathogenetic mechanisms and may be directed towards individuals at high risk 
of alcohol consumption due to genetic predisposition. The recommendation for re-
searchers is to focus upon the translation of basic genetic research into clinical practice 
and to unravel the complex interactions between genes, brain and behavior.  
Maternity care (paragraph 2.6) 
Maternity care is well organized in the Netherlands. What is remarkable is the neglect 
of issues concerning FASD prevention, diagnosis and treatment within the knowledge 
system of maternity care. Maternity care workers - stakeholders - should actively ad-
dress the topic of alcohol exposure before, during, and after pregnancy, and feel re-
sponsible for collecting reliable data about alcohol consumption during pregnancy. It 
would make sense to use the existing maternity care knowledge infrastructure and for 
stakeholders to join forces to develop screening and (brief) evidence-based interven-
tion programs. 
Prevalence of FASD (paragraph 2.7) 
The first publications on the harmful effects of prenatal alcohol exposure date from 
1968 and 1973. Because FASD is a birth defect, we use the term prevalence instead of 
incidence. Prevalence rates of FASD within the general population, as reported in a 
recently conducted systematic meta-analysis (Roozen et al. 2016) were only available 
for 10 countries (data were not available for the Netherlands); prevalence estimates 
varied from 0 to 176.77 per 1,000 livebirths worldwide. For FAS, the global prevalence 
rate was estimated to be 2.89 per 1,000 livebirths [85]. Popova and colleagues [42] 
estimated a global FAS prevalence rate of 14.6 per 10,000 livebirths and FAS preva-
lence rates in Europe of 37.4 per 10,000 livebirths. The figures of these recent studies 
should, however, be interpreted with caution, given the limitations of the available 
data. 
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In the Netherlands, there is no structured surveillance system that monitors FASD, and 
therefore no reliable data are available. The recommendation is to follow the BMA 
(2016) guidelines [15] to determine populations at risk, and to implement uniform 
diagnostic criteria for FASD using the recently updated clinical guidelines proposed by 
Hoyme and colleagues (2016) [14]. 
Risk Behaviors (paragraph 2.8) 
Health promotion messages designed to prevent prenatal alcohol exposure should be 
based on epidemiological data identifying which specific prenatal alcohol drinking 
behaviors lead to risk. That knowledge is currently limited. The main reason for this is 
that studies use various techniques and implement them in different ways, so that 
comparisons across studies are difficult and drawing general conclusions is not justi-
fied. Moreover, meta-analyses are impossible. This is also why all the current guide-
lines (e.g., WHO, BMA, Dutch Health Council) suggest abstinence during pregnancy as 
the only safe advice. However, more attention needs to be given to women who drink 
alcohol during pregnancy, with special attention for specific risk groups such as preg-
nant women who drink heavily. One recommendation is for researchers to make sure 
that their measures of alcohol use are comparable to measures in other studies. 
Moreover, to date, the designs of almost all of these studies have been retrospective, 
and there is a need for more prospective studies. 
Psychosocial determinants of maternal drinking behavior (paragraph 2.9) 
In terms of behavioral change, it is necessary to understand the determinants of the 
behavior and their underlying beliefs. In summary, research on determinants of ma-
ternal drinking shows that there are negative associations between maternal drinking 
and risk perception beliefs about harm to the unborn baby, attitudinal beliefs about 
advantages of not-drinking for the baby, normative beliefs of the partner and of mid-
wives, and self-efficacy beliefs regarding abstaining. There are positive relationships 
between maternal drinking and the risk perception belief that only larger amounts of 
alcohol will hurt the baby, the attitudinal belief that not-drinking has disadvantages 
(e.g. stress), the alcohol intake of the partner, self-efficacy beliefs related to negative 
emotions, higher habitual alcohol intake before pregnancy, and cue-reactivity related 
to alcohol. On the whole, the literature on determinants is limited. The research meth-
ods utilized are too simple and many potentially relevant determinants are not investi-
gated. Most studies focus on pregnant women and ignore women who might be preg-
nant as well as unplanned pregnancies. The only Dutch study of high quality and show-
ing a comparable pattern of results is listed above [118]. 
Environmental conditions (paragraph 2.10) 
Women who are - or may be - pregnant, the child with FASD, caretakers, and child and 
youth health professionals are all embedded in a social and physical environment that 
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influences their behaviors and the determinants of those behaviors. Environmental 
conditions are controlled by decision-makers at the interpersonal (e.g. partner), organ-
izational (e.g. YHC), community (e.g. school) and policy (e.g. alcohol marketing) levels. 
There has been almost no systematic research on these agents, their behavior, or the 
determinants of their behavior. One Dutch study showed that pregnant women re-
ceived the abstinence message from their midwife but only reactively, while alcohol 
use was not systematically screened. Pregnant women who drink receive conflicting 
advice about alcohol from midwives and general practitioners [137]. The recommen-
dation is to identify environmental conditions related to maternal drinking, and identi-
fy who the relevant decision-makers are, following a theory- and evidence-based pro-
cedure. 
Stigma (paragraph 2.11) 
Stigmatization is a process by which a person is identified as different and then deval-
uated. Public stigma of women who use (or have used) alcohol during pregnancy re-
sults in blaming and shaming. Well-intended information about the biological explana-
tions for alcohol dependence may in fact contribute to public stigma. Children and 
youth with FASD can be misunderstood, disrespected and blamed, as they are often 
held responsible for their inability to offset the negative impact of FASD by, for exam-
ple, controlling their behaviors or ‘acting their age’. Mothers of children with FASD 
may hold themselves accountable, leading to self-stigma, and these women may not 
acknowledge the relevant social and cultural influences contributing to their alcohol 
use. Associates of children and youth with FASD and their mothers are also subjected 
to stigmatization. Non-biological parents may feel compelled to disclose that their 
child was adopted. Structural stigma is reflected in the criminalization of women who 
drink alcohol during pregnancy. Even well-intended health promotion messages may 
contribute to structural stigmatization. Fear of stigmatization is therefore an impedi-
ment to the prevention of prenatal exposure to alcohol. The recommendation is to 
systematically investigate the beliefs underlying stigmatization - as well as the struc-
tures that contribute to stigmatization - in order to develop interventions aimed at 
decreasing the amount of stigmatization.  
Legal and ethical issues (paragraph 2.12) 
It is clear that alcohol problems should be investigated within a broader context of 
lifestyle and environmental conditions. There is a need for a more appropriate under-
standing of the complexity of the topic and the dynamics of policy discussions within 
society. Simply blaming the mother and (unborn) child is a pitfall that we shouldn’t fall 
into. Legal and ethical considerations can contribute to our understanding and should 
be used as tools for influencing policy discussions. 
Interventions designed to prevent harm caused by alcohol exposure in pregnancy (par-
agraph 2.13) should be further developed. 
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In order to develop effective interventions, we need to (1) identify the relevant target 
behaviors and their determinants, (2) apply appropriate behavior change methodolo-
gies, and (3) adequately implement the intervention. The range of interventions cur-
rently available is poor, due to the low quality of intervention studies. A 2016 WHO 
report [43] documents case studies from the Member States. The report mentions that 
half of the pregnancies in Europe are unplanned and that our knowledge on determi-
nants is limited. The growing influence of alcohol marketing targeting women is recog-
nized, and the WHO recommends the routine collection of FASD data in all Member 
States. Public health promotion interventions targeting alcohol consumption will also 
impact prenatal alcohol exposure. Effectively using contraception can also prevent 
prenatal alcohol exposure. The evidence for the effects of interventions targeting 
pregnant women is limited, although suggests a potentially positive effect of simply 
assessing alcohol intake. A Dutch study on training midwives suggests that a counsel-
ling intervention as well as an eHealth intervention may contribute to reduced drinking 
in pregnant women, and that the eHealth intervention may be more cost-effective 
[179,180]. There is a lack of interventions based in theory and evidence, despite re-
search showing that promoting risk awareness should always be combined with in-
creasing self-efficacy in order to have the desired effect. The Intervention Mapping 
protocol provides the means for planning theory- and evidence-based health promo-
tion interventions. 
FASD Diagnosis (paragraph 3.2) 
When it comes to FASD diagnosis, the search continues for appropriate methodology 
that can be used to measure key features of FAS (e.g., structural abnormalities, neuro-
developmental deficits). There are several different guidelines available for making a 
diagnosis in the FASD spectrum. However, there is no agreement on a universal diag-
nostic system for FASD. Diagnosis of FASD requires a multidisciplinary approach, and 
guidelines should be developed by the professional associations involved. Multidisci-
plinary evidence-based guidelines can be developed within the existing tradition of 
guideline development used in the Dutch health care system. The recommendation is 
to develop these guidelines and implement them in clinical practice. 
Neuropsychological testing (paragraph 3.3) 
Neuropsychological testing is important for the diagnosis and treatment of individuals 
prenatally exposed to alcohol. Research should use tests measuring cognition, motiva-
tion, and/or temporal processing. Moreover, research should focus on the validity of 
these tests (in relation to FASD) in a developmental context, and norm data should be 
collected for representative standardization samples.  
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Neuroimaging (paragraph 3.4) 
Many technological advances have been made over the last decades in terms of ways 
in which to examine the structure and function of the brain. Several different neu-
roimaging techniques have been applied to study individuals prenatally exposed to 
alcohol, particularly MEG, PET, SPECT, and MRI, each with their own benefits and re-
strictions. These techniques are of great potential value, both in terms of understand-
ing the cognitive deficits exhibited in individuals affected by FASD, as well as in relation 
to future treatments for individuals prenatally exposed to alcohol. The knowledge that 
different cognitive strategies may be utilized by individuals with FASD may suggest the 
need for different treatment approaches to build on the cognitive strategies that indi-
viduals with FASD are already using. 
Child and youth health care (paragraph 3.5) 
Pediatrics. Registration of FASD in the Netherlands is almost non-existent and should 
be improved. Pediatricians may miss the FASD diagnosis because of insufficient 
knowledge or time constraints but also due to fear of stigmatization. It is highly rec-
ommended that pediatricians and their professional associations take an active role in 
the diagnosis of FASD. 
Child and youth health care (CYHC). The report by the Dutch Health Council (2005) 
mentioned the negative effects of prenatal alcohol exposure and FAS [38]. The report 
did not address the role of child and youth health care in reducing morbidity related to 
FASD. The CYHC centers have a high coverage and see almost all children repeatedly 
over their lifespan. Currently, child and youth health care contributes to primary pre-
vention by increasing awareness through school programs, helping adolescents to 
develop the skills to make responsible choices (thereby also preventing unintended 
pregnancies), and focusing on non-pregnant women at risk (e.g. women who have 
already had a child with FASD). Early diagnosis of FASD has a protective effect. The 
recommendation is to promote health professionals’ awareness of considering FASD 
when evaluating children with problem behaviors.  
Socio-economic costs (paragraph 3.6) 
The high prevalence of FASD places an immense financial burden on society in terms of 
unrealized productivity and human suffering. There are three economic evaluation 
studies [261–263] which have explored the cost-effectiveness of interventions for 
FASD. These studies concluded that these interventions were cost-effective. There are 
no available economic evaluation studies for FASD in the Netherlands. We recommend 
that the financial burden FASD places on society is systematically investigated. In addi-
tion, it is recommended that the inter-sectoral costs and benefits of FASD prevention 
are investigated.  
State of the Art 
99 
Interventions to promote early detection and to optimize management and care (para-
graph 3.7) 
Globally, and in the Netherlands, evidence-based knowledge about early diagnosis of 
FASD and the management and care of children with FASD is insufficient. It is im-
portant to identify the relevant decision-makers or stakeholders responsible for early 
diagnosis and optimal management and care. There has been insufficient research 
carried out on interventions to promote early detection and optimize management 
and care. Cross-sectoral cooperation between different systems (e.g., educational and 
justice systems) is essential for the development of good clinical practice. This should 
be for the aim of all professional groups that are involved with prevention and man-
agement of children and adults with FASD.   
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5. SETTING PRIORITIES & CONCLUSION 
Based on the current state of the art, what are the priorities for FASD prevention and 
care in the Netherlands? A dual-track policy would appear to be the best approach, 
consisting of: 1. short-term consensus and action directed at prevention, early detec-
tion and care, combined with 2. a longer-term research and reflection program. At 
least four groups of actors and actions are involved in these priorities:  
(a) Women/mothers/caretakers/foster parents,  
(b) Child and youth healthcare workers,  
(c) Government  
(d) Researchers.  
The short-term action, priority 1, focuses on translating current knowledge into cur-
rent practice; our knowledge is indeed limited, but at the same time, we know much 
more than what is currently applied in practice. The various professionals involved, 
and their organizations, should develop guidelines for best practice in terms of preven-
tion, early diagnosis, management and care. Other areas of research can provide good 
examples of how to build consensus within a group of professionals, and reach agree-
ment on best practices. The government should systematically stimulate and support 
these processes within the relevant professional organizations.  
The longer-term research and development activities, priority 2, should focus on the 
specific Dutch setting - the norms and characteristics of our health care system. There 
is a need for theory- and evidence-based development of (a) more effective preven-
tion messages, as well as (b) training programs for all professionals involved in com-
munication with women, mothers, caretakers and foster parents. The issue of stigma 
reduction is particularly relevant in both proposed research programs, taking into 
account the first recommendation from an ethical perspective: promoting the welfare 
of children with FASD.   
Table 5 provides an overview of current priority questions. The priority scores indicate 
support for the proposed dual-track policy: short-term consensus on action and long-
er-term research for improvement of prevention as well as early diagnosis and provi-
sion of care. 
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Conclusion 
Priority 1: Short-term consensus and action directed at prevention, early detection 
and care 
1.1 The short-term consensus should first focus on the healthcare workers involved in 
prevention, early detection, management and care, urging them to decide on best 
practice and optimal task division, while dealing effectively with stigma and ethical 
challenges.  
1.2 Secondly, focus should turn to what we know about etiology, prevalence and effec-
tive interventions to prevent FASD, especially in high-risk groups.  
1.3   The Government should actively promote and support these activities. 
Priority 2: Longer-term research and reflection program. 
2.1 In the longer-term, a theory- and evidence-based research program should con-
tribute to the systematic development of health promotion interventions directed at 
women before they get pregnant, those planning to get pregnant and pregnant wom-
en, as well as high-risk groups (e.g., binge drinking women), in order to optimize the 
message of not drinking.  
2.2 A second research priority should focus on the optimal implementation of best 
practices in the prevention, early diagnosis, management and care of FAS. Here, again, 
the outcomes depend upon effectively dealing with stigma and ethical challenges, and 
empowering women, mothers and caretakers to cope with a difficult behavior change.  
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Samenvatting 
Deze kennissynthese heeft als onderwerp Foetal Alcohol Spectrum Stoornis (FASD). De 
ontwikkeling van het ongeboren kind komt in gevaar door consumptie van alcohol 
door de moeder tijdens de zwangerschap. FASD is de overkoepelende term voor ge-
boorteafwijkingen ten gevolge van prenatale blootstelling aan de stof ethanol. Het 
handelt hier om een belangrijk en schrijnend probleem, des te meer daar de gezond-
heidsproblemen van het (on)geboren kind te voorkomen zijn. 
Over de omvang en ernst van het probleem weten wij nog te weinig. Ook schiet onze 
kennis over diagnostiek, behandeling en begeleiding tekort. FASD is één van de belang-
rijkste te voorkomen oorzaken van een verstandelijke handicap. De Nederlandse Ge-
zondheidsraad concludeerde al in 2005 dat wij nog te weinig weten over welk drinkge-
drag nu schadelijk is voor het ongeboren kind. 
Het opstellen van een kennissynthese over Foetaal Alcohol Syndroom (FASD) is nood-
zakelijk voor interventieprogramma’s, vervolgonderzoek en beleid. 
FASD is een te voorkomen aandoening. Maar om uiteindelijk effectieve interventies te 
ontwikkelen is een zorgvuldig planningsproces noodzakelijk. Intervention Mapping 
(IM) is zo’n planningsproces. In de kennissynthese wordt aan de hand van het IM pro-
tocol over door ZonMw geformuleerde FASD kennisvragen met betrekking tot de om-
vang van het probleem (prevalentie/incidentie), het vermijden van het probleem (pre-
ventie) en het inventariseren van bestaande knelpunten rond diagnostiek, begeleiding 
en behandeling, nader gerapporteerd. 
De Kennissynthese omvat 5 hoofdstukken. Na een korte uitleg over IM en het noemen 
van de door ZonMw geformuleerde vragen over FASD (hoofdstuk 1) gaat de aandacht 
in hoofdstuk 2 uit naar primaire preventie en in hoofdstuk 3 naar secondaire en tertiai-
re preventie. Hoofdstuk 4 ‘State of the Art’ betreft een samenvatting van de huidige 
stand van zaken rond de in hoofdstuk 2 en 3 besproken thema’s. Aan de orde komen: 
alcohol consumptie, etiologie en pathogenese, biomarkers voor alcohol gebruik, gene-
tische factoren, preconceptiezorg, prevalentie, risicogedrag, psycho-sociale determi-
nanten van drinkgedrag, omgeving condities, stigma, juridische en ethische aspecten 
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en interventies om schade veroorzaakt door blootstelling aan alcohol in zwangerschap 
te voorkomen.  
Op basis van huidige kennis en gesignaleerde tekortkomingen zoals besproken in 
hoofdstuk 2, 3 en 4 wordt in hoofdstuk 5 aandacht besteed aan de prioritering van 
FASD gerelateerde onderzoeksvragen. Naast relevantie wordt tevens haalbaarheid 
voor verandering in ogenschouw genomen. Geconcludeerd wordt dat FASD preventie 
en zorg in Nederland gebaat is met een tweesporenbeleid: voor de korte termijn het 
ondernemen van acties gericht op preventie, vroege detectie en zorg gecombineerd 
met op de lange termijn de nodige aandacht voor verder onderzoek en reflectie op 
deze complexe problematiek. Acties op korte termijn dienen gericht te zijn op het 
vertalen van reeds aanwezige kennis en inzichten naar de huidige zorgpraktijk. Er is 
immers kennis voor handen waar de zorgpraktijk direct bij gebaat is. Een langere ter-
mijn onderzoeksprogramma kan de zorgpraktijk verbeteren door planmatige toepas-
sing van theorie en evidentie bij zowel preventie als diagnostiek, begeleiding en be-
handeling. 
  
109 
References 
1.  O’Leary CM, Nassar N, Kurinczuk JJ, de Klerk N, Geelhoed E, Elliott EJ, et al. Prenatal alcohol exposure 
and risk of birth defects. Pediatrics. 2010;126:e843-50.  
2.  May PA, Gossage JP, White-Country M, Goodhart K, Decoteau S, Trujillo PM, et al. Alcohol consumption 
and other maternal risk factors for fetal alcohol syndrome among three distinct samples of women 
before, during, and after pregnancy: the risk is relative. Am. J. Med. Genet. C. Semin. Med. Genet. 
2004;127C:10–20.  
3.  Morleo M, Woolfall K, Dedman D, Mukherjee R, Bellis MA, Cook PA. Under-reporting of foetal alcohol 
spectrum disorders: an analysis of hospital episode statistics. BMC Pediatr. BioMed Central Ltd; 
2011;11:14.  
4.  World Health Organization. European action plan to reduce the harmful use of alcohol 2012–2020. 
Copenhagen; 2012.  
5.  World Health Organization. Global status report on alcohol and health-2014. Copenhagen; 2014.  
6.  World Health Organization. Alcohol in the European Union. Consumption, harm and policy approaches. 
Copenhagen; 2012.  
7.  May PA, Blankenship J, Marais AS, Gossage JP, Kalberg WO, Barnard R, et al. Approaching the 
Prevalence of the Full Spectrum of Fetal Alcohol Spectrum Disorders in a South African Population-
Based Study. Alcohol. Clin. Exp. Res. 2013;37:818–30.  
8.  Landgren M, Svensson L, Strömland K, Andersson Grönlund M. Prenatal alcohol exposure and 
neurodevelopmental disorders in children adopted from eastern Europe. Pediatrics. 2010;125:e1178-85.  
9.  American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 
Washington DC; 2013.  
10.  Harris JC. New classification for neurodevelopmental disorders in DSM-5. Curr. Opin. Psychiatry. 
2014;27:95–7.  
11.  Hagan JF, Balachova T, Bertrand J, Chasnoff I, Dang E, Fernandez-Baca D, et al. Neurobehavioral 
Disorder Associated With Prenatal Alcohol Exposure. Pediatrics. 2016;138.  
12.  Abel EL, Sokol RJ. Incidence of fetal alcohol syndrome and economic impact of FAS-related anomalies. 
Drug Alcohol Depend. 1987;19:51–70.  
13.  Abel EL, Sokol RJ. Fetal alcohol syndrome is now leading cause of mental retardation. Lancet. 
1986;328:1222.  
14.  Hoyme, H.E., Kalberg, W.O., Elliott, A.J., Blankenship, J., Buckley, D., Marais, A.S., Manning, M.A., 
Robinson, L.K., Adam, M.P., Abdul-Rahman, O. and Jewett T. Updated Clinical Guidelines for Diagnosing 
Fetal Alcohol Spectrum Disorders. Pediatrics. 2016;138.  
15.  British Medical Association. Alcohol and pregnancy Preventing and managing fetal alcohol spectrum 
disorders, june 2007, updated february 2016. 2016.  
16.  Bartholomew Eldredge LK, Markham C, Ruiter RAC, Fernandez M, Kok G. Planning health promotion 
programs: an Intervention Mapping approach. John Wiley & Sons; 2016.  
 110 
17.  Kok G, Gottlieb NH, Peters G-JY, Mullen PD, Parcel GS, Ruiter RAC, et al. A Taxonomy of Behavior 
Change Methods; an Intervention Mapping Approach. Health Psychol. Rev. Taylor & Francis; 
2015;31:1–32.  
18.  Roozen S, Black D, Peters G-JY, Kok G, Townend D, Nijhuis JG, et al. Fetal Alcohol Spectrum Disorders 
(FASD): an Approach to Effective Prevention. Curr. Dev. Disord. Reports. Current Developmental 
Disorders Reports; 2016;3:229–34.  
19.  Carpenter B, Blackburn C, Egerton J. A brief introduction to fetal alcohol spectrum disorders. In: 
Carpenter B, Blackburn C, Egerton J, editors. Fetal alcohol Spectr. Disord. Interdiscip. Perspect. New 
York: Routledge; 2013. p. 3.  
20.  Abel EL, Sokol RJ. A revised conservative estimate of the incidence of FAS and its economic impact. 
Alcohol. Clin. Exp. Res. 1991;15:514–24.  
21.  Popova S, Stade B, Bekmuradov D, Lange S, Rehm J. What do we know about the economic impact of 
fetal alcohol spectrum disorder? A systematic literature review. Alcohol Alcohol. 2011;46:490–7.  
22.  Thanh NX, Jonsson E. Costs of fetal alcohol spectrum disorder in Alberta, Canada. Can. J. Clin. 
Pharmacol. 2009;16:e80–90.  
23.  Koren G, Nulman I, Chudley AE, Loocke C. Fetal alcohol spectrum disorder. CMAJ. 2003;169:1181–5.  
24.  Health Council of the Netherlands. Preconception care: for a good beginning. The Hague; 2007.  
25.  BBC series. Inspector_Lynley_Mysteries. A Cry for Justice. 2004.  
26.  Golden J. Message in a bottle. The making of fetal alcohol syndrome. Cambridge: Harvard University 
Press; 2005.  
27.  Van Laar MW, Van Ooyen-Houben MMJ. Nationale drug monitor jaarbericht 2015. Trimbos-instituut. 
2015.  
28.  Lemmens P. Relationship of alcohol consumption and alcohol problems at the population level. In: 
Heather N, Peters TJ, Stockwell T, editors. Int. Handb. alcohol Depend. Probl. Chichester: Wiley; 2001.  
29.  Lemoine P, Harousseau H, Borteyru JP, Menuet JC. Les enfants des parents alcoholiques: anomolies 
observees a propos de 127 cas. Ouest méd. 1968;21:476–82.  
30.  Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet. 1973;302:999–
1001.  
31.  Armstrong EM, Abel EL. Fetal alcohol syndrome: the origins of a moral panic. Alcohol Alcohol. 
2000;35:276–82.  
32.  Drabble LA, Poole N, Magri R, Tumwesiguy NM, Qing. L, Plant M. Conceiving risk, divergent Responses: 
Perspectives on the evolution of the construction of FASD in six countries. Subst. Use Misuse. 
2011;46:943–58.  
33.  ICAP. International Guidelines on Drinking and Pregnancy. 2009.  
34.  Raad voor Strafrechtstoepassing en Jeugdbescherming. Advies Prenatale kinderbescherming en de rol 
van de overheid. Den Haag; 2015.  
35.  De Wert G, Berghmans R. Neem zwangere verslaafde vroeger op. Schade door alcohol of drugs bij het 
kind is er al voor de 24ste week. NRC-Handelsblad. 2009 Jan 9;9.  
36.  Hondius AJK, Stikker TE, Wennink JMB, Honig A. Wet BOPZ toegepast bij vroege zwangerschap van 
verslaafde. Ned. Tijdschr. Geneeskd. 2011;155.  
37.  Tholen J, Siero S. Alcoholgebruik tijdens de zwangerschap. Tijdschr. voor Soc. gezondheidszorg. 
1989;67:149.  
38.  Health Council of the Netherlands. Risks of alcohol consumption related to conception, pregnancy and 
breastfeeding. The Hague; 2005.  
39.  Lanting CI, van Wouwe JP, Van Dommelen P, De Josselin de Jong S, Kleinjan M, Van Laar M. Factsheet 
“Alcoholgebruik tijdens zwangerschap en borstvoeding.” TNO en Trimbos Instituut; 2015.  
40.  Lanting CI, van Dommelen P, van der Pal-de Bruin KM, Bennebroek Gravenhorst J, van Wouwe JP. 
Prevalence and pattern of alcohol consumption during pregnancy in the Netherlands. BMC Public 
Health. 2015;15.  
41.  ZonMw. Zwangerschap en geboorte Een impressie van het kennisnetwerk geboortezorg en 
onderzoeksprojecten [Internet]. 2014. Available from: www.zonmw.nl/zwangerschapengeboorte 
References 
111 
42.  Popova S, Lange S, Probst C, Gmel G, Rehm J. Estimation of national, regional, and global prevalence of 
alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and meta-analysis. 
Lancet Glob. Heal. 2017;1–10.  
43.  Schölin L. Prevention of harm caused by alcohol exposure in pregnancy. Copenhagen; 2016.  
44.  Koop DR. Alcohol metabolism’s damaging effects on the cell. Alcohol Res Heal. 2006;29:274–80.  
45.  Gupta KK, Gupta VK, Shirasaka T. An Update on Fetal Alcohol Syndrome - Pathogenesis, Risks, and 
Treatment. Alcohol. Clin. Exp. Res. 2016;40:1594–602.  
46.  Sarkar DK. Male germline transmits fetal alcohol epigenetic marks for multiple generations: A review. 
Addict. Biol. 2016;21:23–34.  
47.  Porter NA. Chemistry of lipid peroxidation. Methods Enzymol. 1984;105:273–82.  
48.  Eijkelenboom A, Burgering BMT. FOXOs: signalling integrators for homeostasis maintenance. Nat. Rev. 
Mol. Cell Biol. Nature Publishing Group; 2013;14:83–97.  
49.  Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing 
gastrointestinal cancers. Cochrane Database Syst. Rev. 2008;  
50.  Mathew MC, Ervin A-M, Tao J, Davis RM. Antioxidant vitamin supplementation for preventing and 
slowing the progression of age-related cataract. Cochrane database Syst. Rev. 2012;6:CD004567.  
51.  Bjelakovic G, Ll G, Nikolova D, Bjelakovic M, Nagorni A, Gluud C, et al. Antioxidant supplements for liver 
diseases. Cochrane Database Syst Rev. 2011;16:3–5.  
52.  Eberhart JK, Parnell SE. The Genetics of Fetal Alcohol Spectrum Disorders. Alcohol. Clin. Exp. Res. 
2016;40:1154–65.  
53.  Chokroborty-Hoque A, Alberry B, Singh SM. Exploring the complexity of intellectual disability in fetal 
alcohol spectrum disorders. Front. Pediatr. 2014;2:90.  
54.  Wu D, Cederbaum AI. Alcohol, oxidative stress, and free radical damage. Alcohol Res. Heal. 
2003;27:277–84.  
55.  Wilkinson MD, Dumontier M, Aalbersberg IjJ, Appleton G, Axton M, Baak A, et al. The FAIR Guiding 
Principles for scientific data management and stewardship. Sci. Data. 2016;3:160018.  
56.  Lapatas V, Stefanidakis M, Jimenez RC, Via A, Schneider MV. Data integration in biological research: an 
overview. J. Biol. Res. (Thessalonikē, Greece). Journal of Biological Research-Thessaloniki; 2015;22:9.  
57.  Bearer CF, Stoler JM, Cook JD, Carpenter SJ. Biomarkers of alcohol use in pregnancy. Alcohol Res. Heal. 
2004;28:38–43.  
58.  Chabenne A, Moon C, Ojo C, Khogali A, Nepal B, Sharma S. Biomarkers in fetal alcohol syndrome. 
Biomarkers Genomic Med. Elsevier Taiwan LLC and the; 2014;6:12–22.  
59.  Wassenaar S, Sibbles BJ, Schneider AJT, Aaldriks AA. Testen op alcoholgebruik in de zwangerschap. 
Welke biomarkers zijn geschikt? Ned. Tijdschr. Geneeskd. 2016;160:1–5.  
60.  Bakhireva LN, Savage DD. Focus on: biomarkers of fetal alcohol exposure and fetal alcohol effects. 
Alcohol Res. Heal. 2011;34:56.  
61.  Balaraman S, Schafer JJ, Tseng AM, Wertelecki W, Yevtushok L, Zymak-Zakutnya, N., Chambers CD, et 
al. Plasma miRNA Profiles in Pregnant Women Predict Infant Outcomes following Prenatal Alcohol 
Exposure. PLoS One. 2016;11.  
62.  Montag AC, Hull AD, Yevtushok L, Zymak-Zakutnya N, Sosyniuk Z, Dolhov V, et al. Second-Trimester 
Ultrasound as a Tool for Early Detection of Fetal Alcohol Spectrum Disorders. Alcohol. Clin. Exp. Res. 
2016;40:2418–25.  
63.  Mesa DA, Kable JA, Coles CD, Jones KL, Yevtushok L, Kulikovsky Y, et al. The Use of Cardiac Orienting 
Responses as an Early and Scalable Biomarker of Alcohol-Related Neurodevelopmental Impairment. 
Alcohol. Clin. Exp. Res. 2017;41:128–38.  
64.  Tseng PH, Cameron IGM, Pari G, Reynolds JN, Munoz DP, Itti L. High-throughput classification of clinical 
populations from natural viewing eye movements. J. Neurol. 2013;260:275–84.  
65.  Mandal C, Kim SH, Chai JC, Oh SM, Lee YS, Jung KH, et al. RNA Sequencing Reveals the Alteration of the 
Expression of Novel Genes in Ethanol-Treated Embryoid Bodies. PLoS One. 2016;11:e0149976.  
 112 
66.  Kapoor M, Wang JC, Wetherill L, Le N, Bertelsen S, Hinrichs AL, et al. A meta-analysis of two genome-
wide association studies to identify novel loci for maximum number of alcoholic drinks. Hum. Genet. 
2013;132:1141–51.  
67.  Kutalik Z, Benyamin B, Bergmann S, Mooser V, Waeber G, Montgomery GW, et al. Genome-wide 
association study identifies two loci strongly affecting transferrin glycosylation. Hum. Mol. Genet. 
2011;20:3710–7.  
68.  Clark SL, Aberg KA, Nerella S, Kumar G, Mcclay JL, Chen W, et al. Combined Whole Methylome and 
Genomewide Association Study Implicates CNTN4 in Alcohol Use. Alcohol. Clin. Exp. Res. 
2015;39:1396–405.  
69.  Mimmack ML, Saito H, Evans G, Bresler M, Keverne EB, Emson PC. A novel splice variant of the cell 
adhesion molecule BIG-2 is expressed in the olfactory and vomeronasal neuroepithelia. Mol. Brain Res. 
1997;47:345–50.  
70.  Feeney E, O’Brien S, Scannell A, Markey A, Gibney ER. Genetic variation in taste perception: does it 
have a role in healthy eating? Proc Nutr Soc. 2011;70:135–43.  
71.  Duffy, V.B., Davidson, A.C., Kidd, J.R., Kidd, K.K., Speed, W.C., Pakstis, A.J., Reed, D.R., Snyder, D.J. and 
Bartoshuk LM. Bitter receptor gene (TAS2R38), 6-n-Propylthiouracil (PROP) Bitterness and Alcohol 
Intake. Alcohol Clin Exp Res. 2004;28:1629–1637.  
72.  Hayes JE, Wallace MR, Knopik VS, Herbstman DM, Bartoshuk LM, Duffy VB. Allelic variation in TAS2R 
bitter receptor genes associates with variation in sensations from and ingestive behaviors toward 
common bitter beverages in adults. Chem. Senses. 2011;36:311–9.  
73.  Wang JC, Hinrichs AL, Bertelsen S, Stock H, Budde JP, Dick DM, et al. Functional variants in TAS2R38 and 
TAS2R16 influence alcohol consumption in high-risk families of African-American origin. Alcohol. Clin. 
Exp. Res. 2007;31:209–15.  
74.  Keller M, Liu X, Wohland T, Rohde K, Gast MT, Stumvoll M, et al. TAS2R38 and its influence on smoking 
behavior and glucose homeostasis in the German sorbs. PLoS One. 2013;8:4–9.  
75.  Timpson NJ, Christensen M, Lawlor D a, Gaunt TR, Day IN, Ebrahim S, et al. traits , and eating behavior 
in the British Women ’ s Heart and Health. Am. J. Clin. Nutr. 2005;81:1005–11.  
76.  Carrai M, Steinke V, Vodicka P, Pardini B, Rahner N, Holinski-Feder E, et al. Association between 
TAS2R38 gene polymorphisms and colorectal cancer risk: A case-control study in two independent 
populations of caucasian origin. PLoS One. 2011;6.  
77.  Hurley TD, Edenberg HJ. Genes encoding enzymes involved in ethanol metabolism. Alcohol Res. 
2012;34:339–44.  
78.  Taylor M, Simpkin AJ, Haycock PC, Dudbridge F, Zuccolo L. Exploration of a polygenic risk score for 
alcohol consumption: A longitudinal analysis from the ALSPAC cohort. PLoS One. 2016;11:1–15.  
79.  Midwifery in The Netherlands. R. Dutch Organ. midwives. 2014.  
80.  ZonMw. Zwangerschap en geboorte. Een gezonde start voor moeder en kind. 2016.  
81.  Werkgroep MDR. Multidisciplinaire Richtlijn Stoornissen in het gebruik van Alcohol. 2009.  
82.  Noteborn W. Alcohol ? Even niet !? Tijdschr. voor Verlos. 2014;7:54–6.  
83.  Van der Wulp NY, Hoving C, de Vries H. Dutch midwives’ experiences with implementing health 
counselling to prevent prenatal alcohol use. J. Clin. Nurs. 2014;1–4.  
84.  Mason CA, Kirby RS, Sever LE, Langlois PH. Prevalence is the preferred measure of frequency of birth 
defects. Birth Defects Res. Part A - Clin. Mol. Teratol. 2005;73:690–2.  
85.  Roozen S, Peters G-JY, Kok G, Townend D, Nijhuis J, Curfs L. Worldwide Prevalence of Fetal Alcohol 
Spectrum Disorders: A Systematic Literature Review Including Meta-Analysis. Alcohol. Clin. Exp. Res. 
2016;40:18–32.  
86.  Popova S, Lange S, Probst C, Parunashvili N, Rehm J. Prevalence of alcohol consumption during 
pregnancy and Fetal Alcohol Spectrum Disorders among the general and aboriginal populations in 
Canada and the United States. Eur. J. Med. Genet. Elsevier Ltd; 2016;  
87.  Pereira, R. R., Rijpstra A, van Putten DM, Projectnaam NSCK. Jaarverslag Nederlands Signalerings-
centrum Kindergeneeskunde 2012. 2012.  
References 
113 
88.  Abdelmalik N, van Haelst M, Mancini G, Schrander-Stumpel C, Marcus-Soekarman D, Hennekam R, et 
al. Diagnostic outcomes of 27 children referred by pediatricians to a genetics clinic in the Netherlands 
with suspicion of fetal alcohol spectrum disorders. Am. J. Med. Genet. A. 2013;161A:254–60.  
89.  Swelheim H, Flapper B, van Balkom I. De diagnostiek van FASD, een multidisciplinaire aanpak. Prakt. 
Pediatr. 2014;4:248–51.  
90.  Roozen S, Peters G-JY, Kok G, Townend D, Nijhuis J, Koek G, et al. Which parental alcohol-related 
behaviors are related to Fetal Alcohol Spectrum Disorders (FASD)? A question that cannot be answered 
yet. Manuscr. Prep.  
91.  Jentink J, Zetstra-van der Woude AP, Bos J, de Jong-van den Berg LTW. Evaluation of the 
representativeness of a Dutch non-malformed control group for the general pregnant population: are 
these controls useful for EUROCAT? Pharmacoepidemiol. Drug Saf. 2011;20:1217–23.  
92.  Verkerk PH, Van Noord-Zaanstra BM, Florey CV, De Jonge GA, Verloove-Vanhorick SP. The effect of 
moderate maternal alcohol consumption on birth weight and gestational age in a low risk population. 
Early Hum. Dev. 1993;32:121–9.  
93.  Knottnerus JA, Delgado LR, Knipschild PG, Essed GGM, Smits F. Haematologic parameters and 
pregnancy outcome. J. clin. epidemiol. 1990;43:461–6.  
94.  Vonsee HJ, Stobberingh EE, Bouckaert PX, Van den Bogaard AE. Frequency of Chlamydia trachomatis, 
Mycoplasma hominis and Ureaplasma urealyticum infections in pregnant women. J. Chemother. 
1989;1:904–5.  
95.  Lanting CI, Buitendijk SE, Crone MR, Segaar D, Gravenhorst JB, van Wouwe JP. Clustering of 
socioeconomic, behavioural, and neonatal risk factors for infant health in pregnant smokers. PLoS One. 
2009;4:1–6.  
96.  Bakker R, Pluimgraaff LE, Steegers EAP, Raat H, Tiemeier H, Hofman A, et al. Associations of light and 
moderate maternal alcohol consumption with fetal growth characteristics in different periods of 
pregnancy: the Generation R Study. Int. J. Epidemiol. 2010;39:777–89.  
97.  Goedhart G, Van Eijsden M, Van Der Wal MF, Bonsel GJ. Ethnic differences in term birthweight: The 
role of constitutional and environmental factors. Paediatr. Perinat. Epidemiol. 2008;22:360–8.  
98.  Pfinder M, Kunst AE, Feldmann R, van Eijsden M, Vrijkotte TGM. Preterm birth and small for gestational 
age in relation to alcohol consumption during pregnancy: stronger associations among vulnerable 
women? results from two large Western-European studies. BMC Pregnancy Childbirth. 2013;13:49.  
99.  Mutsaerts MAQ, Groen H, Buiter-Van Der Meer A, Sijtsma A, Sauer PJJ, Land JA, et al. Effects of 
paternal and maternal lifestyle factors on pregnancy complications and perinatal outcome. A 
population-based birth-cohort study: The GECKO Drenthe cohort. Hum. Reprod. 2014;29:824–34.  
100.  Smidts DP, Oosterlaan J. How common are symptoms of ADHD in typically developing preschoolers? A 
study on prevalence rates and prenatal/demographic risk factors. Cortex. 2007;43:710–7.  
101.  Kuppens SMI, Kooistra L, Wijnen HA, Crawford S, Vader HL, Hasaart THM, et al. Maternal thyroid 
function during gestation is related to breech presentation at term. Clin. Endocrinol. (Oxf). 
2010;72:820–4.  
102.  Beijers C, Burger H, Verbeek T, Bockting CLH, Ormel J. Continued smoking and continued alcohol 
consumption during early pregnancy distinctively associated with personality. Addict. Behav. Elsevier 
Ltd; 2014;39:980–6.  
103.  Elliott EJ, Payne J, Morris A, Haan E, Bower C. Fetal alcohol syndrome: a prospective national 
surveillance study. Arch. Dis. Child. 2008;93:732–7.  
104.  Resendiz M, Chen Y, Öztürk NC, Zhou FC. Epigenetic medicine and fetal alcohol spectrum disorders 
Marisol. Epigenomics. 2013;5:73–86.  
105.  McBride N, Johnson S. Fathers’ Role in Alcohol-Exposed Pregnancies. Systematic Review of Human 
Studies. Am. J. Prev. Med. Elsevier; 2016;1–9.  
106.  Dawson DA. Methodological issues in measuring alcohol use. Alcohol Res. Heal. 2003;27:18–29.  
107.  Sobell LC, Sobell MB. Alcohol consumption measures. Assess. alcohol Probl. A Guid. Clin. Res. 1995. p. 
75–99.  
108.  Health Council of the Netherlands. Guidelines Healthy Nutrition. The Hague; 2015.  
 114 
109.  British Medical Association. Alcohol and pregnancy Preventing and managing fetal alcohol spectrum 
disorders. 2016.  
110.  May PA, Gossage JP. Maternal Risk Factors for Fetal Alcohol Spectrum Disorders: Not As Simple As It 
Might Seem. Alcohol Res. Heal. 2011;34:15–26.  
111.  Peters G-JY. A practical guide to effective behavior change: How to identify what to change in the first 
place. Eur. Heal. Psychol. 2014;16:142–55.  
112.  Kristjanson AF, Wilsnack SC, Zvartau E, Tsoy M, Novikov B. Alcohol use in pregnant and nonpregnant 
Russian women. Alcohol. Clin. Exp. Res. 2007;31:299–307.  
113.  Lee SH, Shin SJ, Won S-D, Kim E-J, Oh D-Y. Alcohol Use during Pregnancy and Related Risk Factors in 
Korea. Psychiatry Investig. 2010;7:86–92.  
114.  Balachova T, Bard D, Bonner B, Chaffin M, Isurina G, Tsvetkova L, et al. Do attitudes and knowledge 
predict at-risk drinking among Russian women? Am. J. Drug Alcohol Abuse. 2016;42:306–15.  
115.  Croxford, Julie, and Viljoen D. Alcohol consumption by pregnant women in the Western Cape. South 
African Med. J. 1999;89:962–5.  
116.  Peadon E, Payne J, Henley N, D’Antoine H, Bartu A, O’Leary C, et al. Attitudes and behaviour predict 
women’s intention to drink alcohol during pregnancy: the challenge for health professionals. BMC 
Public Health. 2011;11:584.  
117.  Yamamoto Y, Kaneita Y, Yokoyama E, Sone T, Takemura S, Suzuki K, et al. Alcohol consumption and 
abstention among pregnant Japanese women. J Epidemiol. 2008;18:173–82.  
118.  van der Wulp NY, Hoving C, de Vries H. Partner’s Influences and Other Correlates of Prenatal Alcohol 
Use. Matern. Child Health J. 2015;19:908–16.  
119.  McKnight A, Merrett D. Alcohol consumption in pregnancy—a health education problem. J. R. Coll. Gen. 
Pract. 1987;37:73–6.  
120.  Blume AWA, Resor MRM. Knowledge about health risks and drinking behavior among Hispanic women 
who are or have been of childbearing age. Addict. Behav. 2007;32:2335–9.  
121.  Kaminski M, Lelong N, Bean K, Chwalow J, Subtil D. Change in alcohol, tobacco and coffee consumption 
in pregnant women: evolution between 1988 and 1992 in an area of high consumption. Eur. J. Obstet. 
Gynecol. Reprod. Biol. 1995;60:121–8.  
122.  Kesmodel U, Schiøler Kesmodel P. Drinking during pregnancy: attitudes and knowledge among 
pregnant Danish women, 1998. Alcohol. Clin. Exp. Res. 2002;26:1553–60.  
123.  Leonardson GR, Loudenburg R, Struck J. Factors predictive of alcohol use during pregnancy in three 
rural states. Behav. brain Funct. 2007;3:8.  
124.  Lelong N, Kaminski M, Chwalow J, Bean K, Subtil D. Attitudes and behavior of pregnant women and 
health professionals towards alcohol and tobacco consumption. Patient Educ. Couns. 1995;25:39–49.  
125.  Kaskutas LA. Understanding Drinking During Pregnancy Among Urban American Indians and African 
Americans: Health Messages, Risk Beliefs, and How We Measure Consumption. Alcohol. Exp. Res. 
2000;24:1241–50.  
126.  Pettigrew S, Jongenelis M, Chikritzhs T, Pratt IS, Slevin T, Glance D. A Comparison of Alcohol 
Consumption Intentions Among Pregnant Drinkers and Their Nonpregnant Peers of Child-Bearing Age. 
Subst. Use Misuse. 2016;6084:1–7.  
127.  Moore PJ, Turner R, Park CL, Adler NE. The impact of behavior and addiction on psychological models of 
cigarette and alcohol use during pregnancy. Addict. Behav. 1996;21:645–58.  
128.  Chang G, McNamara T, Wilkins-Haug L, Orav EJ. Stages of change and prenatal alcohol use. J. Subst. 
Abuse Treat. 2007;32:105–9.  
129.  Crawford-Williams F, Steen M, Esterman A, Fielder A, Mikocka-Walus A. “My midwife said that having a 
glass of red wine was actually better for the baby”: a focus group study of women and their partner’s 
knowledge and experiences relating to alcohol consumption in pregnancy. BMC Pregnancy Childbirth. 
2015;15:79.  
130.  Watt MH, Eaton LA, Choi KW, Velloza J, Kalichman SC, Skinner D, et al. “It’s better for me to drink, at 
least the stress is going away”: Perspectives on alcohol use during pregnancy among South African 
women attending drinking establishments. Soc. Sci. Med. 2014;116:119–25.  
References 
115 
131.  World Health Organization. Global strategy to reduce the harmful use of alcohol. Geneva; 2010.  
132.  Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent 
trends. Stud. Fam. Plann. 2014;45:301–14.  
133.  Babor TF, Jernigan D, Brookes C, editors. The Regulation of Alcohol Marketing: From Research to Public 
Health Policy. Addiction. 2017.  
134.  Kok G, Gottlieb NH, Panne R, Smerecnik C. Methods for environmental change; an exploratory study. 
BMC Public Health. BMC Public Health; 2012;12:1037.  
135.  Kok G, Gottlieb NH, Commers M, Smerecnik C. The Ecological Approach in Health Promotion Programs : 
A Decade Later. 2008;22:437–42.  
136.  Barbour BG. Alcohol and pregnancy. J. Nurse. Midwifery. 1990;35:78–85.  
137.  Van der Wulp NY, Hoving C, De Vries H. A qualitative investigation of alcohol use advice during 
pregnancy: experiences of Dutch midwives, pregnant women and their partners. Midwifery. Elsevier; 
2013;29:e89-98.  
138.  Wechsler H, Nelson TF. What we have learned from the Harvard School of Public Health College Alcohol 
Study: Focusing attention on college student alcohol consumption and the environmental conditions 
that promote it. J. Stud. Alcohol Drugs. 2008;69:481–90.  
139.  Swan GE, Carmelli D, Rosenman RH, Fabsitz RR, Christian JC. Smoking and alcohol consumption in adult 
male twins: Genetic heritability and shared environmental influences. J. Subst. Abuse. 1990;2:39–50.  
140.  Kok G, Gurabardhi Z, Gottlieb NH, Zijlstra FRH. Influencing Organizations to Promote Health: Applying 
Stakeholder Theory. Heal. Educ. Behav. 2015;42:123S–132S.  
141.  Grol R, Wensing M, Eccles M, Davis D, editors. Improving patient care: the implementation of change in 
health care. John Wiley & Sons; 2013.  
142.  Bell, E., Andrew, G., Di Pietro, N., Chudley, A. E., Reynolds, J. N., & Racine E. It ’ s a Shame ! Stigma 
Against Fetal Alcohol Spectrum Disorder : Examining the Ethical Implications for Public Health Practices 
and Policies. Public Health Ethics. 2016;9:65–77.  
143.  Racine E, Bell E, Zizzo N, Green C. Public discourse on the biology of alcohol addiction: Implications for 
stigma, self-control, essentialism, and coercive policies in pregnancy. Neuroethics. 2015;8:177–86.  
144.  Bos AER, Pryor JB, Reeder GD, Stutterheim SE. Stigma: Advances in Theory and Research. Basic Appl. 
Soc. Psych. 2013;35:1–9.  
145.  Dovidio JF, Major B, Crocker J. Stigma: Introduction and overview. In: Heatherton TF, Kleck RE, Hebl 
MR, Hull JG, editors. Soc. Psychol. stigma. New York, NY: Guilford Press; 2011. p. 1–28.  
146.  Pryor, J. B., & Reeder GD. HIV-related stigma. In: Hall JC, Hall BJ, Cockerell CJ, editors. HIV/AIDS Post-
HAART Era Manifestations, Treat. Epidemiol. Shelton: CT: PMPH-USA; 2011. p. 790–806.  
147.  Davis JL, Manago B. Motherhood and associative moral stigma: The moral double bind. Stigma Heal. 
2016;1:72–86.  
148.  Stutterheim SE, Baas I, Roberts H, Brands R, Schmidt J, Lechner L, et al. Stigma experiences among 
substance users with HIV. Stigma Heal. 2016;1.  
149.  Hammer R, Dingel M, Ostergren J, Partridge B, McCormick J, Koenig BA. Addiction: Current Criticism of 
the Brain Disease Paradigm. AJOB Neurosci. 2013;4:27–32.  
150.  Copeland B. Searching for, Finding and Experiencing Friendship: A Qualitative Study of Friendship 
Experiences of Seven Young Adults with Fetal Alcohol Syndrome/Effects. Victoria, BC.; 2002.  
151.  Dej E. What Once Was Sick is now Bad: The Shift from Victim to Deviant Identity for Those Diagnosed 
with Fetal Alcohol Spectrum Disorder. Can. J. Sociol. 2011;36:137–60.  
152.  Salmon J, Buetow S. An Exploration of the Experiences and Perspectives of New Zealanders with Fetal 
Alcohol Spectrum Disorder. J. Popul. Ther. Clin. Pharmacol. 2011;19:e41–50.  
153.  Shankar I. Risky Bodies: Allocation of Risk and Responsibility within Fetal Alcohol Spectrum Disorder 
(FASD) Prevention Campaigns. Can. Disabil. Stud. Assoc. 2016;5:152–77.  
154.  Wood M. Journeys of Birth Mothers of Children With FASD (Doctoral dissertation). 2010.  
155.  Salmon J. Fetal alcohol spectrum disorder: New Zealand birth mothers’ experiences. Can. J. Clin. 
Pharmacol. 2008;15:e191-213.  
 116 
156.  Masood AF, Turner LA, Baxter A. Causal Attributions and Parental Attitudes Toward Children With 
Disabilities in the United States and Pakistan. 2007;73:475–87.  
157.  Stade B, Beyene J, Buller K, Ross S, Patterson K, Stevens B, et al. Feeling Different: The Experience of 
Living with Fetal Alcohol Spectrum Disorder. J. Popul. Ther. Clin. Pharmacol. 2010;18:e475–85.  
158.  Pereira R. Burden Experienced by Caregivers of Youth with Fetal Alcohol Spectrum Disorder: An 
Exploratory Study. University of Calgary Faculty; 2010.  
159.  Whitehurst T. Raising a child with foetal alcohol syndrome: Hearing the parent voice. Br. J. Learn. 
Disabil. 2012;40:187–93.  
160.  Bell E, Zizzo N, Racine E. Caution! Warning Labels About Alcohol and Pregnancy: Unintended 
Consequences and Questionable Effectiveness. Am. J. Bioeth. 2015;15:18–20.  
161.  Eggertson L. Stigma a major barrier to treatment for pregnant women with addictions. Can. Med. 
Assoc. J. 2013;185:1562.  
162.  Nelson M, Trussler M, editors. Fetal Alcohol Spectrum Disorder in Adults: Ethical and Legal 
Perspectives. New York: Springer International Publishing; 2016.  
163.  Children Act [Internet]. 1989. Available from: http://www.legislation.gov.uk/ukpga/1989/41/contents 
164.  Children Act [Internet]. UK Public General Act; 2004. Available from: http://www.legislation.gov.uk/ 
ukpga/2004/31/contents 
165.  Allen A. Genetic Privacy: Emerging Concepts and Values. In: Rothstein M, editor. Genet. Secrets Prot. 
Priv. Confidentiality Genet. Era. Yale: Yale University Press; 1997. p. 31–60.  
166.  Medical Treatment Contracts Act - Wet geneeskundige behandelingsovereenkomst (WGBO). Article 
7.457.  
167.  Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the 
protection of individuals with regard to the processing of personal data and on the free movement of 
such data, Official Journal L 281, 23/11/1995 P.0031-0050 [Internet]. Available from: http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31995L0046:en:HTML 
168.  Jane Roe v. Henry Wade. District Attorney of Dallas County 410 U.S. 113; 1973.  
169.  Larcher V, Brierley J. Fetal alcohol syndrome (FAS) and fetal alcohol spectrum disorder (FASD)—
diagnosis and moral policing; an ethical dilemma for paediatricians. Arch. Disabil. Child. 2014;  
170.  Beauchamp T, Childress J. Principles of Biomedical Ethics (7th edition). Oxford: Oxford university Press; 
2013.  
171.  Kok G, Bartholomew LK, Parcel GS, Gottlieb NH, Fernández ME. Finding theory- and evidence-based 
alternatives to fear appeals: Intervention Mapping. Int. J. Psychol. 2014;49:98–107.  
172.  Peters GJY, Ruiter RAC, Kok G. Threatening communication: a critical re-analysis and a revised meta-
analytic test of fear appeal theory. Health Psychol. Rev. 2013;7:1–24.  
173.  Ruiter RAC, Kessels LTE, Peters GJY, Kok G. Sixty years of fear appeal research: current state of the 
evidence. Int. J. Psychol. 2014;49:63–70.  
174.  Kok G. A practical guide to effective behavior change How to apply theory- and evidence-based 
behavior change methods in an intervention. Eur. Heal. Psychol. 2014;16:156–70.  
175.  Skagerstróm J, Chang G, Nilsen P. Predictors of drinking during pregnancy: a systematic review. J 
Womens Heal. 2011;20:901–13.  
176.  Hastings G. “They’ll drink bucket loads of the stuff”: An analysis of internal alcohol industry advertising 
documents. London; 2009.  
177.  France KE, Donovan RJ, Bower C, Elliott EJ, Payne JM, D’Antoine H, et al. Messages that increase 
women’s intentions to abstain from alcohol during pregnancy: results from quantitative testing of 
advertising concepts. BMC Public Health. 2014;14:30.  
178.  Monteiro MG, Babor TF, Jernigan D, Brookes C. Alcohol marketing regulation : from research to public 
policy. Addiction. 2017;112:3–6.  
179.  Van der Wulp NY, Hoving C, Eijmael K, Candel MJ, van Dalen W, De Vries H. Reducing Alcohol Use 
During Pregnancy Via Health Counseling by Midwives and Internet-Based Computer-Tailored Feedback: 
A Cluster Randomized Trial. J. Med. Internet Res. 2014;16.  
References 
117 
180.  Negen Maanden Niet. Voorlichtingsprogramma voor de verloskundigenpraktijk over alcoholgebruik 
tijdens de zwangerschap. Ned. Inst. voor Alcoholbeleid. 2011.  
181.  Buunk AP, Van Vugt M. Applying social psychology: From problems to solutions. London: SAGE 
Publications; 2013.  
182.  Hoyme HE, Kalberg WO, Elliott AJ, Blankenship J, Buckley D, Marais A-S, et al. Updated Clinical 
Guidelines for Diagnosing Fetal Alcohol Spectrum Disorders. Pediatrics. 2016;138:e20154256–
e20154256.  
183.  Stratton K, Howe C, Battaglia FC (Eds. ). Fetal alcohol syndrome: Diagnosis, epidemiology, prevention, 
and treatment. National Academies Press; 1996.  
184.  Hoyme HE, May PA, Kalberg WO, Kodituwakku P, Gossage JP, Trujillo PM, et al. A practical clinical 
approach to diagnosis of fetal alcohol spectrum disorders: clarification of the 1996 institute of medicine 
criteria. Pediatrics. 2005;115:39–47.  
185.  Astley S., Clarren S. Diagnosing the full spectrum of fetal alcohol-exposed individuals: introducing the 4-
digit diagnostic code. Alcohol Alcohol. 2000;35:400–10.  
186.  Astley S. Validation of the fetal alcohol spectrum disorder (FASD) 4-Digit Diagnostic Code. J. Popul. Ther. 
Clin. Pharmacol. 2013;20:e416-67.  
187.  Chudley AE, Conry J, Cook JL, Loock C, Rosales T, Leblanc N. Fetal alcohol spectrum disorder: Canadian 
guidelines for diagnosis. Can. Med. Assoc. J. 2005;172:S1–21.  
188.  Cook JL, Green CR, Lilley CM, Anderson SM, Baldwin ME, Chudley AE, et al. Fetal alcohol spectrum 
disorder: a guideline for diagnosis across the lifespan. Can. Med. Assoc. J. 2016;188:191–7.  
189.  Riley EP, Infante MA, Warren KR. Fetal alcohol spectrum disorders: an overview. Neuropsychol. Rev. 
2011;21:73–80.  
190.  Coles CD, Gailey AR, Mulle JG, Kable JA, Lynch ME, Jones KL. A Comparison Among 5 Methods for the 
Clinical Diagnosis of Fetal Alcohol Spectrum Disorders. Alcohol. Clin. Exp. Res. 2016;n/a-n/a.  
191.  Hoyme HE, May P a, Kalberg WO, Kodituwakku P, Gossage JP, Trujillo PM, et al. A practical clinical 
approach to diagnosis of fetal alcohol spectrum disorders: clarification of the 1996 institute of medicine 
criteria. Pediatrics. 2005;115:39–47.  
192.  Mattson SN, Schoenfeld AM, Riley EP. Teratogenic effects of alcohol on brain and behavior. Alcohol 
Res. Heal. 2001;25:185–91.  
193.  Hellemans KG, Sliwowska JH, Verma P, Weinberg J. Prenatal alcohol exposure: fetal programming and 
later life vulnerability to stress, depression and anxiety disorders. Neurosci. Biobehav. Rev. 
2010;34:791–807.  
194.  Mattson SN, Crocker N, Nguyen TT. Fetal alcohol spectrum disorders: neuropsychological and 
behavioral features. Neuropsychol. Rev. 2011;21:81–101.  
195.  Doyle LR, Mattson SN. Neurobehavioral disorder associated with prenatal alcohol exposure (ND-PAE): 
review of evidence and guidelines for assessment. Curr. Dev. Disord. reports. 2015;2:175–86.  
196.  Mattson SN, Riley EP, Gramling L, Delis DC, Jones KL. Heavy prenatal alcohol exposure with or without 
physical features of fetal alcohol syndrome leads to IQ deficits. J. Pediatr. 1997;131:718–21.  
197.  Testa M, Quigley BM, Eiden RD. The effects of prenatal alcohol exposure on infant mental 
development: a meta-analytical review. Alcohol Alcohol. 2003;38:295–304.  
198.  Rasmussen C, Horne K, Witol A. Neurobehavioral functioning in children with fetal alcohol spectrum 
disorder. Child Neuropsychol. 2006;12:453–68.  
199.  Wechsler D. Wechsler-Bellevue Intelligence Scale. New York: The Psychological Corporation; 1938.  
200.  Deary IJ, Strand S, Smith P, Fernandes C. Intelligence and educational achievement. Intelligence. 
2007;35:13–21.  
201.  Gottfredson LS. The general intelligence factor. Sci. Am. 1998;24–9.  
202.  Hurks PPM, Hendriksen JGM, Dek JE, Kooij AP. Normal Variability of Children’s Scaled Scores on 
Subtests of the Dutch Wechsler Preschool and Primary scale of Intelligence–Third Edition. Clin. 
Neuropsychol. 2013;27:988–1003.  
203.  Van Boxtel H, Hurks PPM. Intelligentiebepaling bij zeer lage niveaus. Tijdschr. voor Neuropsychol. 
2012;7:40–8.  
 118 
204.  Watkins MW, Glutting JJ, Lei PW. Validity of the Full-Scale IQ when there is significant variability among 
WISC-III and WISC-IV factor scores. Appl. Neuropsychol. 2007;14:13–20.  
205.  Anderson P. Assessment and development of executive function (EF) during childhood. Child 
Neuropsychol. 2002;8:71–82.  
206.  Ware AL, Kulesz PA, Williams VJ, Juranek J, Cirino PT, F letcher JM. Gray matter integrity within regions 
of the dorsolateral prefrontal cortical-subcortical network predicts executive function and fine motor 
dexterity in spina bifida. Neuropsychology. 2016;30:492.  
207.  Sonuga-Barke E, Bitsakou P, Thompson M. Beyond the dual pathway model: evidence for the 
dissociation of timing, inhibitory, and delay-related impairments in attention-deficit/hyperactivity 
disorder. J. Am. Acad. Child Adolesc. Psychiatry. 2010;49:345–55.  
208.  Ware AL, Infante MA, O’Brien JW, Tapert SF, Jones KL, Riley EP, et al. An fMRI study of behavioral 
response inhibition in adolescents with and without histories of heavy prenatal alcohol exposure. 
Behav. Brain Res. 2015;278:137–46.  
209.  Fuglestad AJ, Whitley ML, Carlson SM, Boys CJ, Eckerle JK, Fink BA, et al. Executive functioning deficits 
in preschool children with Fetal Alcohol Spectrum Disorders. Child Neuropsychol. 2015;21:716–31.  
210.  Rasmussen C, Bisanz J. Executive functioning in children with fetal alcohol spectrum disorders: profiles 
and age-related differences. Child Neuropsychol. 2009;15:201–15.  
211.  Kodituwakku PW, Kalberg W, May PA. The effects of prenatal alcohol exposure on executive 
functioning. Alcohol Res. Heal. 2001;25:192–8.  
212.  Coggins TE, Olswang LB, Carmichael Olson H, Timler GR. On becoming socially competent 
communicators: The challenge for children with fetal alcohol exposure. Int. Rev. Res. Ment. Retard. 
2003;27:121–50.  
213.  Glass L, Graham DM, Akshoomoff N, Mattson SN. Cognitive factors contributing to spelling 
performance in children with prenatal alcohol exposure. Neuropsychology. 2015;29:817.  
214.  Kodituwakku PW, May PA, Clericuzio CL, Weers D. Emotion-related learning in individuals prenatally 
exposed to alcohol: an investigation of the relation between set shifting, extinction of responses, and 
behavior. Neuropsychologia. 2001;39:699–708.  
215.  Barkley RA, Edwards G, Laneri M, Fletcher K, Metevia L. Executive functioning, temporal discounting, 
and sense of time in adolescents with attention deficit hyperactivity disorder (ADHD) and oppositional 
defiant disorder (ODD). J. Abnorm. Child Psychol. 2001;29:541–56.  
216.  Pennington BF, Ozonoff S. Executive functions and developmental psychopathology. J. child Psychol. 
psychiatry. 1996;37:51–87.  
217.  Reiter A, Tucha O, Lange KW. Executive functions in children with dyslexia. Dyslexia. 2005;11:116–31.  
218.  Geurts HM, Verté S, Oosterlaan J, Roeyers H, Sergeant JA. How specific are executive functioning deficits 
in attention deficit hyperactivity disorder and autism? J. child Psychol. psychiatry. 2004;45:836–54.  
219.  Watson SM, Westby CE, Gable RA. A framework for addressing the needs of students prenatally 
exposed to alcohol and other drugs. Prev. Sch. Fail. Altern. Educ. Child. Youth. 2007;52:25–32.  
220.  Zelazo PD, Carlson SM. Hot and cool executive function in childhood and adolescence: Development 
and plasticity. Child Dev. Perspect. 2012;6:354–60.  
221.  Bechara A. The role of emotion in decision-making: evidence from neurological patients with 
orbitofrontal damage. Brain Cogn. 2004;55:30–40.  
222.  Eslinger PJ, Flaherty-Craig, C. V., Benton AL. Developmental outcomes after early prefrontal cortex 
damage. Brain Cogn. 2004;55:84–103.  
223.  Yau WYW, Zubieta JK, Weiland BJ, Samudra PG, Zucker RA, Heitzeg MM. Nucleus accumbens response 
to incentive stimuli anticipation in children of alcoholics: relationships with precursive behavioral risk 
and lifetime alcohol use. J. Neurosci. 2012;32:2544–51.  
224.  Wass TS, Simmons RW, Thomas JD, Riley EP. Timing accuracy and variability in children with prenatal 
exposure to alcohol. Alcohol. Clin. Exp. Res. 2002;26:1887–96.  
225.  Fryer SL, McGee CL, Matt GE, Riley EP, Mattson SN. Evaluation of psychopathological conditions in 
children with heavy prenatal alcohol exposure. Pediatrics. 2007;119:e733–41.  
References 
119 
226.  Evers A. The internationalization of test reviewing: Trends, differences, and results. Int. J. Test. 
2012;12:136–56.  
227.  van Boxtel HW, Hemker BT. Weten¬schappelijke verantwoording van de Intelligentietest Eindtoets 
Basisonderwijs. Arnhem; 2009.  
228.  Hurks PP, Bakker H. Assessing intelligence in children and youth living in the Netherlands. J. Sch. Educ. 
Psychol. 2016;1–10.  
229.  Grigorenko EL, Sternberg RJ. Dynamic testing. Psychol. Bull. 1998;124:75.  
230.  Resing W, de Jong FM, Bosma T, Tunteler E. Learning during dynamic testing: Variability in strategy use 
by indigenous and ethnic minority children. J. Cogn. Educ. Psychol. 2009;8:22–37.  
231.  D’Onofrio BM, Van Hulle CA, Waldman ID, Rodgers JL, Rathouz PJ, Lahey BB. Causal inferences 
regarding prenatal alcohol exposure and childhood externalizing problems. Arch. Gen. Psychiatry. 
2007;64:1296–304.  
232.  Fan J, Jacobson SW, Taylor PA, Molteno CD, Dodge NC, Stanton ME, et al. White matter deficits mediate 
effects of prenatal alcohol exposure on cognitive development in childhood. Hum. Brain Mapp. 
2016;37:2943–2958.  
233.  Sood B, Delaney-Black, V., Covington, C., Nordstrom-Klee B, Ager J, Templin T, Janisse J, Martier S, et al. 
Prenatal alcohol exposure and childhood behavior at age 6 to 7 years: I. dose-response effect. 
Pediatrics. 2001;108:e34–e34.  
234.  Swaab H, Bouma A, Hendriksen J, König C. Klinische kinderneuropsychologie. Amsterdam: Boom 
Uitgevers; 2011.  
235.  Buck GH, Polloway EA, Kirkpatrick MA, Patton JR, Fad KM. Developing Behavioral Intervention Plans A 
Sequential Approach. Interv. Sch. Clin. 2000;36:3–9.  
236.  Nash K, Stevens S, Greenbaum R, Weiner J, Koren G, Rovet J. Improving executive functioning in 
children with fetal alcohol spectrum disorders. Child Neuropsychol. 2015;21:191–209.  
237.  Melby-Lervåg M, Redick TS, Hulme C. Working memory training does not improve performance on 
measures of intelligence or other measures of “far transfer” evidence from a meta-analytic review. 
Perspect. Psychol. Sci. 2016;11:512–34.  
238.  Norman AL, Crocker N, Mattson SN, Riley EP. Neuroimaging and fetal alcohol spectrum disorders. Dev. 
Disabil. Res. Rev. 2009;15:209–17.  
239.  Wang X, Kroenke CD. Utilization of Magnetic Resonance Imaging in Research Involving Animal Models 
of Fetal Alcohol Spectrum Disorders. Alcohol Res. 2015;37:39–51.  
240.  Moore EM, Migliorini R, Infante MA, Riley EP. Fetal Alcohol Spectrum Disorders: Recent Neuroimaging 
Findings. Curr. Dev. Disord. reports. 2014;1:161–72.  
241.  Wozniak JR, Muetzel RL. What does diffusion tensor imaging reveal about the brain and cognition in 
fetal alcohol spectrum disorders? Neuropsychol. Rev. 2011;21:133–47.  
242.  Rodrigues Pereira R, Rijpstra A. Jaarverslag NSCK 2008. Leiden; 2009.  
243.  Wieringen H Van, Letteboer TGW, Pereira RR, Ruiter S De, Balemans WAF, Lindhout D. Diagnostiek van 
foetale alcoholspectrumstoornissen. 2010;1–8.  
244.  Goh PK, Doyle LR, Glass L, Jones KL, Riley EP, Coles CD, et al. A Decision Tree to Identify Children 
Affected by Prenatal Alcohol Exposure. J. Pediatr. Elsevier Inc.; 2016;177:1–8.  
245.  Streissguth AP, Bookstein FL, Barr HM, Sampson PD, O’Malley K, Young JK. Risk Factors for Adverse Life 
Outcomes in Fetal Alcohol Syndrome and Fetal Alcohol Effects. Dev. Behav. Pediatr. 2004;25:228–329.  
246.  Mukherjee R, Cook PA, Fleming KM, Norgate SH. What can be done to lessen morbidity associated with 
fetal alcohol spectrum disorders? Arch. Dis. Child. 2016;archdischild-2016-310822.  
247.  Siderius EJ, Carmiggelt B, Rijn CS van, Heerkens YF. Preventive Child Health Care within the Framework 
of the Dutch Health Care System. J. Pediatr. [Internet]. Elsevier; 2016;177:S138–41. Available from: 
http://dx.doi.org/10.1016/j.jpeds.2016.04.050 
248.  Montag AC. Fetal alcohol-spectrum disorders: Identifying at-risk mothers. Int. J. Womens. Health. 
2016;8:311–23.  
 120 
249.  Barr HM, Bookstein FL, O’Malley KD, Connor PD, Huggins JE, Streissguth AP. Binge drinking during 
pregnancy as a predictor of psychiatric disorders on the Structured Clinical Interview for DSM-IV in 
Young Adult Offspring. Am. J. Psychiatry. 2006;163:1061–5.  
250.  ArgumentenFabriek., ZonMw. Knelpuntenanalyses jeugdgezondheidszorg [Internet]. 2013. Available 
from: http://www.zonmw.nl/nl/publicaties/detail/derde-knelpuntenanalyses-programma-richtlijnen-
jeugdgezondheidszorg-2013-2018/?no_cache=1&cHash=522a18e34da50412bffc1f35182034e8 
251.  Popova S, Lange S, Burd L, Rehm J. Health care burden and cost associated with fetal alcohol syndrome: 
Based on official canadian data. PLoS One. 2012;7:2–8.  
252.  Popova S, Lange S, Burd L, Nam S, Rehm J. Special Education of Children with Fetal Alcohol Spectrum 
Disorder. Exceptionality,. 2016;24:165–75.  
253.  Popova, S., Lange, S., Burd, L., & Rehm J. Canadian Children and Youth in Care: The Cost of Fetal Alcohol 
Spectrum Disorder. Child Youth Care Forum. 2014;43:83–96.  
254.  Popova S, Lange S, Burd L, Urbanoski K, Rehm J. Cost of specialized addiction treatment of clients with 
fetal alcohol spectrum disorder in Canada. BMC Public Health. 2013;13:570.  
255.  Popova, S., Lange, S., Burd, L., & Rehm J. Cost attributable to Fetal Alcohol Spectrum Disorder in the 
Canadian correctional system. Int J Law Psychiatry. 2015;41:76–81.  
256.  Popova S, Lange S, Burd L, Rehm J. The Economic Burden of Fetal Alcohol Spectrum Disorder in Canada 
in 2013. Alcohol Alcohol. 2016;51:367–75.  
257.  Popova S, Lange S, Burd L, Shield K, Rehm J. Cost of speech-language interventions for children and 
youth with foetal alcohol spectrum disorder in Canada. Int. J. Speech. Lang. Pathol. 2014;16:571–81.  
258.  Thanh NX, Jonsson E. Costs of health services utilization of people with fetal alcohol spectrum disorder 
by sex and age group in Alberta, Canada. J Popul Ther Clin Pharmacol. 2014;21:e421-430.  
259.  Popova S, Lange S, Burd L, Chudley AE, Clarren SK, Rehm J. Cost of Fetal Alcohol Spectrum Disorder 
Diagnosis in Canada. PLoS One. 2013;8.  
260.  Ericson L, Magnusson L, Hovstadius B. Societal costs of fetal alcohol syndrome in Sweden. Eur. J. Heal. 
Econ. Springer Berlin Heidelberg; 2016;1–11.  
261.  Hopkins RB, Paradis J, Roshankar T, Bowen J, Tarride, J. E., Blackhouse, G., . . . Longo CJ. Universal or 
targeted screening for fetal alcohol exposure: a cost-effectiveness analysis. J Stud Alcohol Drugs. 
2008;69:510–9.  
262.  Popova S, Lange S, Burd L, Urbanoski K, Rehm J. Cost of specialized addiction treatment of clients with 
fetal alcohol spectrum disorder in Canada. BMC Public Health. 2013;13:570.  
263.  Thanh NX, Jonsson E, Moffatt J, Dennett L, Chuck AW, Birchard S. An economic evaluation of the 
parent-child assistance program for preventing fetal alcohol spectrum disorder in Alberta, Canada. Adm 
Policy Ment Heal. 2015;42:10–8.  
264.  De Wit GA. Maatschappelijke kosten-baten analyse van beleidsmaatregelen om alcoholgebruik te 
verminderen. RIVM rapport 2016-0133. 2016;148.  
265.  European Union. 2014 Report on the State of the Art of Rare Disease Activities in Europe [Internet]. 2014. 
Available from: http://www.eucerd.eu/upload/file/Reports/2014ReportStateofArtRDActivitiesIT.pdf 
266.  Heus GCBB, Elzen APM Van Den, Brooks AS. Een syndroomdiagnose en dan? Tijdschr. Kindergeneeskd. 
2014;82:49–52.  
267.  Petrenko CLM, Alto ME. Interventions in fetal alcohol spectrum disorders: An international perspective. 
Eur. J. Med. Genet. [Internet]. Elsevier Masson SAS; 2016;60:79–91. Available from: 
http://dx.doi.org/10.1016/j.ejmg.2016.10.005 
268.  Reid N, Dawe S, Shelton D, Harnett P, Warner J, Armstrong E, et al. Systematic Review of Fetal Alcohol 
Spectrum Disorder Interventions Across the Life Span. Alcohol. Clin. Exp. Res. 2015;39:2283–95.  
 
  
121 
Appendices 
  
 122 
LIST OF ABBREVIATIONS 
ADH  Alcohol dehydrogenase 
ADH1B  Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide 
ADH1C  Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide 
ADHD  Attention-deficit/hyperactivity disorder 
ALDH  Aldehyde dehydrogenases 
ALDH2  Aldehyde dehydrogenase 2 family (Mitochondrial) 
ATP  Adenosine triphosphate 
ARBD  Alcohol-related birth defects 
ARND  Alcohol-related neurodevelopmental disorders 
BAC  Blood alcohol content or concentration 
BMA  British Medical Association 
CAT  Catalase 
CDT  Carbohydrate-deficient transferrin 
CNTN4  Contactin 4 
CYHC  Child and Youth Health Care 
CYP2E1  cytochrome P450 2E1 
DHM  Dihydromyricetin 
DNA  Deoxyribonucleic acid 
EtOH  Ethanol 
FAIR  Findable, Accessible, Interoperable, Reusable 
FAS  Fetal alcohol syndrome 
FASD  Fetal alcohol spectrum disorders 
FOXO  Forkhead box O  
FSIQ  Full Scale Intelligence Quotient 
GABA   Gamma-aminobutyric acid 
GPX  Glutathione peroxidase 
GWAS  Genome-wide association study 
IOM  Institute of medicine 
IM   Intervention Mapping 
IQ   Intelligence quotient 
KNOV  Royal Dutch organization of midwives 
NOS  Newcastle-Ottawa Scale 
NSCK  The Dutch Signaling Center for Pediatricians  
NVOG  The national scientific association of gynecologists 
PFAS  Partial fetal alcohol syndrome 
PFC  Prefrontal cortex 
PGM1  Phosphoglucomutase-1 gene 
ROS  Radical oxygen species 
SD   Standard deviation 
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SNPs  Single nucleotide polymorphisms 
SOD  Superoxide dismutase 
TAS2R  Taste 2 receptor 
TAS2R38 Taste 2 receptor member 38 
TF    Transferrin gene 
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SEARCH QUERIES 
Pathogenesis and Biomarkers  
Search Query related to the origin of FASD and screening for alcohol consumption 
Keyword Synonyms 
FASD  ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foetal 
alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol spectrum 
disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol spectrum 
disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alcohol" OR 
"alcohol exposed" OR "alcohol related birth defects" OR "alcohol related 
neurodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy" OR 
"gestational alcohol exposure") 
Pathogenesis (mechanism* OR pathogen* OR pattern* OR system* OR gen* OR expression* protein* 
OR metabol* OR transcript* OR biolog* OR biomarker* OR "oxidative stress") 
Review ("systematic review" OR review OR meta*) 
Ebscohost (CINAHL, PsychINFO, PsychARTICLES, MEDLINE) 
("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy" OR "gesta-
tional alcohol exposure") AND (mechanism* OR pathogen* OR pattern* OR system* 
OR gen* OR expression* OR protein* OR metabol* OR transcript* OR biolog* OR bi-
omarker* "oxidative stress") AND ("systematic review" OR review OR meta*) 
PubMed Query Search 
((fetal alcohol spectrum disorder* [TI]) OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI]) OR (gestational alcohol exposure [TI])) 
AND ((mechanism* [TI]) OR (pathogen*[TI]) OR (pattern* [TI]) OR (system* [TI]) OR 
(gen* [TI]) OR (expression* [TI]) OR (protein* [TI]) OR (metabol* [TI]) OR (transcript* 
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[TI]) OR (biolog* [TI]) OR (biomarker* [TI]) OR (oxidative stress [TI])) AND ((systematic 
review [TI]) OR (review [TI]) OR (meta* [TI])) 
(((fetal alcohol spectrum disorder* [TIAB]) OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
alcohol syndrome [TIAB]) OR (foetal alcohol syndrome [TIAB]) OR (partial fetal alcohol 
syndrome [TIAB]) OR (partial fetal alcohol spectrum disorder* [TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder* [TIAB]) OR 
(prenatal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB]) OR (gestational alcohol exposure [TIAB])) AND ((mechanism* [TIAB]) OR (path-
ogen*[TIAB]) OR (pattern* [TIAB]) OR (system* [TIAB]) OR (gen* [TIAB]) OR (expres-
sion* [TIAB]) OR (protein* [TIAB]) OR (metabol* [TIAB]) OR (transcript* [TIAB]) OR 
(biolog* [TIAB]) OR (biomarker* [TIAB]) OR (oxidative stress [TIAB])) AND ((systematic 
review [TIAB]) OR (review [TIAB]) OR (meta* [TIAB])) 
(((fetal alcohol spectrum disorder* [Text Word]) OR (foetal alcohol spectrum disorder* 
[Text Word]) OR (fetal alcohol exposure [Text Word]) OR (foetal alcohol exposure [Text 
Word]) OR (fetal alcohol syndrome [Text Word]) OR (foetal alcohol syndrome [Text 
Word]) OR (partial fetal alcohol syndrome [Text Word]) OR (partial fetal alcohol spec-
trum disorder* [Text Word]) OR (partial foetal alcohol syndrome [Text Word]) OR (par-
tial foetal alcohol spectrum disorder* [Text Word]) OR (prenatal alcohol exposure 
[Text Word]) OR (prenatal exposure to alcohol [Text Word]) OR (alcohol exposed [Text 
Word]) OR (alcohol related birth defects [Text Word]) OR (alcohol related neurodevel-
opmental disorder [Text Word]) OR (fetal effects [Text Word]) OR (alcoholic embryopa-
thy [Text Word]) OR (gestational alcohol exposure [Text Word])) AND ((mechanism* 
[Text Word]) OR (pathogen*[Text Word]) OR (pattern* [Text Word]) OR (system* [Text 
Word]) OR (gen* [Text Word]) OR (expression* [Text Word]) OR (protein* [Text Word]) 
OR (metabol* [Text Word]) OR (transcript* [Text Word]) OR (biolog* [Text Word]) OR 
(biomarker* [Text Word]) OR (oxidative stress [Text Word])) AND ((systematic review 
[Text Word]) OR (review [Text Word]) OR (meta* [Text Word])) 
Embase (Ovid) 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy" OR "gesta-
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tional alcohol exposure")  AND (mechanism* OR pathogen* OR pattern* OR system* 
OR gen* OR expression* OR protein* OR metabol* OR transcript* OR biolog* OR bi-
omarker* "oxidative stress") AND ("systematic review" OR review OR meta*)).ti. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy" OR "gesta-
tional alcohol exposure") AND (mechanism* OR pathogen* OR pattern* OR system* 
OR gen* OR expression* OR protein* OR metabol* OR transcript* OR biolog* OR bi-
omarker* "oxidative stress") AND ("systematic review" OR review OR meta*)).ti.ab. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy" OR "gesta-
tional alcohol exposure")  AND (mechanism* OR pathogen* OR pattern* OR system* 
OR gen* OR expression* OR protein* OR metabol* OR transcript* OR biolog* OR bi-
omarker* "oxidative stress") AND ("systematic review" OR review OR meta*)).tw. 
Note; If no reviews are available, use the queries below 
Ebscohost (CINAHL, PsychINFO, PsychARTICLES, MEDLINE) 
("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy" OR "gesta-
tional alcohol exposure") AND (mechanism* OR pathogen* OR pattern* OR system* 
OR gen* OR expression* OR protein* OR metabol* OR transcript* OR biolog* OR bi-
omarker* "oxidative stress")  
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PubMed Query Search 
((fetal alcohol spectrum disorder* [TI]) OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI]) OR (gestational alcohol exposure [TI])) 
AND ((mechanism* [TI]) OR (pathogen*[TI]) OR (pattern* [TI]) OR (system* [TI]) OR 
(gen* [TI]) OR (expression* [TI]) OR (protein* [TI]) OR (metabol* [TI]) OR (transcript* 
[TI]) OR (biolog* [TI]) OR (biomarker* [TI]) OR (oxidative stress [TI])) 
(((fetal alcohol spectrum disorder* [TIAB]) OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
alcohol syndrome [TIAB]) OR (foetal alcohol syndrome [TIAB]) OR (partial fetal alcohol 
syndrome [TIAB]) OR (partial fetal alcohol spectrum disorder* [TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder* [TIAB]) OR 
(prenatal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB]) OR (gestational alcohol exposure [TIAB])) AND ((mechanism* [TIAB]) OR (path-
ogen*[TIAB]) OR (pattern* [TIAB]) OR (system* [TIAB]) OR (gen* [TIAB]) OR (expres-
sion* [TIAB]) OR (protein* [TIAB]) OR (metabol* [TIAB]) OR (transcript* [TIAB]) OR 
(biolog* [TIAB]) OR (biomarker* [TIAB]) OR (oxidative stress [TIAB])) 
(((fetal alcohol spectrum disorder* [Text Word]) OR (foetal alcohol spectrum disorder* 
[Text Word]) OR (fetal alcohol exposure [Text Word]) OR (foetal alcohol exposure [Text 
Word]) OR (fetal alcohol syndrome [Text Word]) OR (foetal alcohol syndrome [Text 
Word]) OR (partial fetal alcohol syndrome [Text Word]) OR (partial fetal alcohol spec-
trum disorder* [Text Word]) OR (partial foetal alcohol syndrome [Text Word]) OR (par-
tial foetal alcohol spectrum disorder* [Text Word]) OR (prenatal alcohol exposure 
[Text Word]) OR (prenatal exposure to alcohol [Text Word]) OR (alcohol exposed [Text 
Word]) OR (alcohol related birth defects [Text Word]) OR (alcohol related neurodevel-
opmental disorder [Text Word]) OR (fetal effects [Text Word]) OR (alcoholic embryopa-
thy [Text Word]) OR (gestational alcohol exposure [Text Word])) AND ((mechanism* 
[Text Word]) OR (pathogen*[Text Word]) OR (pattern* [Text Word]) OR (system* [Text 
Word]) OR (gen* [Text Word]) OR (expression* [Text Word]) OR (protein* [Text Word]) 
OR (metabol* [Text Word]) OR (transcript* [Text Word]) OR (biolog* [Text Word]) OR 
(biomarker* [Text Word]) OR (oxidative stress [Text Word])) AND ((systematic review 
[Text Word]) 
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Embase (Ovid) 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy" OR "gesta-
tional alcohol exposure")  AND (mechanism* OR pathogen* OR pattern* OR system* 
OR gen* OR expression* OR protein* OR metabol* OR transcript* OR biolog* OR bi-
omarker* "oxidative stress")).ti. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy" OR "gesta-
tional alcohol exposure") AND (mechanism* OR pathogen* OR pattern* OR system* 
OR gen* OR expression* OR protein* OR metabol* OR transcript* OR biolog* OR bi-
omarker* "oxidative stress")).ti.ab. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy" OR "gesta-
tional alcohol exposure")  AND (mechanism* OR pathogen* OR pattern* OR system* 
OR gen* OR expression* OR protein* OR metabol* OR transcript* OR biolog* OR bi-
omarker* "oxidative stress")).tw. 
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Prevalence  
Search Query related to FASD prevalence. 
Keyword Synonyms 
FASD  ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR 
"foetal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to 
alcohol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related 
neurodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") 
Prevalence ("burden" OR "burden of disease" OR "prevalen*" OR "inciden*" OR "epidemiology" 
OR "epidemic*" OR “outcome*” OR “screening” OR “rate” OR “rating” OR “estimate” 
OR “experience”) 
Review ("systematic review" OR review OR meta*) 
EbscoHost (CINAHL, ERIC, PsychINFO, PsychARTICLES, MEDLINE) Query Search 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND ("bur-
den" OR "burden of disease" OR "prevalen*" OR "inciden*" OR "epidemiology" OR 
"epidemic*" OR “outcome*” OR “screening” OR “rate” OR “rating” OR “estimate” OR 
“experience”) AND ("systematic review" OR review OR meta*)) 
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PubMed Query Search 
(((fetal alcohol spectrum disorder* [TI]) OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI])) AND ((burden [TI]) OR (burden of disease 
[TI]) OR (prevalen* [TI]) OR (inciden* [TI]) OR (epidemiology [TI]) OR (epidemic* [TI]) 
OR (outcome* [TI]) OR (screening [TI]) OR (rate [TI]) OR (rating [TI]) OR (estimate [TI]) 
OR (experience [TI])) AND ((systematic review [TI]) OR (review [TI]) OR (meta* [TI])) 
(((fetal alcohol spectrum disorder* [TIAB]) OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
alcohol syndrome [TIAB]) OR (foetal alcohol syndrome [TIAB]) OR (partial fetal alcohol 
syndrome [TIAB]) OR (partial fetal alcohol spectrum disorder* [TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder* [TIAB]) OR 
(prenatal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB])) AND ((burden [TIAB]) OR (burden of disease [TIAB]) OR (prevalen* [TIAB]) OR 
(inciden* [TIAB]) OR (epidemiology [TIAB]) OR (epidemic* [TIAB]) OR (outcome* 
[TIAB]) OR (screening [TIAB]) OR (rate [TIAB]) OR (rating [TIAB]) OR (estimate [TIAB]) 
OR (experience [TIAB])) AND ((systematic review [TIAB]) OR (review [TIAB]) OR (meta* 
[TIAB])) 
(((fetal alcohol spectrum disorder* [Text Word]) OR (foetal alcohol spectrum disorder* 
[Text Word]) OR (fetal alcohol exposure [Text Word]) OR (foetal alcohol exposure [Text 
Word]) OR (fetal alcohol syndrome [Text Word]) OR (foetal alcohol syndrome [Text 
Word]) OR (partial fetal alcohol syndrome [Text Word]) OR (partial fetal alcohol spec-
trum disorder* [Text Word]) OR (partial foetal alcohol syndrome [Text Word]) OR (par-
tial foetal alcohol spectrum disorder* [Text Word]) OR (prenatal alcohol exposure 
[Text Word]) OR (prenatal exposure to alcohol [Text Word]) OR (alcohol exposed [Text 
Word]) OR (alcohol related birth defects [Text Word]) OR (alcohol related neurodevel-
opmental disorder [Text Word]) OR (fetal effects [Text Word]) OR (alcoholic embryopa-
thy [Text Word])) AND ((burden [Text Word]) OR (burden of disease [Text Word]) OR 
(prevalen* [Text Word]) OR (inciden* [Text Word]) OR (epidemiology [Text Word]) OR 
(epidemic* [Text Word]) OR (outcome* [Text Word]) OR (screening [Text Word]) OR 
(rate [Text Word]) OR (rating [Text Word]) OR (estimate [Text Word]) OR (experience 
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[Text Word])) AND ((systematic review [Text Word]) OR (review [Text Word]) OR (me-
ta* [Text Word]))) 
Embase Query Search 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND ("bur-
den" OR "burden of disease" OR "prevalen*" OR "inciden*" OR "epidemiology" OR 
"epidemic*" OR "outcome*" OR "screening" OR "rate" OR "rating" OR "estimate" OR 
"experience") AND ("systematic review" OR review OR meta*)).ti.  
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND ("bur-
den" OR "burden of disease" OR "prevalen*" OR "inciden*" OR "epidemiology" OR 
"epidemic*" OR "outcome*" OR "screening" OR "rate" OR "rating" OR "estimate" OR 
"experience") AND ("systematic review" OR review OR meta*)).ti.ab. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND ("bur-
den" OR "burden of disease" OR "prevalen*" OR "inciden*" OR "epidemiology" OR 
"epidemic*" OR "outcome*" OR "screening" OR "rate" OR "rating" OR "estimate" OR 
"experience") AND ("systematic review" OR review OR meta*)).tw.  
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Behavior 
Search Query related to maternal drinking behaviors. 
Keyword Synonyms 
FASD  ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR 
"foetal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to 
alcohol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related 
neurodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") 
Pregnancy (pregnan* OR gestat* OR maternal OR prenatal) 
Behaviour ("alcohol use" OR "binge drinking" OR "alcohol abuse" OR "maternal drinking" OR 
"prenatal alcohol" OR "alcohol consumption" OR "alcohol drinking" OR "alcohol in 
utero" OR "maternal behav*" OR "ethanol teratogenesis" OR alcoholism OR "alcohol 
and pregnancy" OR "heavy drinking" OR "drinking during pregnancy" OR "behav* of 
mother*") 
Correlate (associat* OR correlat* OR predict* OR relat* OR caus* OR differ* OR determ* OR 
"risk factor") 
Review ("systematic review" OR review OR meta*) 
Exclude (animal* OR drug* OR cocaine OR heroin) 
Ebscohost 
("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND 
(pregnan* OR gestat* OR maternal OR prenatal) AND ("alcohol use" OR "binge drink-
ing" OR "alcohol abuse" OR "maternal drinking" OR "prenatal alcohol" OR "alcohol 
consumption" OR "alcohol drinking" OR "alcohol in utero" OR "maternal behav*" OR 
"ethanol teratogenesis" OR alcoholism OR "alcohol and pregnancy" OR "heavy drink-
ing" OR "drinking during pregnancy" OR "behav* of mother*")) AND (associat* OR 
correlat* OR predict* OR relat* OR caus* OR differ* OR determ* OR "risk factor") AND 
("systematic review" OR review OR meta*) NOT (animal* OR drug* OR cocaine OR 
heroin)) 
PubMed Query Search 
((fetal alcohol spectrum disorder* [TI]) OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome[TI]) OR (partial fetal alcohol syndrome [TI]) 
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OR (partial fetal alcohol spectrum disorder* [TI])  OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI])) AND ((pregnan* [TI]) OR (gestat* [TI]) OR 
(maternal [TI]) OR (prenatal [TI])) AND ((alcohol use [TI]) OR (binge drinking [TI]) OR 
(alcohol abuse [TI]) OR (maternal drinking [TI]) OR (prenatal alcohol [TI]) OR (alcohol 
consumption [TI]) OR (alcohol drinking [TI]) OR (alcohol in utero [TI])  OR (maternal 
behav* [TI]) OR (ethanol teratogenesis [TI]) OR (alcoholism [TI]) OR (alcohol and preg-
nancy [TI]) OR (heavy drinking [TI]) OR (drinking during pregnancy [TI]) OR (behav* of 
mother* [TI])) AND ((associat* [TI]) OR (correlat* [TI]) OR (predict* [TI]) OR (relat* [TI]) 
OR (caus* [TI]) OR (differ* [TI])  OR (determ* [TI]) OR (risk factor [TI]) AND ((systematic 
review [TI]) OR (review [TI]) OR (meta* [TI])) NOT ((animal* [TI]) OR (drug* [TI]) OR 
(cocaine [TI]) OR (heroin [TI]))  
((fetal alcohol spectrum disorder* [TIAB]) OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
alcohol syndrome [TIAB]) OR (foetal alcohol syndrome[TIAB]) OR (partial fetal alcohol 
syndrome[TIAB]) OR (partial fetal alcohol spectrum disorder*[TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder*[TIAB]) OR (pre-
natal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB])) AND ((pregnan* [TIAB])  OR (gestat* [TIAB]) OR (maternal [TIAB]) OR (prenatal 
[TIAB])) AND ((alcohol use [TIAB])  OR (binge drinking [TIAB])  OR (alcohol abuse [TIAB])  
OR (maternal drinking [TIAB]) OR (prenatal alcohol [TIAB]) OR (alcohol consumption 
[TIAB]) OR (alcohol drinking [TIAB]) OR (alcohol in utero [TIAB]) OR (maternal behav* 
[TIAB]) OR (ethanol teratogenesis [TIAB]) OR (alcoholism [TIAB]) OR (alcohol and preg-
nancy [TIAB]) (heavy drinking [TIAB]) OR (drinking during pregnancy [TIAB]) OR (behav* 
of mother* [TIAB])) AND ((associat* [TIAB])  OR (correlat* [TIAB])  OR (predict* [TIAB]) 
OR (relat* [TIAB]) OR (caus* [TIAB])  OR (differ* [TIAB]) OR (determ* [TIAB]) OR (risk 
factor [TIAB]) AND ((systematic review [TIAB]) OR (review [TIAB]) OR (meta* [TIAB])) 
NOT ((animal* [TIAB]) OR (drug* [TIAB])  OR (cocaine [TIAB]) OR (heroin [TIAB])) 
((fetal alcohol spectrum disorder* [TEXT WORD])  OR (foetal alcohol spectrum disor-
der* [TEXT WORD])  OR (fetal alcohol exposure [TEXT WORD])  OR (foetal alcohol ex-
posure [TEXT WORD])  OR (fetal alcohol syndrome [TEXT WORD])  OR (foetal alcohol 
syndrome[TEXT WORD])  OR (partial fetal alcohol syndrome[TEXT WORD])  OR (partial 
fetal alcohol spectrum disorder*[TEXT WORD])  OR (partial foetal alcohol syndrome 
[TEXT WORD])  OR (partial foetal alcohol spectrum disorder*[TEXT WORD])  OR (prena-
tal alcohol exposure [TEXT WORD])  OR (prenatal exposure to alcohol [TEXT WORD])  
OR (alcohol exposed [TEXT WORD])  OR (alcohol related birth defects [TEXT WORD])  
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OR (alcohol related neurodevelopmental disorder [TEXT WORD])  OR (fetal effects 
[TEXT WORD])  OR (alcoholic embryopathy [TEXT WORD])) AND ((pregnan* [TEXT 
WORD])  OR (gestat* [TEXT WORD]) OR (maternal [TEXT WORD]) OR (prenatal [TEXT 
WORD])) AND ((alcohol use [TEXT WORD])  OR (binge drinking [TEXT WORD])  OR (al-
cohol abuse [TEXT WORD])  OR (maternal drinking [TEXT WORD])  OR (prenatal alcohol 
[TEXT WORD])  OR (alcohol consumption [TEXT WORD])  OR (alcohol drinking [TEXT 
WORD])  OR (alcohol in utero [TEXT WORD])  OR (maternal behav* [TEXT WORD])  OR 
(ethanol teratogenesis [TEXT WORD])  OR (alcoholism [TEXT WORD]) OR (alcohol and 
pregnancy [TEXT WORD]) (heavy drinking [TEXT WORD]) OR (drinking during pregnancy 
[TEXT WORD]) OR (behav* of mother* [TEXT WORD])) AND ((associat* [TEXT WORD])  
OR (correlat* [TEXT WORD])  OR (predict* [TEXT WORD])  OR (relat* [TEXT WORD])  OR 
(caus* [TEXT WORD])  OR (differ* [TEXT WORD])  OR (determ* [TEXT WORD]) OR (risk 
factor [TEXT WORD]) AND ((systematic review [TEXT WORD]) OR (review [TEXT 
WORD]) OR (meta* [TEXT WORD])) NOT ((animal* [TEXT WORD])  OR (drug* [TEXT 
WORD])  OR (cocaine [TEXT WORD])  OR (heroin [TEXT WORD]))  
Embase Query Search 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND 
(pregnan* OR gestat* OR maternal OR prenatal) AND ("alcohol use" OR "binge drink-
ing" OR "alcohol abuse" OR "maternal drinking" OR "prenatal alcohol" OR "alcohol 
consumption" OR "alcohol drinking" OR "alcohol in utero" OR "maternal behav*" OR 
"ethanol teratogenesis" OR alcoholism OR "alcohol and pregnancy" OR "heavy drink-
ing" OR "drinking during pregnancy" OR "behav* of mother*")) AND (associat* OR 
correlat* OR predict* OR relat* OR caus* OR differ* OR determ* OR "risk factor") AND 
("systematic review" OR review OR meta*) NOT (animal* OR drug* OR cocaine OR 
heroin)).ti. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND 
(pregnan* OR gestat* OR maternal OR prenatal) AND ("alcohol use" OR "binge drink-
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ing" OR "alcohol abuse" OR "maternal drinking" OR "prenatal alcohol" OR "alcohol 
consumption" OR "alcohol drinking" OR "alcohol in utero" OR "maternal behav*" OR 
"ethanol teratogenesis" OR alcoholism OR "alcohol and pregnancy" OR "heavy drink-
ing" OR "drinking during pregnancy" OR "behav* of mother*")) AND (associat* OR 
correlat* OR predict* OR relat* OR caus* OR differ* OR determ* OR "risk factor") AND 
("systematic review" OR review OR meta*) NOT (animal* OR drug* OR cocaine OR 
heroin)).ti.ab. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND 
(pregnan* OR gestat* OR maternal OR prenatal) AND ("alcohol use" OR "binge drink-
ing" OR "alcohol abuse" OR "maternal drinking" OR "prenatal alcohol" OR "alcohol 
consumption" OR "alcohol drinking" OR "alcohol in utero" OR "maternal behav*" OR 
"ethanol teratogenesis" OR alcoholism OR "alcohol and pregnancy" OR "heavy drink-
ing" OR "drinking during pregnancy" OR "behav* of mother*")) AND (associat* OR 
correlat* OR predict* OR relat* OR caus* OR differ* OR determ* OR "risk factor") AND 
("systematic review" OR review OR meta*) NOT (animal* OR drug* OR cocaine OR 
heroin)).tw. 
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Determinants 
Search Query related to determinants of maternal drinking behavior. 
Keyword Synonyms 
Pregnancy (pregnan* OR gestat* OR maternal OR prenatal OR antenatal) 
Alcohol (alcohol* OR drink* OR ethanol) 
Determinant (determin* OR intention* OR knowlegde OR risk perception OR reason* OR motiv* OR 
attitude* OR belief* OR outcome* OR expect* OR norm* OR self-efficacy OR perceived 
control OR perceived behav* control OR correlat* OR anteced* OR factor*) 
Review (systematic review OR review OR "meta*") 
Exclude (animal* OR mouse OR mice OR rat OR rats) 
PsycINFO, PsycARTICLES, CINAHL, ERIC, MEDLINE 
(("prenat*" OR "maternal" OR "prenatal" OR "antenatal" OR "gestat*") AND ("alco-
hol*" OR "drink*" OR "ethanol") AND ("determin*" OR "intention*" OR "knowlegde" 
OR "risk perception" OR "reason*" OR "motiv*" OR "attitude*" OR "belief*" OR "out-
come*" OR "expect*" OR "norm*" OR "self-efficacy" OR "perceived control" OR "per-
ceived behav* control" OR "correlat*" OR "anteced*" OR "factor*") AND ("systematic 
review" OR review OR meta*) NOT ("animal*" OR "mouse" OR "mice" OR "rat" OR 
"rats")) 
PubMed 
(((pregnan* [Text Word]) OR (maternal [Text Word]) OR (prenatal [Text Word]) OR 
(antenatal [Text Word]) OR (gestat* [Text Word])) AND ((alcohol* [Text Word]) OR 
(drink* [Text Word]) OR (ethanol [Text Word])) AND ((determin* [Text Word]) OR 
(intention* [Text Word]) OR (knowledge [Text Word]) OR (risk perception [Text Word]) 
OR (reason* [Text Word]) OR (motiv* [Text Word]) OR (attitude* [Text Word]) OR 
(belief* [Text Word]) OR (outcome* [Text Word]) OR (expect* [Text Word]) OR (norm 
[Text Word]) OR (norms [Text Word]) OR (normative [Text Word])  OR (self-efficacy 
[Text Word]) OR (perceived control [Text Word]) OR (perceived behav* control [Text 
Word]) OR (control belief* [Text Word]) OR (correlat* [Text Word]) OR (anteced* [Text 
Word]) OR (factor* [Text Word])) AND ((systematic review [TI]) OR (review [TI]) OR 
(meta* [TI])) NOT ((animal* [Text Word]) OR (mouse [Text Word]) OR (mice [Text 
Word]) OR (rat [Text Word])  OR (rats [Text Word]))) 
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Stakeholders 
Search Query related to stakeholders 
Keyword Synonyms 
FASD  ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR 
"foetal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to 
alcohol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related 
neurodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") 
Pregnancy (pregnan* OR gestat* OR maternal OR prenatal) 
Stakeholders (stakeholder* OR parent* OR individual* OR industry OR "healthcare professional*" 
OR researcher* OR "policy maker") 
Review ("systematic review" OR review OR meta*) 
Ebscohost 
((("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")) OR 
((pregnan* OR gestat* OR maternal OR prenatal)) AND (stakeholder* OR parent* OR 
individual* OR industry OR "healthcare professional*" OR researcher* OR "policy mak-
er")) 
Pubmed 
(((fetal alcohol spectrum disorder* [TI]) OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI])) OR ((pregnan* [TI]) OR (gestat* [TI]) OR 
(maternal [TI]) OR (prenatal [TI])) AND ((stakeholder* [TI]) OR (parent* [TI]) OR (indi-
vidual* [TI]) OR (industry [TI]) OR (healthcare professional* [TI]) OR (researcher* [TI]) 
OR (policy maker [TI]))) 
(((fetal alcohol spectrum disorder* [TIAB]) OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
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alcohol syndrome [TIAB]) OR (foetal alcohol syndrome [TIAB]) OR (partial fetal alcohol 
syndrome [TIAB]) OR (partial fetal alcohol spectrum disorder* [TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder* [TIAB]) OR 
(prenatal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB])) OR ((pregnan* [TIAB]) OR (gestat* [TIAB]) OR (maternal [TIAB]) OR (prenatal 
[TIAB])) AND ((stakeholder* [TIAB]) OR (parent* [TIAB]) OR (individual* [TIAB]) OR 
(industry [TIAB]) OR (healthcare professional* [TIAB]) OR (researcher* [TIAB]) OR (poli-
cy maker [TIAB]))) 
(((fetal alcohol spectrum disorder* [TEXT WORD]) OR (foetal alcohol spectrum disor-
der* [TEXT WORD]) OR (fetal alcohol exposure [TEXT WORD]) OR (foetal alcohol expo-
sure [TEXT WORD]) OR (fetal alcohol syndrome [TEXT WORD]) OR (foetal alcohol syn-
drome [TEXT WORD]) OR (partial fetal alcohol syndrome [TEXT WORD]) OR (partial 
fetal alcohol spectrum disorder* [TEXT WORD]) OR (partial foetal alcohol syndrome 
[TEXT WORD]) OR (partial foetal alcohol spectrum disorder* [TEXT WORD]) OR (prena-
tal alcohol exposure [TEXT WORD]) OR (prenatal exposure to alcohol [TEXT WORD]) OR 
(alcohol exposed [TEXT WORD]) OR (alcohol related birth defects [TEXT WORD]) OR 
(alcohol related neurodevelopmental disorder [TEXT WORD]) OR (fetal effects [TEXT 
WORD]) OR (alcoholic embryopathy [TEXT WORD])) OR ((pregnan* [TEXT WORD]) OR 
(gestat* [TEXT WORD]) OR (maternal [TEXT WORD]) OR (prenatal [TEXT WORD])) AND 
((stakeholder* [TEXT WORD]) OR (parent* [TEXT WORD]) OR (individual* [TEXT 
WORD]) OR (industry [TEXT WORD]) OR (healthcare professional* [TEXT WORD]) OR 
(researcher* [TEXT WORD]) OR (policy maker [TEXT WORD]))) 
Embase 
((("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")) OR 
((pregnan* OR gestat* OR maternal OR prenatal)) AND (stakeholder* OR parent* OR 
individual* OR industry OR "healthcare professional*" OR researcher* OR "policy mak-
er")).ti. 
((("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
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spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")) OR 
((pregnan* OR gestat* OR maternal OR prenatal)) AND (stakeholder* OR parent* OR 
individual* OR industry OR "healthcare professional*" OR researcher* OR "policy mak-
er")).ti.ab. 
((("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")) OR 
((pregnan* OR gestat* OR maternal OR prenatal)) AND (stakeholder* OR parent* OR 
individual* OR industry OR "healthcare professional*" OR researcher* OR "policy mak-
er")).tw. 
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Preconception healthcare, midwifery, obstetrics, gynecology, and pediatrics 
Search Query related to preconception healthcare, midwifery, obstetrics, gynecology, 
and pediatrics 
Keyword Synonyms 
FASD  ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR 
"foetal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal 
alcohol spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal 
alcohol spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure 
to alcohol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol 
related neurodevelopmental disorder" OR "fetal effects" OR "alcoholic 
embryopathy") 
Midwivery, 
Gynaecology, Pediatry 
midw* OR obstetric* OR gynaec* OR paediatric* OR pediatr* 
Review ("systematic review" OR review OR meta*) 
Search Query for review articles 
 
Pubmed 
(((fetal alcohol spectrum disorder* [TI]) OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI])) AND ((midw* [TI] OR (obstetric* [TI]) OR 
(gynaec* [TI]) OR (paediatric* [TI]) OR pediatric* [TI]) AND ((systematic review [TI]) OR 
(review [TI]) OR (meta* [TI])))  
(((fetal alcohol spectrum disorder* [TIAB]) OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
alcohol syndrome [TIAB]) OR (foetal alcohol syndrome [TIAB]) OR (partial fetal alcohol 
syndrome [TIAB]) OR (partial fetal alcohol spectrum disorder* [TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder* [TIAB]) OR 
(prenatal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB])) AND ((midw* [TIAB] OR (obstetric* [TIAB]) OR (gynaec* [TIAB]) OR (paediatric* 
[TIAB]) OR pediatric* [TIAB])) AND ((systematic review [TIAB]) OR (review [TIAB]) OR 
(meta* [TABI])))  
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Search Query if there are no review articles available 
(((fetal alcohol spectrum disorder* [TI]) OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI])) AND ((midw* [TI] OR (obstetric* [TI]) OR 
(gynaec* [TI]) OR (paediatric* [TI]) OR pediatric* [TI])))  
(((fetal alcohol spectrum disorder* [TIAB]) OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
alcohol syndrome [TIAB]) OR (foetal alcohol syndrome [TIAB]) OR (partial fetal alcohol 
syndrome [TIAB]) OR (partial fetal alcohol spectrum disorder* [TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder* [TIAB]) OR 
(prenatal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB])) AND ((midw* [TIAB] OR (obstetric* [TIAB]) OR (gynaec* [TIAB]) OR (paediatric* 
[TIAB]) OR pediatric* [TIAB]))) 
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Stigma 
Search Query related to stigma and stereotyping aspects of FASD and drinking during 
pregnancy 
Keyword Synonyms 
FASD ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foetal 
alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol spectrum 
disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol spectrum 
disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alcohol" OR 
"alcohol exposed" OR "alcohol related birth defects" OR "alcohol related 
neurodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")  
Pregnancy (pregnan* OR gestat* OR maternal OR prenatal) 
Behavior (alcohol OR ‘alcohol consumption’ OR drink*) 
Stigma  (determinant* OR attitude OR stigma OR stereotyp* OR prejudice OR blame OR 
responsibility OR norm OR intent* OR belief* OR emotion* OR cognit* OR discrim*) 
Review ("systematic review" OR review OR meta*) 
Ebscohost (CINAHL, ERIC, PsychARTICLES, PsychINFO, MEDLINE) 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") OR 
(pregnan* OR gestat* OR maternal OR prenatal)) AND (alcohol OR "alcohol consump-
tion" OR drink*) AND (determinant* OR attitude OR stigma OR stereotyp* OR preju-
dice OR blame OR responsibility OR norm OR intent* OR belief* OR emotion* OR cog-
nit* OR discrim*) AND ("systematic review" OR review OR meta*)) 
Ebscohost Query when no review articles are available 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") OR 
(pregnan* OR gestat* OR maternal OR prenatal)) AND (alcohol OR "alcohol consump-
tion" OR drink*) AND (determinant* OR attitude OR stigma OR stereotyp* OR preju-
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dice OR blame OR responsibility OR norm OR intent* OR belief* OR emotion* OR cog-
nit* OR discrim*)) 
Pubmed 
(((fetal alcohol spectrum disorder* [TI] OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI]) OR ((pregnan* [TI]) OR (gestat* [TI]) OR 
(maternal [TI]) OR (prenatal [TI])) AND ((alcohol [TI]) OR (alcohol consumption [TI]) OR 
(drink* [TI])) AND ((determinant* [TI]) OR (attitude [TI]) OR (stigma [TI]) OR (stereo-
typ* [TI]) OR (prejudice [TI]) OR (blame [TI]) OR (responsibility [TI]) OR (norm [TI]) OR 
(intent* [TI]) OR (belief* [TI]) OR (emotion* [TI]) OR (cognit* [TI]) OR (discrim* [TI]) 
AND (((systematic review [TI]) OR (review [TI]) OR (meta* [TI]))) 
(((fetal alcohol spectrum disorder* [TIAB] OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
alcohol syndrome [TIAB]) OR (foetal alcohol syndrome [TIAB]) OR (partial fetal alcohol 
syndrome [TIAB]) OR (partial fetal alcohol spectrum disorder* [TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder* [TIAB]) OR 
(prenatal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB]) OR ((pregnan* [TIAB]) OR (gestat* [TIAB]) OR (maternal [TIAB]) OR (prenatal 
[TIAB])) AND ((alcohol [TIAB]) OR (alcohol consumption [TIAB]) OR (drink* [TIAB])) AND 
((determinant* [TIAB]) OR (attitude [TIAB]) OR (stigma [TIAB]) OR (stereotyp* [TIAB]) 
OR (prejudice [TIAB]) OR (blame [TIAB]) OR (responsibility [TIAB]) OR (norm [TIAB]) OR 
(intent* [TIAB]) OR (belief* [TIAB]) OR (emotion* [TIAB]) OR (cognit* [TIAB]) OR (dis-
crim* [TIAB]) AND (((systematic review [TIAB]) OR (review [TIAB]) OR (meta* [TIAB]))) 
(((fetal alcohol spectrum disorder* [TEXT WORD] OR (foetal alcohol spectrum disor-
der* [TEXT WORD]) OR (fetal alcohol exposure [TEXT WORD]) OR (foetal alcohol expo-
sure [TEXT WORD]) OR (fetal alcohol syndrome [TEXT WORD]) OR (foetal alcohol syn-
drome [TEXT WORD]) OR (partial fetal alcohol syndrome [TEXT WORD]) OR (partial 
fetal alcohol spectrum disorder* [TEXT WORD]) OR (partial foetal alcohol syndrome 
[TEXT WORD]) OR (partial foetal alcohol spectrum disorder* [TEXT WORD]) OR (prena-
tal alcohol exposure [TEXT WORD]) OR (prenatal exposure to alcohol [TEXT WORD]) OR 
(alcohol exposed [TEXT WORD]) OR (alcohol related birth defects [TEXT WORD]) OR 
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(alcohol related neurodevelopmental disorder [TEXT WORD]) OR (fetal effects [TEXT 
WORD]) OR (alcoholic embryopathy [TEXT WORD]) OR ((pregnan* [TEXT WORD]) OR 
(gestat* [TEXT WORD]) OR (maternal [TEXT WORD]) OR (prenatal [TEXT WORD])) AND 
((alcohol [TEXT WORD]) OR (alcohol consumption [TEXT WORD]) OR (drink* [TEXT 
WORD])) AND ((determinant* [TEXT WORD]) OR (attitude [TEXT WORD]) OR (stigma 
[TEXT WORD]) OR (stereotyp* [TEXT WORD]) OR (prejudice [TEXT WORD]) OR (blame 
[TEXT WORD]) OR (responsibility [TEXT WORD]) OR (norm [TEXT WORD]) OR (intent* 
[TEXT WORD]) OR (belief* [TEXT WORD]) OR (emotion* [TEXT WORD]) OR (cognit* 
[TEXT WORD]) OR (discrim* [TEXT WORD]) AND (((systematic review [TEXT WORD]) OR 
(review [TEXT WORD) OR (meta* [TEXT WORD]))) 
Pubmed Query when no review articles are available 
(((fetal alcohol spectrum disorder* [TI] OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI]) OR ((pregnan* [TI]) OR (gestat* [TI]) OR 
(maternal [TI]) OR (prenatal [TI])) AND ((alcohol [TI]) OR (alcohol consumption [TI]) OR 
(drink* [TI])) AND ((determinant* [TI]) OR (attitude [TI]) OR (stigma [TI]) OR (stereo-
typ* [TI]) OR (prejudice [TI]) OR (blame [TI]) OR (responsibility [TI]) OR (norm [TI]) OR 
(intent* [TI]) OR (belief* [TI]) OR (emotion* [TI]) OR (cognit* [TI]) OR (discrim* [TI]))) 
(((fetal alcohol spectrum disorder* [TIAB] OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
alcohol syndrome [TIAB]) OR (foetal alcohol syndrome [TIAB]) OR (partial fetal alcohol 
syndrome [TIAB]) OR (partial fetal alcohol spectrum disorder* [TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder* [TIAB]) OR 
(prenatal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB]) OR ((pregnan* [TIAB]) OR (gestat* [TIAB]) OR (maternal [TIAB]) OR (prenatal 
[TIAB])) AND ((alcohol [TIAB]) OR (alcohol consumption [TIAB]) OR (drink* [TIAB])) AND 
((determinant* [TIAB]) OR (attitude [TIAB]) OR (stigma [TIAB]) OR (stereotyp* [TIAB]) 
OR (prejudice [TIAB]) OR (blame [TIAB]) OR (responsibility [TIAB]) OR (norm [TIAB]) OR 
(intent* [TIAB]) OR (belief* [TIAB]) OR (emotion* [TIAB]) OR (cognit* [TIAB]) OR (dis-
crim* [TIAB]))) 
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(((fetal alcohol spectrum disorder* [TEXT WORD] OR (foetal alcohol spectrum disor-
der* [TEXT WORD]) OR (fetal alcohol exposure [TEXT WORD]) OR (foetal alcohol expo-
sure [TEXT WORD]) OR (fetal alcohol syndrome [TEXT WORD]) OR (foetal alcohol syn-
drome [TEXT WORD]) OR (partial fetal alcohol syndrome [TEXT WORD]) OR (partial 
fetal alcohol spectrum disorder* [TEXT WORD]) OR (partial foetal alcohol syndrome 
[TEXT WORD]) OR (partial foetal alcohol spectrum disorder* [TEXT WORD]) OR (prena-
tal alcohol exposure [TEXT WORD]) OR (prenatal exposure to alcohol [TEXT WORD]) OR 
(alcohol exposed [TEXT WORD]) OR (alcohol related birth defects [TEXT WORD]) OR 
(alcohol related neurodevelopmental disorder [TEXT WORD]) OR (fetal effects [TEXT 
WORD]) OR (alcoholic embryopathy [TEXT WORD]) OR ((pregnan* [TEXT WORD]) OR 
(gestat* [TEXT WORD]) OR (maternal [TEXT WORD]) OR (prenatal [TEXT WORD])) AND 
((alcohol [TEXT WORD]) OR (alcohol consumption [TEXT WORD]) OR (drink* [TEXT 
WORD])) AND ((determinant* [TEXT WORD]) OR (attitude [TEXT WORD]) OR (stigma 
[TEXT WORD]) OR (stereotyp* [TEXT WORD]) OR (prejudice [TEXT WORD]) OR (blame 
[TEXT WORD]) OR (responsibility [TEXT WORD]) OR (norm [TEXT WORD]) OR (intent* 
[TEXT WORD]) OR (belief* [TEXT WORD]) OR (emotion* [TEXT WORD]) OR (cognit* 
[TEXT WORD]) OR (discrim* [TEXT WORD]))) 
Embase (Ovid) 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") OR 
(pregnan* OR gestat* OR maternal OR prenatal) AND (alcohol OR "alcohol consump-
tion" OR drink*) AND (determinant* OR attitude OR stigma OR stereotyp* OR preju-
dice OR blame OR responsibility OR norm OR intent* OR belief* OR emotion* OR cog-
nit* OR discrim*) AND ("systematic review" OR review OR meta*)).ti. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") OR 
(pregnan* OR gestat* OR maternal OR prenatal) AND (alcohol OR "alcohol consump-
tion" OR drink*) AND (determinant* OR attitude OR stigma OR stereotyp* OR preju-
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dice OR blame OR responsibility OR norm OR intent* OR belief* OR emotion* OR cog-
nit* OR discrim*) AND ("systematic review" OR review OR meta*)).ti.ab. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") OR 
(pregnan* OR gestat* OR maternal OR prenatal) AND (alcohol OR "alcohol consump-
tion" OR drink*) AND (determinant* OR attitude OR stigma OR stereotyp* OR preju-
dice OR blame OR responsibility OR norm OR intent* OR belief* OR emotion* OR cog-
nit* OR discrim*) AND ("systematic review" OR review OR meta*)).tw. 
Embase Query when no review articles are available 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") OR 
(pregnan* OR gestat* OR maternal OR prenatal) AND (alcohol OR "alcohol consump-
tion" OR drink*) AND (determinant* OR attitude OR stigma OR stereotyp* OR preju-
dice OR blame OR responsibility OR norm OR intent* OR belief* OR emotion* OR cog-
nit* OR discrim*)).ti. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") OR 
(pregnan* OR gestat* OR maternal OR prenatal) AND (alcohol OR "alcohol consump-
tion" OR drink*) AND (determinant* OR attitude OR stigma OR stereotyp* OR preju-
dice OR blame OR responsibility OR norm OR intent* OR belief* OR emotion* OR cog-
nit* OR discrim*)).ti.ab. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
Appendices 
155 
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") OR 
(pregnan* OR gestat* OR maternal OR prenatal) AND (alcohol OR "alcohol consump-
tion" OR drink*) AND (determinant* OR attitude OR stigma OR stereotyp* OR preju-
dice OR blame OR responsibility OR norm OR intent* OR belief* OR emotion* OR cog-
nit* OR discrim*)).tw. 
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Ethics, Law 
Search Query related to ethical and legal issues 
Keyword Synonyms 
FASD  ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foetal 
alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol spectrum 
disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol spectrum 
disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alcohol" OR 
"alcohol exposed" OR "alcohol related birth defects" OR "alcohol related 
neurodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") 
Pregnancy (pregnan* OR gestat* OR maternal OR prenatal OR fetus OR "unborn child") 
Normative 
 
(ethic* OR law OR regulation* OR rule* OR "acceptable behav*" OR ought OR moral* OR 
responsibility OR duty OR right* OR autonomy OR "future child" OR "rights of unborn 
child" OR "right to choose" OR "negligence" OR criminal* OR stigma OR privacy) 
Review ("systematic review" OR review OR meta*) 
HeinOnline 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND 
(pregnan* OR gestat* OR maternal OR prenatal OR fetus OR "unborn child") AND (eth-
ic* OR law OR regulation* OR rule* OR "acceptable behav*" OR ought OR moral* OR 
responsibility OR duty OR right* OR autonomy OR "future child" OR "rights of unborn 
child" OR "right to choose" OR "negligence" OR criminal* OR stigma OR privacy) AND 
("systematic review" OR review OR meta*)) 
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Neuropsychological and behavioral effects 
Search Query related to FASD neuropsychological characteristics 
Keyword Synonyms 
FASD  ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR 
"foetal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal 
alcohol spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal 
alcohol spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure 
to alcohol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol 
related neurodevelopmental disorder" OR "fetal effects" OR "alcoholic 
embryopathy") 
Neurodevelopment (neuro* OR brain* OR neural* OR cogn* OR pathway* OR process* OR productivit* 
OR fluenc* OR pattern* OR behav* OR structural OR motiv*) 
Review ("systematic review" OR review OR meta*) 
Ebscohost (CINAHL, ERIC, PsychARTICLES, PsychINFO, MEDLINE): 
("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND (neu-
ro* OR brain* OR neural* OR cogn* OR pathway* OR process* OR productivit* OR 
fluenc* OR pattern* OR behav* OR structural OR motiv*) AND ("systematic review" OR 
review OR meta*) 
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Neuroimaging 
Search Query related to FASD neuroimaging 
Keyword Synonyms 
FASD  ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foetal 
alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol spectrum 
disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol spectrum 
disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alcohol" OR "alcohol 
exposed" OR "alcohol related birth defects" OR "alcohol related neurodevelopmental 
disorder" OR "fetal effects" OR "alcoholic embryopathy") 
Neuroimaging (neuroimag* OR neuroanat* OR brain* OR "Magnetic resonance imaging" OR FMRI OR 
"Diffusion tensor imaging" OR DTI OR MRS) 
Review ("systematic review" OR review OR meta*) 
Ebscohost 
("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") AND (neu-
roimag* OR neuroanat* OR brain* OR "Magnetic resonance imaging" OR FMRI OR 
"Diffusion tensor imaging" OR DTI OR MRS) AND ("systematic review" OR review OR 
meta*) 
PubMed Query Search  
((fetal alcohol spectrum disorder* [TI]) OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI])) AND ((neuroimag* [TI]) OR (neuroanat* 
[TI]) OR (brain* [TI]) OR (Magnetic resonance imaging [TI]) OR (FMRI [TI]) OR (diffusion 
tensor imaging [TI]) OR (DTI [TI]) OR (MRS [TI])) AND ((systematic review [TI]) OR (re-
view [TI]) OR (meta* [TI]])) 
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Diagnostics 
Search Query related to FASD diagnostics 
Keyword Synonyms 
FASD  ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foetal 
alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol spectrum 
disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol spectrum 
disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alcohol" OR 
"alcohol exposed" OR "alcohol related birth defects" OR "alcohol related 
neurodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") 
Diagnosis (diagn* OR guideline OR protocol OR rule OR proced* OR instruct* OR standard*)  
Review ("systematic review" OR review OR meta*) 
Ebscohost 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")  AND (di-
agn* OR guideline OR protocol OR rule OR proced* OR instruct* OR standard*) AND 
("systematic review" OR review OR meta*))  
Pubmed 
((fetal alcohol spectrum disorder* [TI]) OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI])) AND ((diagn* [TI]) OR (guideline [TI]) OR 
(protocol [TI]) OR (rule [TI]) OR (proced* [TI]) OR (instruct* [TI]) OR (standard* [TI])) 
AND ((systematic review [TI]) OR (review [TI]) OR (meta* [TI]))  
((fetal alcohol spectrum disorder* [TIAB]) OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
alcohol syndrome [TIAB]) OR (foetal alcohol syndrome [TIAB]) OR (partial fetal alcohol 
syndrome [TIAB]) OR (partial fetal alcohol spectrum disorder* [TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder* [TIAB]) OR 
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(prenatal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB])) AND ((diagn* [TIAB]) OR (guideline [TIAB]) OR (protocol [TIAB]) OR (rule [TIAB]) 
OR (proced* [TIAB]) OR (instruct* [TIAB]) OR (standard* [TIAB])) AND ((systematic 
review [TIAB]) OR (review [TIAB]) OR (meta* [TIAB]))  
((fetal alcohol spectrum disorder* [TEXT WORD]) OR (foetal alcohol spectrum disor-
der* [TEXT WORD]) OR (fetal alcohol exposure [TEXT WORD]) OR (foetal alcohol expo-
sure [TEXT WORD]) OR (fetal alcohol syndrome [TEXT WORD]) OR (foetal alcohol syn-
drome [TEXT WORD]) OR (partial fetal alcohol syndrome [TEXT WORD]) OR (partial 
fetal alcohol spectrum disorder* [TEXT WORD]) OR (partial foetal alcohol syndrome 
[TEXT WORD]) OR (partial foetal alcohol spectrum disorder* [TEXT WORD]) OR (prena-
tal alcohol exposure [TEXT WORD]) OR (prenatal exposure to alcohol [TEXT WORD]) OR 
(alcohol exposed [TEXT WORD]) OR (alcohol related birth defects [TEXT WORD]) OR 
(alcohol related neurodevelopmental disorder [TEXT WORD]) OR (fetal effects [TEXT 
WORD]) OR (alcoholic embryopathy [TEXT WORD])) AND ((diagn* [TEXT WORD]) OR 
(guideline [TEXT WORD]) OR (protocol [TEXT WORD]) OR (rule [TEXT WORD]) OR (pro-
ced* [TEXT WORD]) OR (instruct* [TEXT WORD]) OR (standard* [TEXT WORD])) AND 
((systematic review [TEXT WORD]) OR (review [TEXT WORD]) OR (meta* [TEXT 
WORD]))  
Embase 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")  AND (di-
agn* OR guideline OR protocol OR rule OR proced* OR instruct* OR standard*) AND 
("systematic review" OR review OR meta*)).ti. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")  AND (di-
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agn* OR guideline OR protocol OR rule OR proced* OR instruct* OR standard*) AND 
("systematic review" OR review OR meta*)).ti.ab. 
(("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")  AND (di-
agn* OR guideline OR protocol OR rule OR proced* OR instruct* OR standard*) AND 
("systematic review" OR review OR meta*)).tw. 
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Prevention / Intervention 
Search Query related to prevention and intervention of FASD/ prenatal alcohol expo-
sure 
Keyword Synonyms 
FASD  ("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foetal 
alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol spectrum 
disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol spectrum 
disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alcohol" OR 
"alcohol exposed" OR "alcohol related birth defects" OR "alcohol related 
neurodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy") 
Pregnancy (pregnan* OR gestat* OR maternal OR prenatal) 
Prevention 
Intervention 
(preven* OR interve* OR strategy OR education OR "health promot*"  OR program*) 
Review ("systematic review" OR review OR meta*) 
Exclude (animal* OR mouse OR mice OR rat OR rats) 
Ebscohost 
((("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")) OR 
((pregnan* OR gestat* OR maternal OR prenatal)) AND (preven* OR interve* OR strat-
egy OR education OR "health promot*" OR program*) AND ("systematic review" OR 
review OR meta*) NOT (animal* OR mouse OR mice OR rat*)) 
Pubmed 
(((fetal alcohol spectrum disorder* [TI]) OR (foetal alcohol spectrum disorder* [TI]) OR 
(fetal alcohol exposure [TI]) OR (foetal alcohol exposure [TI]) OR (fetal alcohol syn-
drome [TI]) OR (foetal alcohol syndrome [TI]) OR (partial fetal alcohol syndrome [TI]) 
OR (partial fetal alcohol spectrum disorder* [TI]) OR (partial foetal alcohol syndrome 
[TI]) OR (partial foetal alcohol spectrum disorder* [TI]) OR (prenatal alcohol exposure 
[TI]) OR (prenatal exposure to alcohol [TI]) OR (alcohol exposed [TI]) OR (alcohol relat-
ed birth defects [TI]) OR (alcohol related neurodevelopmental disorder [TI]) OR (fetal 
effects [TI]) OR (alcoholic embryopathy [TI])) OR ((pregnan* [TI]) OR (gestat* [TI]) OR 
(maternal [TI]) OR (prenatal [TI])) AND ((preven* [TI]) OR (interve* [TI]) OR (strategy 
[TI]) OR (education [TI]) OR (health promot* [TI]) OR (program* [TI])) AND ((systematic 
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review [TI]) OR (review [TI]) OR (meta* [TI])) NOT ((animal* [TI]) OR (mouse [TI]) OR 
(mice [TI]) OR (rat* [TI]))) 
(((fetal alcohol spectrum disorder* [TIAB]) OR (foetal alcohol spectrum disorder* 
[TIAB]) OR (fetal alcohol exposure [TIAB]) OR (foetal alcohol exposure [TIAB]) OR (fetal 
alcohol syndrome [TIAB]) OR (foetal alcohol syndrome [TIAB]) OR (partial fetal alcohol 
syndrome [TIAB]) OR (partial fetal alcohol spectrum disorder* [TIAB]) OR (partial foetal 
alcohol syndrome [TIAB]) OR (partial foetal alcohol spectrum disorder* [TIAB]) OR 
(prenatal alcohol exposure [TIAB]) OR (prenatal exposure to alcohol [TIAB]) OR (alcohol 
exposed [TIAB]) OR (alcohol related birth defects [TIAB]) OR (alcohol related neurode-
velopmental disorder [TIAB]) OR (fetal effects [TIAB]) OR (alcoholic embryopathy 
[TIAB])) OR ((pregnan* [TIAB]) OR (gestat* [TIAB]) OR (maternal [TIAB]) OR (prenatal 
[TIAB])) AND ((preven* [TIAB]) OR (interve* [TIAB]) OR (strategy [TIAB]) OR (education 
[TIAB]) OR (health promot* [TIAB]) OR (program* [TIAB])) AND ((systematic review 
[TIAB]) OR (review [TIAB]) OR (meta* [TIAB])) NOT ((animal* [TIAB]) OR (mouse [TIAB]) 
OR (mice [TIAB]) OR (rat* [TIAB]))) 
(((fetal alcohol spectrum disorder* [TEXT WORD]) OR (foetal alcohol spectrum disor-
der* [TEXT WORD]) OR (fetal alcohol exposure [TEXT WORD]) OR (foetal alcohol expo-
sure [TEXT WORD]) OR (fetal alcohol syndrome [TEXT WORD]) OR (foetal alcohol syn-
drome [TEXT WORD]) OR (partial fetal alcohol syndrome [TEXT WORD]) OR (partial 
fetal alcohol spectrum disorder* [TEXT WORD]) OR (partial foetal alcohol syndrome 
[TEXT WORD]) OR (partial foetal alcohol spectrum disorder* [TEXT WORD]) OR (prena-
tal alcohol exposure [TEXT WORD]) OR (prenatal exposure to alcohol [TEXT WORD]) OR 
(alcohol exposed [TEXT WORD]) OR (alcohol related birth defects [TEXT WORD]) OR 
(alcohol related neurodevelopmental disorder [TEXT WORD]) OR (fetal effects [TEXT 
WORD]) OR (alcoholic embryopathy [TEXT WORD])) OR ((pregnan* [TEXT WORD]) OR 
(gestat* [TEXT WORD]) OR (maternal [TEXT WORD]) OR (prenatal [TEXT WORD])) AND 
((preven* [TEXT WORD]) OR (interve* [TEXT WORD]) OR (strategy [TEXT WORD]) OR 
(education [TEXT WORD]) OR (health promot* [TEXT WORD]) OR (program* [TEXT 
WORD])) AND ((systematic review [TEXT WORD]) OR (review [TEXT WORD]) OR (meta* 
[TEXT WORD])) NOT ((animal* [TEXT WORD]) OR (mouse [TEXT WORD]) OR (mice 
[TEXT WORD]) OR (rat* [TEXT WORD]))) 
Embase 
((("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
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rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")) OR 
((pregnan* OR gestat* OR maternal OR prenatal)) AND (preven* OR interve* OR strat-
egy OR education OR "health promot*" OR program*) AND ("systematic review" OR 
review OR meta*) NOT (animal* OR mouse OR mice OR rat*)).ti. 
((("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")) OR 
((pregnan* OR gestat* OR maternal OR prenatal)) AND (preven* OR interve* OR strat-
egy OR education OR "health promot*" OR program*) AND ("systematic review" OR 
review OR meta*) NOT (animal* OR mouse OR mice OR rat*)).ti.ab. 
((("fetal alcohol spectrum disorder*" OR "foetal alcohol spectrum disorder*" OR "fetal 
alcohol exposure" OR "foetal alcohol exposure" OR "fetal alcohol syndrome" OR "foe-
tal alcohol syndrome" OR "partial fetal alcohol syndrome" OR "partial fetal alcohol 
spectrum disorder*" OR "partial foetal alcohol syndrome" OR "partial foetal alcohol 
spectrum disorder*" OR "prenatal alcohol exposure" OR "prenatal exposure to alco-
hol" OR "alcohol exposed" OR "alcohol related birth defects" OR "alcohol related neu-
rodevelopmental disorder" OR "fetal effects" OR "alcoholic embryopathy")) OR 
((pregnan* OR gestat* OR maternal OR prenatal)) AND (preven* OR interve* OR strat-
egy OR education OR "health promot*" OR program*) AND ("systematic review" OR 
review OR meta*) NOT (animal* OR mouse OR mice OR rat*)).tw. 
 
 
